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SUMMARY  
 
Background 
In the past fifteen years, the world has made substantial progress towards reducing malaria 
mortality and morbidity. Global malaria incidence and deaths have declined by 41 and 62%, 
respectively, between 2000 and 2016. 17 countries have eliminated malaria, six of which have been 
certified as malaria-free by the World Health Organization (WHO). According to the WHO, an 
additional 21 countries are in a position to achieve at least one year of zero indigenous cases of 
malaria by 2020. Achieving the malaria elimination goals will require sustained financial and 
political commitment at the global and domestic levels. However, external funding is on the decline 
particularly for the subset of malaria eliminating countries which tend to be low burden and middle 
income countries. The malaria landscape is further complicated by the emergence and spread of 
antimalarial drug resistance arising from the Greater Mekong Subregion (GMS). Failure to maintain 
resources for malaria elimination and the health systems that support it has the potential to 
reverse the impressive gains made. 
 
Aim and objectives 
The aim of thesis is to examine the economic evidence for malaria elimination and generate results 
relevant to policy for continued investment for malaria elimination. Specifically: 
• To review and interpret the existing information on the costs and benefits of malaria 
elimination from published and unpublished sources of literature 
• To estimate the costs and benefits and develop a national investment case for malaria 
elimination in Sri Lanka 
• To estimate the costs and benefits and develop a regional investment case for malaria 
elimination in the Asia Pacific region 
• To track and interpret trends in development assistance and government financing for 
malaria from 1990-2017 
• To assess the implications of changing donor policies on financing for malaria programmes 
and their potential impact on malaria elimination targets 
 
Methodology 
A variety of quantitative and qualitative methods were used. A systematic review of published and 
grey literature was conducted to gain an understanding of the current evidence on the costs and 
benefits of malaria elimination. The cost of malaria elimination and prevention of reintroduction 
(POR) at the national level was estimated using ingredients based costing methodology. A 
hypothetical resurgence scenario was modeled as the counterfactual scenario using historical data. 
The total income approach was used to quantify the benefits of elimination and the return on 
investment was computed. The cost of maintaining elimination activities was compared to the 
financing available to estimate the funding gap. To develop the regional investment case in the Asia 
Pacific, a mathematical transmission model coupled with a cost model was used to estimate the 
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minimum set of interventions to reach elimination on or before 2030 and the regional cost of these 
interventions. An investment case was generated using the outputs of these models compared to a 
scenario of maintaining the status quo. The benefits of elimination were quantified using the total 
income approach and a return on investment was computed as with the national investment case. 
 
Building on the Institute for Health Metrics and Evaluation’s (IHME) annual Financing Global Health 
research methodology, data were collected from organizations that channel development 
assistance for health to the 35 countries actively pursuing malaria elimination and categorized by 
type of expenditure. A diverse set of data points were used to estimate government health 
expenditure on malaria, including World Malaria Reports and government reports when available. 
Projections were made using regression analyses taking recipient country averages and earmarked 
funding into account.  
 
Lastly, average annual Global Fund allocations for eligible malaria-eliminating countries for the 
period of 2014–2017 were computed. Estimated funding ranges were calculated using the 
proposed national allocation plus any possible adjustments and additional funding. The minimum 
and maximum funding estimates were compared to average annual disbursements under the 
previous funding model to determine the impact of the allocation model on funding for malaria 
elimination. A qualitative analysis of the new Global Fund transition policy was conducted and 
interpreted for challenges for malaria elimination programmes. Policy recommendations were 
developed for donors and countries to ensure uninterrupted service delivery. 
 
Principal findings 
Of the 54 studies included in the systematic review, twenty-two were focused on elimination or 
eradication. The annual per capita cost of malaria control to a health system ranged from USD0.11 
to USD 39.06, while that for malaria elimination ranged from USD 0.18 to USD 27. Overall, the 
investments needed for malaria control and elimination varied greatly amongst the various 
countries and contexts. However, the findings illustrated that while the cost of elimination in most 
cases was greater than the cost of control, the benefits greatly outweighed the cost. 
 
The total current economic cost of the elimination and POR program in Sri Lanka was estimated at 
USD 0.57 per capita per year with a financial cost of USD 0.37 per capita in 2014. The cost of 
potential malaria resurgence was, however, much higher providing an economic return on 
investment of 13 times or a financial return on investment of 21. Despite the phenomenal returns, 
current financing for malaria elimination in Sri Lanka meets only 53 % of needs leaving a significant 
funding gap.  
 
The investment case generated for the Asia Pacific region demonstrated a median return of about 
six times the investment for malaria elimination. The cost of elimination was estimated at USD 
29.02 billion between 2017-2030. Malaria elimination was shown to save about 400,000 lives and 
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avert 123 million malaria cases, translating to almost USD 90 billion in economic benefits. Total 
financing for malaria in the Asia Pacific however, covered only 30% of the estimated annual cost of 
elimination between 2018-2020. 
 
Despite these demonstrated returns on investment from malaria elimination, external financing 
declined by about 65% since 2010 from USD 176 million in 2010 to USD 62 million in 2013 for the 
35 countries actively pursuing malaria elimination. Government expenditures on malaria, while 
increasing, have not kept pace with diminishing external funding. The Global Fund to Fight AIDS, 
Tuberculosis and Malaria, the largest external financier for malaria, provided 96% of the total 
external funding for malaria in 2013. Under the allocation model, there was a cumulative 31 % 
decrease in financing for malaria elimination. Even if countries received the maximum possible 
funding allowable, 46 % of the countries included in the analysis would receive less than they 
received under the previous funding model, potentially leaving critical gaps in essential program 
activities. 
 
Eight key challenges are faced by countries undergoing transition from donor financing: challenges 
in management capacity; lack of financial planning data; diminishing political will; concurrent 
epidemiological changes and changing priorities after elimination; parallel donor and government 
systems; integration of vertical programs; procurement pricing and quality commodities and; 
strategic program delivery and management. Policy recommendations for donors and national 
malaria programs to facilitate a more successful transition process included the need for adequate 
time and resources for transition, the consideration of strategic investments of the transitional 
financing for health for capacity building in information systems and management and a robust 
transition plan that allows for sustainability of core functions of the program. 
 
Conclusion 
This body of work provides strong evidence on the uncertainty about the future availability of 
financing for malaria elimination. It also demonstrates that malaria elimination is a worthwhile 
investment providing robust health and economic returns at the national and regional level. A 
concerted effort is needed to use the generated evidence to build an advocacy strategy to ensure 
that financing for malaria elimination is maintained until the end game. Anything less will 
undermine decades of investment and the unprecedented gains achieved towards achieving a 
global public good - a world free of malaria. 
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1.1 Global epidemiological and economic burden of malaria 
 
The launch of the Roll Back Malaria Partnership (RBM) in 1998 and the Millennium Development 
Goals in 2000 catalyzed unprecedented political and financial commitment for malaria from donors, 
such as the Global Fund, the United States President’s Malaria Initiative (PMI), the World Bank, and 
others as well as endemic countries themselves. As a result, global malaria incidence and deaths 
have dramatically declined by 41 and 62%, respectively, between 2000 and 2015 [1]. During this 
period, 17 countries eliminated malaria, six of which have been certified as malaria-free by the 
World Health Organization (WHO) [2]. Thirty-five countries are currently actively pursuing malaria 
elimination, with elimination goals ranging from 2018 to 2035 [3]. In 2016, 44 countries reported 
fewer than 10 000 malaria cases. According to WHO, 21 countries are in a position to achieve at 
least one year of zero indigenous cases of malaria by 2020 [4]. Of the 106 countries with ongoing 
malaria transmission in 2000, 57 reduced malaria incidence more than 75 % by 2015 and an 
additional 18 countries reduced incidence by more than 50 % [2].  
 
Bolstered by these successes, the idea of malaria eradication is once again on the global health 
agenda. Many countries have developed national elimination goals, and regional networks have 
been formed to facilitate collaboration [3, 5]. Leaders from the Asia Pacific Leaders Malaria Alliance 
(APLMA) and the African Leaders Malaria Alliance (ALMA) have endorsed regional goals for malaria 
elimination by 2030 in November 2014 and January 2015, respectively, galvanizing support for 
elimination and eradication [6, 7]. 
 
Despite this progress, malaria continues to place a heavy toll on the world. In 2016, 216 million 
cases occurred globally, leading to 445,000 deaths, most of which occurred in children under age 
five years in Africa [8]. These estimates are likely to be conservative, as adult cases and deaths from 
Chapter 1: Background and Introduction 
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malaria might well be underestimated in much of Africa and Asia due to the high proportion of 
treatment seeking behavior in the private sector [9-12]. 
 
Furthermore, global progress in malaria control and elimination is marked by vast disparities 
between and within countries, with vulnerable groups that have poor access to health services 
continuing to be marginalized. A few countries that have successfully reduced malaria transmission 
are struggling to maintain their gains. An increased number of cases have recently been reported 
from a number of countries, including Cambodia, Djibouti, Rwanda, Madagascar, Uganda, and 
República Bolivariana de Venezuela [13] The WHO reported that between 2014 and 2016, case 
incidence increased in the Americas, South-East Asia and the Western Pacific and in Africa [8]. 
 
Some of the challenges impeding countries’ abilities to maintain their gains and advance towards 
malaria elimination include a lack of sustainable and predictable international and domestic 
funding. This is compounded by the emergence of parasite resistance to antimalarial medicines and 
mosquito resistance to insecticides, posing a serious threat to global health security. Since 2010, 
donor funding for malaria has plateaued and is projected to continue to decline [14]. These 
reductions in external financing are even greater for the sub-set of malaria eliminating countries 
despite demonstrated evidence on the returns on investment from elimination [15,16]. By nature, 
these countries have lower disease burdens and are often lower-middle or middle-income 
countries and therefore a lesser priority for donors [17,18]. In some cases, donors are moving away 
from disease-based funding to general system strengthening to address Universal Health Coverage 
or concerns of global health security [19]. While integrated systems might help countries in the 
final push to malaria elimination and prevent reintroduction of malaria, a well-funded malaria 
programme, maintaining a level of vertical oversight, is crucial in the short to medium term. At the 
same time, as the disease becomes less “visible”, government funds for malaria are often diverted 
to other health priorities that are perceived to be greater health threats, risking a reversal of the 
recent gains made in malaria elimination [15, 20, 21]. 
 
The Global Fund, which has been the largest external financing channel supporting eliminating 
nations representing more than half (57%) of the total resources for malaria control and 
elimination, has historically dispersed about 7% of its total portfolio to eligible malaria-eliminating 
countries. However, under the New Funding Model adopted in 2012, resources for this sub- set of 
countries declined to less than 5% [22] and have declined further under a revised allocation-based 
model adopted by the Global Fund Board in November 2016 [23]. Other bilateral and multilateral 
donors are similarly diverting resources to higher-burden countries with the least ability to pay as 
measured by their Gross National Income (GNI). For example, PMI launched in 2005, focuses on 
reducing malaria-related mortality in 24 high burden countries in sub-Saharan Africa in addition to 
targeted support in the Greater Mekong Subregion in Asia, aimed at combating antimalarial drug 
resistance [24]. 
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The reductions in financing for countries eliminating malaria comes at a critical time—WHO’s 
Global Technical Strategy (GTS) for Malaria 2016–2030 [25] and the Roll Back Malaria Partnership’s 
Action and Investment to Defeat Malaria 2016–2030 (AIM) [26] together with the recently 
endorsed Sustainable Development Goals, have set their sights on rapid progress with malaria 
elimination towards attainment of malaria free status in 35 countries by 2030. The GTS estimated 
that USD 6.4 billion will be needed annually to achieve a reduction of at least 40% in malaria case 
incidence and mortality by 2020 compared to 2015 levels. However, total funding for malaria 
control and elimination was estimated at USD 2.7 billion in 2016 [25], representing just 42% of the 
annual need.  
 
Table 1.1. Global malaria goals and targets 
 
Goal Milestones Target 
2020 2025 2030 
Reduce malaria mortality rates 
globally compared with 2015 
At least 40% At least 75% At least 90% 
Reduce malaria case incidence 
globally compared with 2015 
At least 40% At least 75% At least 90% 
Eliminate malaria from 
countries in which malaria was 
transmitted in 2015 
At least 10 
countries 
At least 20 
countries 
At least 35 
countries 
Prevent the reestablishment of 
malaria in all countries that are 
malaria free 
Reestablishment 
prevented 
Reestablishment 
prevented 
Reestablishment 
prevented 
Source: [25] 
 
Achieving the global goals will require sustained financial and political commitment at the global 
and domestic levels. These investments have the potential to deliver strong health benefits through 
fewer deaths and less illness valued at over USD 49 billion, exceeding investment costs by a factor 
of 40 between 2015 and 2030 [26].  
 
Although the contribution of malaria elimination to the colossal health and development returns of 
global eradication is implicitly recognized [15, 16, 21], malaria elimination requires additional front-
loading of investments into robust surveillance-response systems to detect and respond to 
remaining cases. While socio-economic and other structural changes will eventually change the 
intrinsic baseline potential for transmission in countries such that active measures are no longer 
required [27], the decision facing policymakers is how to best allocate finite resources in the short 
term. Countries who have successfully lowered their malaria burden are faced with the risk of 
losing or severely reducing their recurrent expenditure for elimination and preventing the re-
introduction of malaria at a critical period in the malaria elimination efforts [3, 18]. At the same 
Chapter 1: Background and Introduction 
 
10 
 
 
time, they face the risk of resurgence due to the persistent importation of new cases which will not 
only have devastating effects on the health and welfare of individuals, but will also place an 
additional economic burden on the health system. A review on malaria resurgence occurring from 
the 1930s through to the 2000s demonstrated that almost all resurgence events could be 
attributed, at least in part, to the weakening of malaria control programmes for a variety of 
reasons, of which resource constraints were the most common [28]. In addition, lessons learned 
from the Global Malaria Eradication Programme (GMEP), which ended in 1969, affirm that while 
well-funded interventions can have a major impact on the disease, such gains are fragile and can 
easily be reversed particularly in the short term in areas that continue to be epidemiologically and 
entomologically receptive and vulnerable [29].  
 
1.2 Malaria elimination and eradication 
 
Malaria elimination is defined as the reduction to zero of the incidence of infection caused by a 
specified agent in a defined geographical area as a result of deliberate efforts. Global eradication of 
malaria is the permanent reduction to zero of the worldwide incidence of infections caused by the 
malaria parasite as a result of deliverable efforts [30]. 
 
In areas of moderate to high transmission that are implementing malaria control, interventions are 
deployed on a large scale to reduce the public health burden of the disease. In elimination settings, 
targeted interventions aim to interrupt local transmission in the specific places where it becomes 
increasingly concentrated, that is, small geographic areas or special subpopulations that may be 
harder and costlier to reach. The key decisions facing policy makers in low- and moderate-
transmission settings are when to embark on malaria elimination [31,32]; which interventions to 
implement and where and when; and at what levels of intensity and reach. Critical to this debate 
are the political and financial commitments that are needed long after the disease stops being a 
public health burden.  
 
Malaria elimination involves stopping indigenous transmission through active control measures. 
The complete absence of local incidence is very unlikely to be achieved in places with high intrinsic 
potential for transmission and elevated importation of cases [33]. For example, even the United 
States, a relatively low transmission risk area, identified 156 locally acquired cases between 1957 
and 2003 [34]. Even countries that do not contiguously border endemic neighbors experience 
considerable importation annually: Sri Lanka reported 49 confirmed imported malaria cases in 
2014, and in Tanzania, Zanzibar’s estimated importation of 1.6 cases per 1,000 residents could 
potentially produce 1,300 incident cases [35]. Transmission from imported cases may lead to first 
degree introduced cases; a second degree of transmission from an introduced case produces an 
indigenous case: both are products of local transmission. Elimination accordingly requires 
preventing all indigenous cases, but introduced cases may continue to occur sporadically. As more 
Chapter 1: Background and Introduction 
 
11 
 
 
countries and regions eliminate malaria and implement measures to prevent reintroduction, fewer 
imported infections will occur, and eradication will become increasingly feasible. 
 
The first malaria eradication attempt was made as part of the Global Malaria Eradication 
Programme, or the GMEP, which ran from 1955-1970. Until the mid-nineteenth century, malaria 
was endemic in most countries across the globe. Between 1900 and 1945, only nine countries in 
Europe eliminated malaria [20,21]. Sparked by the availability of chloroquine for treatment and 
dichloro-diphenyl-trichloroethane (DDT) for vector control, WHO launched the GMEP in 1955 to 
interrupt transmission in all endemic areas outside of Africa [29]. The programme relied on vector 
control—mainly indoor residual spraying—and systematic detection and treatment of cases. The 
campaign which targeted elimination in countries with low or intermediate malaria intensity, 
succeeded in eliminating malaria in 37 of the 143 countries or economies where it was endemic in 
1950 [36], including some lower-income areas with tropical climates such as Maldives; Mauritius; 
Réunion; Taiwan, China; much of the Caribbean; Brunei Darussalam; most of China; Hong Kong SAR, 
China; Singapore [20,21,36]. In many other countries, such as Sri Lanka, the burden of disease and 
deaths from malaria was greatly reduced [37]. However, failure to sustain strong funding for the 
program, particularly in the face of increasing costs due to mounting drug and insecticide 
resistance, led to the end of the GMEP in 1969 [38] when the World Health Assembly 
recommended that countries not yet ready for “eradication” focus on controlling malaria as a first 
step toward the ultimate goal of elimination. Multilateral agencies withdrew their support for 
malaria programmes in favor of general health programmes. In the ensuing years, although most 
countries that had eliminated malaria continued to remain malaria free, the scaling back of control 
efforts in malarious countries led to a global resurgence of the disease during the 1970s and 1980s 
and a complete reversal of progress in some countries, such as Sri Lanka and Pakistan [28,39]. The 
experience of the GMEP provides critical lessons for contemporary elimination programmes about 
the need to maintain vigilance and sustain investments during the latter stages of elimination 
efforts. 
 
1.3 Malaria elimination and health security 
 
As countries become more interconnected through increased infrastructure and air links, health 
security is also becoming a major concern. Recent outbreaks of severe acute respiratory syndrome, 
H5N1 (“avian flu”) and H1N1 (“swine flu”) influenza, Middle Eastern respiratory syndrome 
coronavirus, Ebola, and more recently the Zika virus have highlighted the need for governments to 
invest in health security to tackle emerging and re-emerging infectious diseases. Artemisinin 
resistance similarly poses a risk to health security. Investing in malaria elimination has a direct 
positive contribution to the health security of the countries and communities involved. Malaria’s 
key interventions—including strengthened surveillance, health information systems, disease 
surveillance, and preparedness—provides a platform to tackle other emerging infectious diseases 
by improving the capacity to detect and report disease outbreaks, respond faster to public health 
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emergencies, and collaborate across borders [40,41].  
 
Across most malaria endemic countries, weak health systems are a major constraint to the 
planning, implementation, monitoring, and sustainability of effective interventions. Malaria 
elimination can be viewed as an entry point to strengthen health systems and has the potential to 
highlight how elimination can lead to increased equity. In low transmission settings, where cases 
cluster among high-risk populations, programs must tackle areas and communities that lack access 
to critical health services. These systems will also be able to deliver universal health coverage, and 
the funds no longer needed for malaria, can be redirected to tackle other pressing health 
challenges. The malERA Refresh research agenda has highlighted the role of health systems 
improvement for the continuous and timely delivery of malaria interventions [42]. Given the 
context of declining malaria case numbers across the region, malaria advocacy is increasingly being 
tied to a wider narrative that includes other communicable diseases such as dengue, which has 
seen a dramatic resurgence in recent years, and Zika as part of a regional health security response.  
 
1.4 Malaria in the Asia Pacific Region 
 
Malaria remains a major cause of death and illness in the region with an estimated 1.72 billion 
people at risk of the disease [8] About 20 different Anopheles vectors have been implicated in 
malaria transmission in the Asia Pacific. Some of these vectors bite outdoors, between early 
evening to the early hours of the morning, and exhibit zoophilic biting—behaviors that require 
expanded vector control interventions beyond long-lasting insecticidal nets (LLINs) and indoor 
residual spraying (IRS) and improved targeting of high risk populations [40].  
 
Approximately 260 million people live in high-transmission areas. In 2016, among the 21 countries 
in the region with ongoing malaria transmission or working towards POR, there were 6,345,208 
presumed and confirmed cases of malaria according to the World Malaria Repot of the World 
Health Organization (WHO) of which 53% of cases were due to Plasmodium falciparum (P. 
falciparum) and 41% due to Plasmodium vivax (P. vivax) cases. The remaining infections (6%) are 
mixed. Of this total, 14,729 cases were imported. India, South Asia carries the highest burden of 
disease with India alone accounting for 49% of global P. vivax malaria cases and 51% of global P. 
vivax malaria deaths in 2015 [8]. 
 
The Asia Pacific region has achieved significant gains against malaria over the last 15 years.  Malaria 
cases and deaths have been reduced by more than 50% between 2010 and 2015 in the region’s 22 
malaria-endemic countries.1 Sri Lanka was declared malaria-free in 2016, becoming only the second 
                                                        
1 The Asia Pacific region in this report encompasses the 22 malaria-endemic countries as defined by APLMA. Sri Lanka has since been 
declared as malaria free but still implements prevention of reintroduction activities. Countries include: Afghanistan, Bangladesh, 
Bhutan, Cambodia, Democratic People’s Republic of Korea (DPRK), India, Indonesia, Lao People’s Democratic Republic  (Lao PDR), 
Malaysia, Myanmar, Nepal, Pakistan, Papua New Guinea (PNG), People’s republic of China, Philippines, Republic of Korea (ROK), 
Solomon Islands, Sri Lanka, Thailand, Timor Leste, Vanuatu and Vietnam. 
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country in Southeast Asia (after the Maldives) to successfully eliminate malaria [43,44]. Apart from 
India, Indonesia, Myanmar, and Thailand, malaria-endemic countries reported decreases of malaria 
incidence of more than 75% since 2000. Cases and deaths declined by more than 50% between 
2010 and 2015 in the majority of the countries in the region, surpassing the WHO milestone of a 
40% reduction by 2015 [1]. In some cases, they have declined by almost 100%, with Bhutan, China, 
and Timor-Leste reporting less than 200 cases in 2016 [8]. Progress in driving down malaria is 
attributed to the scale-up of effective interventions to prevent, diagnose, and treat malaria, 
facilitated by strong political and financial support from governments and donors like the Global 
Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund).  
 
The numbers of confirmed cases by country and species are shown in Figure 1.1. 
 
Figure 1.1. Confirmed P. falciparum and P. vivax malaria cases in Asia Pacific, 2015 
 
 
Source: [1,45] 
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1.5 Financing for Malaria in the Asia Pacific Region 
 
Over the past decade and a half, the Asia Pacific region has invested in excess of USD 3 billion in 
malaria control interventions [40]. Annual financing for malaria in the region increased 
exponentially from less than USD 100 million in 2000 to about USD 415 million in 2016 [41,46].  
 
The main sources of financing are domestic government resources and external financing from 
donors. Most national malaria control programs (NMCPs) in the region continue to be highly reliant 
on external financing, particularly from the Global Fund to Fight AIDS, Tuberculosis and Malaria 
(Global Fund). As Figure 4 illustrates, almost 50% of the total funding for malaria in Asia Pacific in 
2016 was from the Global Fund. This dependence on external financing is projected to continue 
beyond 2017. 
 
Figure 1.2.  Financing for malaria in the Asia Pacific region 
 
 
Source: [46] 
 
However, there has been a plateau in external financing for malaria, particularly for countries that 
have middle-income status and experience relatively lower transmission of malaria. Between 2006-
2010, the Asia Pacific region attracted between 12% and 21% of global malaria funding from the 
Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) [22].  Although domestic 
financing for malaria has increased in many countries in the last decade, the need for malaria 
control and elimination far exceeds the available resources. This is particularly important in the 
context of elimination where malaria is no longer perceived as a threat with countries 
simultaneously facing competing disease priorities. At the same time, the region has experienced 
unprecedented economic growth, providing unparalleled opportunities to reach and sustain 
resources for malaria elimination. 
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With the growing threat of antimalarial drug resistance arising from the Greater Mekong Subregion 
(GMS) and the urgent need to contain its spread, the case for malaria elimination has never been 
stronger [47]. However, in order to achieve a malaria-free Asia Pacific – a goal endorsed by leaders 
at the highest levels though the Asia Pacific Leaders Malaria Alliance (APLMA)2 – financial resources 
will need to be sustained [48]. Failure to maintain resources for malaria elimination has the 
potential to reverse the impressive gains made [16,28]. 
 
1.6 Economic transition of countries in the Asia Pacific Region 
Asia Pacific economies have been growing by approximately 6.5% over the past five years, and 
although the International Monetary Fund (IMF) expects the region’s growth to decelerate to 5.3% 
in 2017, the Asia Pacific is still the world’s fastest growing region [49]. The growth in wealth is 
however, unequally distributed between and within countries, but in some cases it has increased 
countries' fiscal space to invest in socio-economic development. This strong economic growth has 
also led to changes in the way economies are classified by the World Bank. In 2001, the World Bank 
classified 14 countries in the region as low-income countries (LICs), 13 as lower-middle-income 
countries (LMICs), and only three as upper-middle-income countries (UMICs) [50]. In 2016, only 
three countries were classified as LIC, 21 as LMIC, and eight as UMIC. The income classification 
dictates countries’ abilities to attract development financing, including grants and concessional 
loans from donors and multilateral development banks (MDBs). In the coming years, external 
donors like the Global Fund will increasingly focus on sustainability, transition, and co-financing 
(STC). The Global Fund’s new STC policy [51] emphasizes long-term sustainability as a key aspect of 
health financing and that all countries, regardless of their economic capacity and disease burden, 
should embed sustainability considerations within national strategies, program design, and 
implementation. This focus will be particularly relevant for UMICs and LMICs in the Asia Pacific, 
with moderate disease burdens, such as Malaysia, the Philippines, Sri Lanka, and Thailand. Figure 
1.4 illustrates the projected growth of select economies in the region to 2020. 
 
  
                                                        
2 At the 2013 East Asia Summit (EAS), the Asia Pacific Leaders Malaria Alliance (APLMA) was established to accelerate 
progress towards a reduction in malaria cases and deaths. In 2014 at the ninth EAS, the APLMA Co- Chairs (the Prime 
Ministers of Viet Nam and Australia) tabled a recommendation for the Asia Pacific region to become free of malaria by 
2030. EAS Heads of Government agreed to the goal, and tasked APLMA Co- Chairs to present a plan to reach malaria 
elimination through a “Leaders Malaria Elimination Roadmap”. The APLMA roadmap was presented to Heads of 
Government during the 10th EAS Meeting in 2015.  
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Figure 1.4. GDP per capita in 2015 and 2020 (projected) for select Asia Pacific countries 
 
 
 
The 22 countries in the Asia Pacific region have collectively reported domestic financing levels of 
USD 267.6 million for malaria to the Global Fund in 2016 [45]. This amount mostly refers to funding 
directly available for vertical malaria control activities. Government commitments for 2015-2017 
have seen an overall 46% increase compared to 2012-2014 levels. Nevertheless, there is still an 
estimated funding gap of about 50% of the total need, as estimated through expressions of need in 
the National Strategic Plans (NSPs) for malaria [53]. 
 
The premise of the health financing transition, which forms the basis of donor policies is that as 
countries develop as measured by their Gross Domestic Product (GDP) or Gross National Income 
(GNI), government contributions will correspondingly increase. However, in most countries, these 
increases are not proportional or immediate. Figure 1.5 illustrates the variation in the proportion of 
Government Health Expenditure (GHE) as a function of the GDP per capita. The Pacific Islands of 
Vanuatu and the Solomon Islands as well as Timor Leste have a high proportion of government 
financing despite the relatively low GDP while Malaysia and the Republic of Korea have lower 
contributions by the government despite having a higher GDP. 
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Figure 1.5. Government Health Expenditure as a percentage of Total Health Expenditure and 
Gross Domestic Product in the Asia Pacific countries 
 
 
1.7 Rationale for PhD thesis 
 
The economic impact of malaria has been studied for well over a century. While there is a plethora 
of literature on the economics and financing of malaria control there is little information on the 
economics of malaria elimination including information on the marginal costs of elimination or the 
economic returns that can be used by policymakers for decision-making. Policymakers need to 
know how much it costs to achieve reductions in malaria burden and elimination, whether the cost 
savings of elimination will offset the initial investment and what are the financial returns of 
elimination versus maintaining the status quo. In addition, there are major gaps in the published 
literature about the sources of funding for malaria elimination efforts and about how these funds 
are spent. The Institute for Health Metrics and Evaluation (IHME) [54, 55] has been tracking 
Development Assistance for Health (DAH) from 1990 onwards, disaggregating spending by the 
source of funding, intermediary channel and recipient country while others have concentrated on 
specific health focus areas, such as HIV and maternal, child and newborn health [56]. WHO annually 
publishes a World Malaria Report [8], which includes government expenditure information 
obtained from countries’ national malaria control programmes. However, expenditure data are 
often unavailable and replaced by budget information. Past analyses have either focused on single 
countries and/or disease programmes or across multiple countries aimed at measuring the 
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effectiveness of funding.  To better understand past and future trends in financing for malaria 
elimination, a better tracking of malaria-specific estimates expenditures from all sources is needed. 
A clear perspective on where resources have been and will be available will uncover critical 
investment gaps and investment opportunities. 
 
In order to fill these gaps, this research and thesis seeks to accomplish four aims. The first aim is to 
review the existing literature on the costs and benefits of malaria elimination. The second aim is to 
estimate the costs and benefits and develop regional and national investment cases for malaria 
elimination in the Asia Pacific. The third is to track development assistance and government 
financing for health and the forth is to discuss the implications of the changing financing landscape 
and opportunities for resource mobilization. 
 
For the first aim, a systematic literature review on the costs and benefits of malaria elimination was 
conducted. For the second objective, methods to collect data on the costs of malaria elimination 
were developed as well as two different methodologies for developing regional and national 
investment cases for malaria elimination. Both quantitative and qualitative data collection and 
analysis was conducted. Ingredients based costing methodology was developed and the full-income 
approach to estimating the benefits of elimination were employed. 
 
For the third aim, financing flows for malaria elimination were collected from various sources from 
1990 through 2013. Building on the Institute for Health Metrics and Evaluation’s annual Financing 
Global Health research, data were collected from primary agencies and organizations that channel 
DAH or third party organizations or private organizations that collect such data [55] and split into 
categories identifying the type of investment. The Organization for Economic Cooperation’s (OECD) 
Creditor Reporting System (CRS) database [57] was used to collect information on financing 
channeled through bilateral agencies and budget data from the Global Fund malaria grants were 
extracted by service delivery areas. A diverse set of data points and reports were used to estimate 
the share of domestic government health budgets spent on malaria from 2000 through 2014 
including the World Malaria Report (WMR). 
 
For the fourth aim, data from Global Fund disbursements and allocation were compared across 
years and a quantitative analysis was performed. A qualitative analysis was use to determine the 
effect of Global Fund transitions and provide policy recommendations.  
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2.1 General aims 
2.2 Specific Objectives 
2.3 References 
 
2.1 General Aims 
 
The overall aim of this PhD thesis is to provide the economic evidence for continued investment for 
malaria elimination. The first approach was to gain an understanding of the costs and benefits of 
malaria elimination. The second approach was to estimate the cost of malaria elimination at the 
national and regional level and develop investment cases using various methodologies that can be 
used for advocacy for continued financing for malaria elimination. The third approach was to the 
understand sources of financing for malaria elimination. The fourth approach was to understand 
the implications of the changing financing landscape on malaria elimination and to identify new 
opportunities for resource mobilization. 
 
2.2 Specific Objectives 
 
In order to fill these gaps, this research and thesis seeks to accomplish five specific objectives: The 
first objective is to understand the existing information on the costs and benefits of malaria 
elimination from published and unpublished sources of literature. The second objective is to 
estimate the costs and benefits and develop a national investment case for malaria elimination in 
Sri Lanka. The third aim is to estimate the costs and benefits and develop a regional investment 
case for malaria elimination in the Asia Pacific region. The fourth is to track development assistance 
and government financing for malaria from 1990-2017. The fifth objective is to understand the 
implications of changing donor policies on malaria elimination programmes. 
 
A. To understand the existing information on the costs and benefits of malaria elimination 
from published and unpublished sources of literature (Paper 1, Chapter 4). 
 
The objective of this paper was to review the existing literature and evidence on the costs 
and benefits of malaria elimination. Specifically, this paper presents a comprehensive 
review of literature on the cost of malaria control as well as those of achieving and of 
sustaining elimination and the benefits generated by malaria elimination compared to the 
cost of malaria control. The review was intended to elicit evidence along the various 
phases of the programme: control, elimination and Prevention of Reintroduction (POR). 
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B. To estimate the costs and benefits and develop a national investment case for malaria 
elimination in Sri Lanka. (Paper 2, Chapter 5). 
 
The purpose of this study was to estimate the current costs of the malaria programme and 
to develop an investment case for malaria POR in Sri Lanka. In addition, the paper reviewed 
the funding landscape for malaria in the country and identified anticipated gaps in the near 
future. The findings provides the AMC with an estimate of the resources required to 
prevent the reintroduction of malaria, as well as robust evidence to advocate for sustained 
funding from both domestic and external sources.  
 
C. To estimate the costs and benefits and develop a regional investment cases for malaria 
elimination in the Asia Pacific. (Paper 3, Chapter 6). 
 
The purpose of this study was to model the cost of achieving malaria elimination in all the 
malaria endemic countries of the Asia Pacific on or before 2030 and to develop an 
investment case for malaria elimination that advocates can use to advocate for sustained 
resources. The study also assessed current and future sources of financing to estimate the 
gaps in funding and potential opportunities for resource mobilization. 
 
D. To track development assistance and government financing for malaria elimination from 
1990 through 2017 (Paper 4, Chapter 7). 
 
To better understand past and future trends in financing for malaria elimination, this paper 
systematically tracks development assistance for the prevention and treatment of malaria 
from channel to recipient country or region, for 1990– 2013; generates lower-bound 
estimates of how development assistance for the prevention and treatment of malaria was 
used by activity or intervention area for the same time period; estimates government 
health expenditures (GHE) for malaria from 2000 to 2014; and, projected Development 
Assistance for Health (DAH) from 2014 to 2017 in 35 eliminating countries.  
 
E. To understand the implications of the changing donor policies by assessing the impact of 
the Global Fund allocation model on funding for malaria elimination programmes (Paper 5, 
Chapter 8). 
 
In 2011, the Global Fund transitioned to a new funding model (NFM), which prioritizes 
grants to high burden, lower income countries. Many low transmission countries, 
dependent on GFATM financing to achieve their malaria elimination goals, would receive 
less funding under the NFM. This study aims to understand the projected increase or 
decrease in national and regional funding from the GFATM’s NFM to the 34 malaria-
eliminating countries. 
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F. To understand the implications of the changing donor policies by understanding the 
challenges of Global Fund transitions for malaria elimination programmes (Paper 6, 
Chapter 9). 
 
Seven malaria-eliminating countries are in their final round of Global Fund Support or will 
reach the Global Fund’s eligibility thresholds in the next five years. This paper outlines the 
key challenges faced by countries undergoing this transition, explore gaps that exist in 
current evidence, and highlight policy recommendations for donors and national malaria 
programmes to facilitate a more successful transition process. 
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3.1 Literature review 
 
A systematic search of peer-reviewed literature in English, French and Spanish, pertaining to 
economics of malaria, published on or before September 2014 was conducted. Databases searched 
were MEDLINE via PubMed, SCOPUS and Google Scholar using MeSH terms as well as other key- 
words. The term ‘malaria’ was combined with ‘elimination’ and ‘eradication’ and the following 
search terms: ‘economics’, ‘cost’, ‘cost analysis’, ‘cost allocation’, ‘cost apportionment’, ‘cost 
control’, ‘cost of illness’, ‘employer health costs’, ‘hospital costs’, ‘health care costs’, ‘drug costs’, 
‘direct service costs’, ‘health expenditures’, ‘financing’, and ‘cost-benefit analysis’. A detailed list of 
search terms and corresponding results are available upon request. Two independent database 
searches were carried out to ensure an exhaustive search of the literature. The two lists of papers 
were subsequently merged and duplicates were removed. Reference lists of papers that met the 
inclusion criteria were also screened. Titles and abstracts of all initial search results were reviewed 
for relevance, and those that included some form of economic analysis were assessed further for 
eligibility. Articles that did not have abstracts available online but were thought to be relevant 
based on their titles alone were included in the full-text assessment. Articles were excluded during 
full-text assessment if they did not meet the inclusion criteria or if their full-text versions could not 
be located after multiple attempts. A full description of the inclusion and exclusion criteria is 
contained in Chapter 4. 
 
A comprehensive literature review was conducted for the Sri Lanka investment case to gain an 
understanding of the current and historical structure, activities, and financing of the malaria 
program.  A search was conducted using Google, Google Scholar, Pubmed, World Health 
Organization Library (WHOSIS) [1], World Health Organization (WHO) Office of the South-East Asia 
Region [2], and the Global Fund website using the search terms “Sri Lanka” AND “malaria” AND 
“cost” OR “burden” OR “elimination. References were also identified by cross-referencing 
bibliographies of relevant publications. The inclusion criteria included any articles that included the 
above key words and were in English. 
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3.2 National investment case in Sri Lanka 
 
3.2.1 History of malaria control and elimination in Sri Lanka 
Sri Lanka has made extraordinary gains in reducing the burden of malaria in the last decade. 
Between 2000 and 2011, the number of malaria cases declined by more than 99% [6, 7]. With zero 
locally transmitted malaria cases recorded since November 2012 and no indigenous deaths since 
2007, Sri Lanka received the World Health Organization (WHO) certification of elimination in 
September 2016, an official recognition of its malaria-free status [6, 7, 8]. This period of progress 
coincided with increased political and financial commitment from the government and external 
donors, particularly the Global Fund to Fight AIDS, Tuberculosis and Malaria [9]. 
 
However, funding for malaria from the Global Fund is declining and being prioritized for high- 
burden, low-income countries and there is waning political interest and a rising disinterest toward 
malaria among health workers within the country as the disease is no longer considered a major 
public health threat. At the same time, the country continues to face a significant risk of resurgence 
especially in areas of high receptivity and vulnerability [10].  
 
In 1963, malaria elimination was on the horizon with only 17 cases recorded in public facilities, of 
which only six were locally transmitted [11]. However, a severe cutback in political and financial 
support for malaria control, led to the withdrawal of malaria control measures and rapid 
resurgence of malaria [12]. To implement its new strategy for the POR of malaria, the Antimalaria 
Campaign (AMC) needs continued resources particularly in the short- to medium-term until the 
intrinsic transmission potential is sufficiently altered to make elimination stable.  
 
3.2.2 Ingredients based costing and quantitative cost data extraction in Sri Lanka 
A micro-costing approach was used to calculate the costs of POR in Sri Lanka. A detailed cost 
analysis was conducted for ongoing program activities from expenditure and financial records, 
historical record reviews as well as extraction from existing reports and key informant interviews. 
Available information was obtained from existing reports and grey and published literature, 
including AMC Directorate records at the national and regional levels. 
 
All fixed and recurrent costs incurred by the health system for malaria activities including resources 
received as donations and other in-kind or indirect expenditures were captured. Costs were 
categorized by source of funding, type of cost input, and by activity or intervention. Benefits were 
measured as the averted costs of resurgence were estimated under a hypothetical scenario of 
resurgence, which was constructed based on historical data and expert opinion in the country. 
Under this counterfactual scenario, it was assumed that all POR activities would be halted in 2014 
resulting in an increase in malaria cases between 2015 and 2020 with a peak in 2017, mimicking the 
magnitude and trend of the malaria epidemic between 1997 and 2002, adjusted for population 
growth. The cost of resurgence was estimated as the direct and indirect cost incurred by the health 
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system to prevent and treat the increased cases as well as the direct and indirect cost incurred by 
individual households and the society.  
 
3.2.3 Study setting and sampling 
Sri Lanka is divided into nine provinces and 25 administrative districts. Five districts were 
purposively sampled in five different provinces to collect data on the cost of the malaria activities 
for POR: Hambantota (Southern Province), Ampara (Eastern Province), Anuradhapura (North 
Central Province), Puttalam (North Western Province), and Jaffna (Northern Province). The sampled 
districts represented regions where recent cases had been identified and included a range of 
previously endemic regions that used different mixes of interventions. Based on input from the 
AMC and other in-country experts, these sampled districts were deemed to be representative of 
the remaining 20 districts with respect to programmatic costs and levels of receptivity and 
vulnerability to malaria trans- mission. In addition, cost data were also collected from the AMC at 
the national level. 
 
Financial costs of malaria: The financial costs of malaria POR were obtained from the estimates of 
economic costs without accounting for capital costs or the cost of the general health system or 
personnel that are financed through integrated national and provincial health budgets not specific 
to malaria.  
 
Data collection: Data collection for this study took place between February and July 2015. Data on 
the costs of malaria POR activities for 2014 were obtained from inter- views and a review of the 
most recent budget and expenditure records. Staff at the regional malaria offices (RMOs) in each of 
the sampled districts was interviewed in a semi- structured format. The time spent on each activity 
was recorded based on self-reporting by the RMOs and other interviewees triangulated with 
interviews with the AMC director. At the central level, officers at the AMC including the AMC 
director, director of finance and accounting, surveillance, and monitoring and evaluation unit staff, 
and the Global Fund project finance manager were interviewed. 
 
Data analysis: Estimating cost of POR. Primary data on costs collected from each sample district 
and the AMC were aggregated based on three dimensions—funding source, activity or intervention, 
and input type—to identify the cost drivers for malaria POR activities. All costs were expressed in 
2013 U.S. dollars (USD), using a mid-year exchange rate of 131.5 Sri Lankan rupees per USD [3]. 
 
3.2.4 Estimating cost of resurgence 
The benefit of sustained investments in malaria and hence the corresponding cost saving from POR 
activities was obtained by estimating the cost of potential malaria resurgence. A hypothetical 
resurgence scenario was constructed based on the assumption that all POR activities would have 
been halted in 2014 resulting in an increase in malaria cases between 2015 and 2020 similar to that 
observed during the epidemic between 1997 and 2002, after adjusting for population growth. The 
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cases and deaths averted in the elimination scenario were used to calculate the cost savings or 
benefits from POR activities. 
 
3.2.5 Economic benefits estimation 
The health benefits were then monetized by looking at the averted cost to the health system, 
averted cost to individual households, and averted cost to society. 
 
1. Cost averted to the health system includes costs associated with diagnosis and treatment 
costs of IPs and Ops; 
2. Cost averted to the individual households is out-of-pocket (OOP) expenditures for seeking 
care; and  
3. Cost averted to the society includes patients’ lost productivity due to premature death and 
morbidity and caregivers’ reduced economic output. 
 
Unit costs for case management included costs for OP visits, diagnostic tests, and drug treatments 
for OP malaria cases, as well as hospital hotel costs and drug treatments for IP malaria cases. OOP 
expenditures were estimated by applying country-specific OOP expenditure per capita separately 
for OP and IP cases. Productivity losses among patients and caretakers were calculated by 
multiplying an estimate of daily productivity by the number of days lost due to illness or care 
seeking. 
 
The full-income approach was used to estimate the economic impact of lost productivity due to 
premature death from malaria. The numbers of averted deaths were multiplied by the value of 
additional life years (VLYs) and life expectancies at age 40 among males and females, which was the 
assumed average age of death due to malaria. One VLY was estimated to be 2.8 times the GDP per 
capita for Sri Lanka, as suggested by the Lancet Commission on Investing in Health [4].  
 
3.2.6 Uncertainty analysis 
To test the sensitivity of the costs to discounting, the discount rate used for capital goods was 
varied between 1% and 7% for the Sri Lanka study. In addition, to assess the robustness of our 
estimates with regard to the uncertain risk of resurgence, we conducted a sensitivity analysis by 
generating several alternative scenarios of resurgence with varying assumptions of severity and 
probability based on historical data. Following the application in the insurance industry and recent 
literature on pandemic influenza risk, we used the notion of “exceedance probability” to test 
probability of a resurgence with a certain thresh- old severity. Using historical data on malaria 
incidence, the maximum annual growth rate and the maximum total growth rate (between trough 
years) were used to vary the severity levels. Additional probabilities for the risk of resurgence were 
based on available historical data in the literature. Cohen and others [5] noted that 75 malaria 
resurgence events occurred over 70 years in 61 different countries, which translates to a 2% 
probability of resurgence. We used this as a lower bound estimate to analyze the sensitivity of the 
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ROI to varying probabilities of resurgence between 2% and 100%.  
 
The detailed methodology used to estimate costs is provided in chapter 5. 
 
3.3 Regional investment case for the Asia Pacific 
 
3.3.1 Developing a transmission model 
We used outputs from a mathematical transmission model to estimate the costs and benefits of 
malaria elimination in the Asia Pacific. The model estimated the impact of several intervention 
scenarios on the transmission of P. falciparum and P. vivax malaria from 2016 to 2030 in each of 
the 22 countries and is described elsewhere [6]. 
 
The elimination scenarios modeled were categorized into two groups: “Accelerate” includes scaling 
up existing malaria control and elimination interventions while “Innovate” explores new and 
emerging interventions (Figure 3.1).   
 
Elimination was defined as the first year in which less than one reported clinical case is achieved. 
Note that the model does not distinguish between indigenous and imported cases; hence, we 
estimated malaria elimination thresholds using a regression model of indigenous and imported 
cases from countries that have recently eliminated malaria. The scenario that allowed attainment 
of the elimination threshold was considered the elimination scenario. The scenarios used are 
described in detail in Table 3.1. The outputs of averted mortality and morbidity under the 
elimination scenarios were then used to estimate the cost, benefits, and return on investment 
(ROI). 
 
Counterfactual scenarios 
Two scenarios were used as the counterfactuals to malaria elimination: business as usual and 
reverse scenarios (see “Reverse” and “Continue” in Figure 3.1). 
 
• Business as usual 
This scenario projects the malaria burden in 2016-2030 based on continuing the mix and scale 
of malaria interventions implemented in 2015. 
• Reverse scenario 
This scenario projects the malaria burden in 2016-2030 assuming that LLIN distribution ceases 
and treatment rates fall by 50% 
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Figure 3.1. Scenarios used in the transmission model 
 
 
 
 
3.3.2 Cost projections for Asia Pacific 
A cost estimation model aligned with the outputs of the transmission model was developed to 
estimate the total costs associated with implementing each of the scenarios above. Program costs 
included the costs of testing and treating uncomplicated or outpatient (OP) and severe or inpatient 
(IP) malaria cases; vector control (i.e., LLIN distribution and IRS); supply chains; surveillance through 
community health workers; information, education, communication; training; MDA; new 
treatments (e.g., tafenoquine for P. vivax); and rollout of new LLINs. Unit costs for each activity 
were obtained using a combination of empirical data collected in various Asia Pacific countries by 
the MEI, literature reviews, and proxies when the previous options were unavailable. 
 
The total cost of the elimination scenarios was used to in this investment case. The costs to reach 
elimination were calculated separately for each country and then summed them to obtain the total 
cost for elimination in the Asia Pacific region. To calculate the incremental or additional costs of 
malaria elimination, the estimated costs of the business as usual and reverse scenarios were 
subtracted from the elimination scenario. All monetary figures are expressed in 2015 constant USD. 
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Table 3.1. Modeled scenarios 
 
 Scenario Description 
1 Business as usual Continue all interventions at 2014 levels from 2016 
through 2030 
2 Reverse scenario 1 • Business as usual 
• IRS activities ceased 
3 Reverse scenario 2 • Reverse scenario 1 
• Distribution of new LLINs ceased 
4 Reverse scenario 3 • Reverse scenario 2 
• Treatment rates reduced by 50% 
5 Universal coverage • Business as usual 
• Coverage test and treat increased from 2017 
onwards in a linear fashion over eight years to 
80% by 2025 
• Quinine is switched to injectable artesunate 
for management of severe disease in 2017 
6 IRS • Universal coverage 
• IRS coverage in 2017 doubled in a linear 
fashion over eight years 
7 Effective usage • Universal coverage 
• Effectiveness of LLINs increased 
• Surveillance increased 
8 New P. vivax treatment • Effective usage 
• Replace primaquine with a new P. vivax 
treatment 
9 New LLINs • New P. vivax treatment 
• Life of LLINs doubled 
10 New P. falciparum treatment • New LLINs 
• First-line ACT replaced with new candidate for 
P. falciparum treatment 
 Assumption Description 
A Artemisinin resistance 5% probability of treatment failure from ACTs 
across all countries is constant until 2018 and then 
increased to 30% through 2025 
B MDA Five annual rounds of MDA at 50% coverage from 
2018 starting four months before the peak of the 
transmission season 
C LLINs Scaling up LLINs to 80% effective coverage 
deployed in a 3-year cycle (50%, 25% and 25%) 
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3.3.3 Economic benefits estimation 
Using outputs from the model for the Asia Pacific, the estimated the mortality and morbidity 
averted from malaria elimination was estimated by subtracting the estimated cases and deaths of 
the elimination scenario from the corresponding outputs of the business as usual and reverse 
scenarios. 
 
For the Sri Lanka benefits estimation, the cases and deaths averted in the elimination scenario were 
used to calculate the cost savings from POR. 
 
The health benefits were then monetized by looking at the averted cost to the health system, 
averted cost to individual households, and averted cost to society. 
 
• Cost averted to the health system includes costs associated with diagnosis and treatment 
costs of IPs and Ops; 
• Cost averted to the individual households is out-of-pocket (OOP) expenditures for seeking 
care; and  
• Cost averted to the society includes patients’ lost productivity due to premature death and 
morbidity and caregivers’ reduced economic output. 
 
The same cost inputs used in the cost estimation were used for calculating the economic benefits. 
Unit costs for case management included costs for OP visits, diagnostic tests, and drug treatments 
for OP malaria cases, as well as hospital hotel costs and drug treatments for IP malaria cases. OOP 
expenditures were estimated by applying country-specific OOP expenditure per capita separately 
for OP and IP cases. Productivity losses among patients and caretakers were calculated by 
multiplying an estimate of daily productivity by the number of days lost due to illness or care 
seeking.  
 
The full-income approach was used to estimate the economic impact of lost productivity due to 
premature death from malaria. The number of deaths averted, were multiplied by the country-
specific values of additional life years (VLYs) and life expectancies at age 40 among males and 
females, which was the assumed average age of death due to malaria. One VLY was estimated to be 
2.2 times the GDP per capita for each of the countries in South East Asia and the Pacific and 2.8 
times the GDP per capita for each of the countries in South Asia, as suggested by the Lancet 
Commission on Investing in Health [4].  
 
All costs and economic benefits were discounted at 3%. 
 
3.3.4 Return on investment  
The Return on Investment (ROI) was calculated by subtracting the incremental cost of elimination 
from the economic benefits, and dividing the resulting figure by the incremental cost of 
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elimination. The ROI is interpreted as the economic return from every additional dollar spent on 
malaria elimination and prevention of reintroduction. 
 
For the Asia Pacific investment case, we performed the ROI analysis for 2016-2030 by comparing 
the elimination scenario with the business as usual and reverse scenarios under the stable and 
increasing resistance assumptions.  
 
3.3.5. Uncertainty analysis 
For the Asia Pacific costing, to assess the robustness of our estimates with regard to the uncertain 
risk of resurgence, we conducted a sensitivity analysis by generating several alternative scenarios of 
resurgence with varying assumptions of severity and probability based on historical data. We 
performed stochastic sensitivity analysis on the epidemiological and cost outputs of the malaria 
transmission model. The minimum, median, and maximum malaria cases and deaths predicted by 
the model for each scenario were used to calculate the minimum, median, and maximum economic 
benefits. For the costs, we assigned an uncertainty interval of +/-25% on the value of the input 
costs used. Three hundred random samples were drawn, which generated a range of costs. From 
the range of costs generated, we determined the minimum, maximum, median, mean, and other 
measures (e.g., percentiles). 
 
3.4 Finance Tracking 
 
Building on the Institute for Health Metrics and Evaluation’s annual Financing Global Health 
research, data were collected from primary agencies and organizations that channel DAH or third 
party organizations or private organizations that collect such data [REF] and split into categories 
identifying the type of investment. The Organization for Economic Cooperation’s (OECD) Creditor 
Reporting System (CRS) database was used to collect information on financing channeled through 
bilateral agencies and budget data from the Global Fund malaria grants were extracted by service 
delivery areas [7]. A diverse set of data points and reports were used to estimate the share of 
domestic government health budgets spent on malaria from 2000 through 2014 including the 
World Malaria Report (WMR). To track development assistance and government financing for 
health financing flows for malaria elimination were collected from various sources from 1990 
through 2013. 
 
3.4.1 The 35 Malaria Eliminating Countries 
Of the approximate 100 countries with endemic malaria, 35 have been identified as malaria-
eliminating defined here as a country that has a national or subnational evidence-based elimination 
goal and/or is actively pursuing elimination (zero malaria transmission) within its borders (Fig 3.2) 
[4,5]. 
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Fig. 3.2. List of malaria eliminating countries included in this analysis 
Asia Pacific 
• Bhutan 
• China 
• Democratic People's Republic of Korea 
• Malaysia 
• Nepal 
• Philippines 
• Republic of Korea (ROK) 
• Solomon Islands 
• Sri Lanka 
• Thailand 
• Vanuatu 
• Vietnam 
 
North Africa, Europe, Middle East, Central 
Asia 
• Algeria 
• Azerbaijan 
• Iran 
• Saudi Arabia  
• Tajikistan 
• Turkey 
Latin America and Caribbean 
• Belize 
• Costa Rica 
• Dominican Republic 
• El Salvador 
• Guatemala 
• Honduras 
• Mexico 
• Nicaragua 
• Panama 
• Paraguay 
 
Sub-Saharan Africa 
• Botswana 
• Cape Verde 
• Mayotte* 
• Namibia 
• São Tomé and Príncipe 
• South Africa 
• Swaziland 
*No data available 
 
3.5 Global Fund financing to the malaria-eliminating countries under the new funding model 
 
This analysis was conducted on nineteen of the eliminating countries that were eligible for an 
allocation. Five countries were not eligible for national malaria grants, but were expected to receive 
funds through regional grants: Belize, Costa Rica, Dominican Republic, Panama, and South Africa. 
 
Publicly available GFATM grant data [8, 9] was collated in Microsoft Excel 2010. The average annual 
funding from the old funding model was calculated using the total disbursed amounts from each 
country’s most recent active malaria grant(s) averaged over the respective grant start date through 
to December 2013, the Global Fund specified cut-off date for the round based system. Disbursed 
amounts rather than the signed amounts in grant agreements were used in order to avoid “double 
counting” of money not yet disbursed that will later be incorporated into the national allocation. 
Regional grant amounts were excluded from this portion of the analysis and analyzed separately. 
Average annual grant amounts disbursed under the old funding model were compared to average 
annual national allocated amounts under the NFM to determine the percent change between old 
and new average annual funding.  
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3.5.1 Regional grants  
Funding channeled to malaria-eliminating countries through the E8, EMMIE, and RAI GF regional 
malaria grants was included. While the RAI grant has a predetermined country-level breakdown of 
funding, country shares for EMMIE and E8 was assumed to be divided equally among the countries 
involved. For eliminating countries included in a regional grant, the country share of regional grant 
funding was added to the national allocations and a new percent change of funding from the 
previous funding model compared to the NFM was calculated. 
 
3.5.2 Funding ranges under new allocation model 
The minimum and maximum funding range that each country could receive was estimated to 
include potential variations in allocation should a country not meet their willingness to pay criteria 
and to account for any changes in national disease split, incentive funding or other qualitative 
adjustments that may be applied. The minimum and maximum amounts were averaged over the 4-
year period (2014–2017) and compared to the average annual disbursements under the previous 
funding model to determine the range of percent change in funding for eligible countries. More 
details are available in Chapter 8. 
 
3.5.3 Ethical clearance 
The Sri Lanka costing study was approved by the institutional review boards of the University of 
California, San Francisco Committee on Human Research (Study no. 14-14546, Reference no. 
093635) and the Ethics Review Committee of the Faculty of Medicine, University of Kelaniya, Sri 
Lanka (Reference no. P/209/10/2014). Verbal informed consent procedures were conducted before 
each interview. Ethical clearance was not needed for the other studies. 
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4.1 Abstract 
 
Background: Declining donor funding and competing health priorities threaten the sustainability of 
malaria programmes. Elucidating the cost and benefits of continued investments in malaria could 
encourage sustained political and financial commitments. The evidence, although available, 
remains disparate. This paper reviews the existing literature on the economic and financial cost and 
return of malaria control, elimination and eradication. 
 
Methods:  A review of articles that were published on or before September 2014 on the cost and 
benefits of malaria control and elimination was performed. Studies were classified based on their 
scope and were analysed according to two major categories: cost of malaria control and elimination 
to a health system, and cost-benefit studies. Only studies involving more than two control or 
elimination interventions were included. Outcomes of interest were total programmatic cost, cost 
per capita, and benefit-cost ratios (BCRs). All costs were converted to 2013 USD for standardization. 
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Results: Of the 6425 articles identified, 54 studies were included in this review. Twenty-two were 
focused on elimination or eradication while 32 focused on intensive control. Forty-eight per cent of 
studies included in this review were published on or after 2000. Overall, the annual per capita cost 
of malaria control to a health system ranged from USD 0.11 to USD 39.06 (median: USD 2.21) while 
that for malaria elimination ranged from USD 0.18 to USD 27 (median: USD 3.00). BCRs of investing 
in malaria control and elimination ranged from 2.4 to over 145. 
 
Conclusion: Overall, investments needed for malaria control and elimination varied greatly 
amongst the various countries and contexts. While the cost of elimination in most cases was 
greater than the cost of control, the benefits greatly outweighed the cost. Information from this 
review provides guidance to national malaria programmes on the cost and benefits of malaria 
elimination in the absence of data. Importantly, the review highlights the need for more robust 
economic analyses using standard inputs and methods to strengthen the evidence needed for 
sustained financing for malaria elimination. 
 
4.2 Background 
 
In the past decade and a half, remarkable progress in malaria control has been achieved with a 37% 
decline in malaria incidence and 60% reduction in malaria deaths globally [1]. Almost half of the 
world’s nations are now malaria free [2] and several countries have reduced malaria transmission 
to levels low enough to allow them to embark on, and in many cases achieve, elimination [3]. 
 
Despite international consensus that malaria elimination leading to global eradication is a 
worthwhile goal [2], sustaining domestic and international funding as the malaria burden declines is 
a serious concern for many countries. External aid is on the decline [4] and multilateral and bilateral 
donor funds are increasingly shifting away from disease-specific financing or being targeted 
towards low-income, high-burden countries. At the same time, domestically there is mounting 
competition for limited resources from other pressing disease priorities. 
 
There is little disagreement that elimination is an attractive investment in the long term due to its 
ability to pay for itself through future reductions in spending and its generation of broader 
economic benefits. The contribution of malaria elimination to colossal health and development 
returns of global eradication is also implicitly recognized [5, 6]. Notwithstanding, malaria 
elimination requires additional front-loading of investments into robust surveillance systems to 
detect and respond to remaining cases. While socio-economic and other structural changes will 
eventually change the intrinsic baseline potential for transmission in countries such that active 
measures are no longer required [7], the decision facing policymakers is how to best allocate finite 
resources in the short term. Countries who have successfully lowered their malaria burden are 
faced with the risk of losing or severely reducing their recurrent expenditure for elimination and 
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preventing the re-introduction of malaria at a critical period in the malaria elimination eﬀorts [8]. 
At the same time, they face the risk of resurgence due to the persistent importation of new cases 
which will not only have devastating eﬀects on the health and welfare of individuals, but will also 
place an additional economic burden on the health system. A review on malaria resurgence 
occurring from the 1930s through to the 2000s demonstrated that almost all resurgence events 
could be attributed, at least in part, to the weakening of malaria control programmes for a variety 
of reasons, of which resource constraints were the most common [9]. In addition, lessons learned 
from the Global Malaria Eradication Programme (GMEP), which ended in 1969, aﬃrm that while 
well-funded interventions can have a major impact on the disease, such gains are fragile and can 
easily be reversed particularly in the short term in areas that continue to be epidemiologically and 
entomologically receptive and vulnerable. 
 
The economic impact of malaria has been studied for well over a century. The numbers of such 
studies have escalated since the conclusion of the GMEP in the late 1960s and more so starting 
early 2000. Many of these studies have reported data on the economic burden of malaria and the 
cost of malaria programmes. However, evidence on the economics of malaria elimination remains 
disparate without a comprehensive synthesis of the marginal costs of elimination that can be used 
by policymakers for decision-making. Policymakers need to know how much it costs to achieve 
reductions in malaria burden and elimination, whether the cost savings of elimination will oﬀset the 
initial investment given that elimination requires, to avert the last few cases, and what are the 
financial returns of elimination versus maintaining the status quo. 
 
Economic methods such as cost-eﬀectiveness analysis (CEA) and cost-benefit analysis (CBA) have 
commonly been used to assess the comparative value of investing in malaria control interventions. 
CEA, which calculates the amount of funding an intervention needs to prevent loss of a standard 
unit of disease burden, is the most commonly used approach to compare the economic 
attractiveness of health programmes. In an elimination context, CEA is relevant for identifying the 
optimum mix of interventions needed to sustain elimination. However, it does not help drive 
decisions on the economic appeal of malaria elimination as a whole [10]. In addition, as the burden 
of malaria diminishes, elimination interventions become less cost-eﬀective because the 
incremental health gains are significantly smaller compared to programme costs. Furthermore, 
malaria transmission becomes increasingly concentrated in small geographic areas that are often 
diﬃcult, and more expensive to reach such that a simple cost-eﬀectiveness ratio (CER) is unlikely to 
be favourable [11]. When evaluated as a CER, the health and economic gains associated with 
elimination may already be captured by control [12]. Lastly, CERs may not fully capture all the 
benefits and positive externalities that malaria elimination and prevention of re-introduction (POR) 
may bring, particularly when considering the cost of malaria resurgence [9, 13]. 
 
To generate results most relevant to policy, malaria elimination requires a comparison of cost with 
a counterfactual scenario of malaria control to reflect programmatic realities. In practice, most 
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economic analyses in malaria use a loosely defined status quo, which varies substantially but is 
most often that of partial control. WHO recommends a null state of disease without intervention as 
the counterfactual scenario. Used in several analyses, this alternative is neither pragmatic nor 
sustainable but can provide information to understand the benefits of continued investment in 
malaria when the disease is greatly reduced or absent. Others have recommended the use of 
controlled low-endemic malaria as the most policy-relevant alternative for economic analyses of 
elimination [13]. However, the threats of drug and insecticide resistance and the instability of 
international financing mean that malaria control may not be sustained in the long term. In 
addition, elimination delivers additional indirect benefits outside of health. As a country 
approaches and reaches elimination, other countries benefit from reduced importation of malaria 
conferring positive externalities to neighbouring countries as well. A comprehensive CBA enables 
these broader benefits to be translated into a common metric and is therefore a more eﬀective 
means to inform strategic decisions. 
 
The aim of this paper is to review the existing literature and evidence on the costs and benefits of 
malaria elimination. Specifically, this paper presents a comprehensive review of literature on the 
cost of malaria control as well as those of achieving and of sustaining elimination and the benefits 
generated by malaria elimination compared to the cost of malaria control. The review intends to 
elicit evidence along the various phases of the programme: control, elimination and POR [14]. 
 
4.3 Methods 
 
4.3.1 Search strategy 
Following PRISMA guidelines [15], a systematic search of peer-reviewed literature in English, French 
and Spanish, pertaining to economics of malaria, published on or before September 2014 was 
conducted. Databases searched were MEDLINE via PubMed, SCOPUS and Google Scholar using 
MeSH terms as well as other keywords. The term ‘malaria’ was combined with ‘elimination’ and 
‘eradication’ and the following search terms: ‘economics’, ‘cost’, ‘cost analysis’, ‘cost allocation’, 
‘cost apportionment’, ‘cost control’, ‘cost of illness’, ‘employer health costs’, ‘hospital costs’, 
‘health care costs’, ‘drug costs’, ‘direct service costs’, ‘health expenditures’, ‘financing’, and ‘cost-
benefit analysis’. A detailed list of search terms and corresponding results are available upon 
request. 
 
Two independent database searches were carried out to ensure an exhaustive search of the 
literature. AA, who conducted the literature search, was blinded to the initial search strategy but 
used the same databases and publication timeframe. The two lists of papers were subsequently 
merged and duplicates were removed. Reference lists of papers that met the inclusion criteria were 
also screened and included 13 additional articles that were deemed relevant. 
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4.3.2 Article screening and selection 
Titles and abstracts of all initial search results were reviewed for relevance, and those that included 
some form of economic analysis were assessed further for eligibility. Articles that did not have 
abstracts available online but were thought to be relevant based on their titles alone were included 
in the full-text assessment. Articles were excluded during full-text assessment if they did not meet 
the inclusion criteria or if their full-text versions could not be located after multiple attempts. In 
case of a disagreement during article selection, inclusion and exclusion, data extraction, article 
categorization and quality appraisal, the authors discussed each case separately until a consensus 
was reached. 
 
4.3.3 Inclusion criteria 
Articles were included if they: (a) evaluated at least three interventions, suggesting intensive 
control or elimination rather than individual or limited interventions; (b) presented final costs and 
benefits in economic or monetary terms; and, (c) provided a clear description of data sources and 
methodology. Micro-economic studies that assessed the cost of delivering malaria interventions to 
the health system were included and economic evaluations that included cost-benefit type analyses 
on malaria interventions were also included. 
 
4.3.4 Exclusion criteria 
Studies that used preference approaches (e.g., willingness to pay) for valuing costs and benefits 
were excluded as a way to limit the analysis to studies that used empirical or secondary cost data 
rather than elicitation methods. Papers that only presented descriptive statistics or reiterated 
findings from other studies already included in the review were also excluded. However, any review 
papers that either conducted any primary analysis on scientific literature were included [10, 16]. 
 
4.3.5 Data abstraction, standardization and qualitative synthesis  
A standard Microsoft Excel® template was used to abstract detailed information about each study’s 
publication year, study setting, study period, sources of data, and the outcomes of interest. 
Monetary data were first adjusted to USD in the year of the initial study (if the authors had not 
already done so) using historical exchange rates provided in the article. If the article did not provide 
exchange rates, historical exchange rates were obtained from the World Bank oﬃcial exchange rate 
database for year 1981 onwards [17] and other online sources such as OANDA [18]. For studies 
where the currency year was not provided, the publication date or date of article submission was 
used for the currency conversion. All monetary data were standardized to 2013 USD using 
consumer price index conversion factors published by Oregon State University, USA [19]. 
 
Studies that assessed health system costs of malaria control and elimination were abstracted for 
total costs, cost per population at risk (PAR), and cost per capita. When total costs only were 
provided, the annual cost per capita was calculated by dividing the annual aggregate or total cost 
by either the PAR or total population numbers reported in the articles or their supplements 
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published online. Similarly, the authors attempted to convert other averaged costs (e.g., cost per 
person protected, cost per suspected case, cost per case treated) into cost per capita whenever 
possible to help account for diﬀerences in intended programme coverage. It is important to note, 
however, that a standardized way to measure or calculate PAR does not exist [20–22] making 
comparisons among such reported costs potentially problematic. 
 
For CBAs, net benefits (also referred to as net present value or net social benefit) and benefit-cost 
ratios (BCRs) were extracted. If net benefits or BCRs were not calculated in the original study, they 
were computed based on total benefits and total costs reported in the study whenever possible to 
facilitate comparisons among CBA. 
 
4.3.6 Quality assessment and critical appraisal 
The quality of the included studies was assessed using two checklists published in the literature. For 
CBAs, the ten-point Drummond checklist first developed by Drummond and colleagues in 1997 [23, 
24] was adapted. Each study was assigned a total score equal to the number of ‘yes’ ratings it 
received out of ten questions in the checklist. For cost analysis studies, the two-point evaluation 
criteria developed by Fukuda and Imanaka was adapted to assess the quality and transparency of 
costing exercises [25]. The Fukuda and Imanaka criteria evaluated each costing study based on its 
clarity of scope and accuracy of costing methodology, with activity-based micro costing getting the 
highest score. 
 
4.4 Results 
 
4.4.1 Literature search 
A total of 6425 articles were identified through database searches. After removal of duplicates, 
5505 titles and abstracts were initially screened, and 390 full-text articles were reviewed further for 
eligibility. After reviewing full text articles, 40 from the database searches and 14 from citation 
snowballing were included in the final qualitative analysis (Fig. 4.1). Most of the studies conducted 
more than one type of economic analysis and therefore are not classified into mutually exclusive 
categories. 
 
Of the 54 articles in this review, 22 were focused on elimination while the remaining 32 were on 
intensive control. Fifty-three studies estimated the programmatic costs of malaria control and 
elimination, and ten studies estimated both costs and benefits (Table 4.1). 
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Figure 4.1. PRISMA diagram 
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Table 4.1. Summary of included articles 
 
Total number of studies included in qualitative review 54 
Number of studies with more than one economic outcome reported 9 
Type of study Total number Percent (%) 
Cost to health systems 53 98.1 
Cost-benefit analyses 10 18.5 
Focus of study Total number Percent (%) 
Elimination 22 40.7 
Control 32 59.3 
Publication date Total number Percent (%) 
On or after 2000 26 48.1 
Before 2000 28 51.9 
 
4.4.2 Cost to the health system 
Among the 53 studies that reported the cost of malaria on health systems, 32 were on the cost of 
control (Table 4.2; Table S4.1) and 21 on elimination and eradication (Table 4.3; Table S4.1). These 
studies reported direct costs associated with an entire malaria programme or a set of control and 
elimination interventions. The earliest study was published in 1903, with about 47% of studies 
being published on or after 2000. Seven studies looked at the costs of malaria control and 
elimination during the GMEP era (1955–1969). More than half (27) of the studies were on Asian 
countries, such as India, Sri Lanka and Thailand, and a number of states in western Asia. Eight 
studies were in African countries, while another 12 had a global, regional or multi-country focus. 
Five studies were in South American countries and only one was in Europe. Overall, programmatic 
costs varied immensely from a few hundred dollars to a several hundred million, owing to 
heterogeneity in study setting or geographic reach, study period, mix and scale of interventions, 
and costing methodology, among others. Tables 4.2 and 4.3 summarize the findings by country, 
region, focus (malaria control and elimination), and study period. 
 
Table 4.2. Cost of malaria control to the health system 
 
Country or 
region 
Study period Cost per capita 
(2013 USD)a 
Cost per PAR (2013 USD) Source 
Global 2006-2015 2.50 Not provided [25] 
2003-2009 Not provided 1.42-11.13 [26] 
2002-2007 Not provided 0.47-0.80 [27] 
Africa 
Ethiopia 2011-2015 1.67 2.94 [28] 
Kenya 1990 0.28 Not provided [29] 
Liberia 1953-1961 31.25-39.06 Not provided [30] 
Mauritius 10-year time horizon 2.37 2.37 [13] 
Rwanda 2011-2015 4.76 6.64 [28] 
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Country or 
region 
Study period Cost per capita 
(2013 USD)a 
Cost per PAR (2013 USD) Source 
Senegal 2011-2015 4.26 4.26 [28] 
Sub-Saharan 
Africa 
2003 1.21-2.22 1.76-2.61 [31] 
2006-2015 3.47 4.65 [32] 
Swaziland 10-year time horizon 0.94 4.88 [13] 
Tanzania 2011-2015 2.14-2.21 2.14-2.21 [28] 
10-year time horizon 3.26 3.26 [13] 
2011-2015 2.87 2.87 [28] 
Zambia 1929-1949 11.86 Not provided [33] 
Americas 
Brazil 1989-1996 2.15 6.60 [34] 
Colombia 1993-1998 0.54-3.48 Not provided [35] 
Asia 
Afghanistan 1953 1.34 Not provided [36] 
Bangladesh 
 
2008-2012 Not provided 0.40 [37] 
1990 Not provided 0.02 [38] 
China 10-year time horizon 0.12-0.21 0.16-0.22 [13] 
India 1953 0.30 Not provided [36] 
1990 Not provided 0.12 [38] 
1953-1977 0.36 Not provided  [39] 
1989 9.39  Not provided  [40] 
Indonesia 1990 Not provided 2.16 [38] 
Nepal 1990 Not provided 0.52 [38] 
Unspecified 0.11-1.21 Not provided [41] 
1984-1985 0.45-1.36 Not provided [42] 
Palestine 1921-1922 19-32 Not provided [43] 
Sri Lanka 2009 Not provided 1.95 [44] 
2004 Not provided 0.87-2.06 [44] 
1994-1995 Not provided 0.36-4.26 per person protectedc [45] 
1977-1981 1.71  Not provided [46] 
1953 0.80 Not provided [36] 
1934-1955 0.63-5.22 Not provided [47] 
Thailand 1995 Not provided 12.94-15.40 per caseb [48] 
1990 Not provided 1.59 [38] 
a Unless otherwise stated, the costs reported here are costs per capita, computed by dividing total program costs by the 
total population in the area of implementation. 
b These costs represent the costs for detecting and treating cases and may not include prevention costs. 
c These costs reflect the cost of selected interventions and not the entire program. 
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Table 4.3. Cost of malaria elimination to the health system 
 
Country or 
region 
Study period Cost per capita 
(2013 USD)a 
Cost per PAR (2013 USD) Source 
Africa 
Mauritius 10-year time horizon 4.63 4.63 [13] 
1955-2008 3.03-6.22 Not provided [49] 
São Tomé and 
Principe 
2007 (modeled over 20 
years) 
12 Not provided [50] 
Swaziland 2007 (modeled over 20 
years) 
3.00 Not provided [50] 
10-year time horizon 2.65 13.77 [13] 
Tanzania 10-year time horizon 4.22 4.22 [13] 
Americas 
Mexico 1971-1976 0.18 Not provided [51] 
1970 0.54 Not provided [52] 
Asia 
China 1994-1995 1.23 per 
suspected caseb 
0.05 [53] 
2007 (modeled over 20 
years) 
0.27 2 [50] 
2007 (modeled over 20 
years) 
0.27 2.17 [54] 
10-year time horizon 0.23-0.54 0.30-0.55 [13] 
India Unspecified  Not provided 0.58 per person protected  [10] 
Indonesia Unspecified Not provided  0.97 per person protected  [10] 
Iran Unspecified 20.95 Not provided [55] 
Iraq 1964-1970 2.96 Not provided [56] 
Jordan 1964-1970 0.95 Not provided [56] 
Lebanon 1964-1970 1.68 Not provided [56] 
Philippines 1998-2010 Not provided 0.67-13.08 [57] 
Solomon 
Islands 
2008 1.60 Not provided [58] 
2007 (modeled over 20 
years) 
20 Not provided [50] 
Sri Lanka 2007 (modeled over 20 
years) 
1.00 Not provided [50] 
Unspecified Not provided 0.86 per person protectedc [10] 
Syria 1964-1970 0.73 Not provided [56] 
Taiwan Unspecified  Not provided 0.52 per person protectedc [10] 
1952-1957 15.06 Not provided [59] 
Thailand Unspecified Not provided 1.54 per person protectedc [10] 
Vanuatu 2008 3.34 Not provided [58] 
2007 (modeled over 20 27 Not provided [50] 
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Country or 
region 
Study period Cost per capita 
(2013 USD)a 
Cost per PAR (2013 USD) Source 
years) 
1991 18.44  Not provided [60] 
a Unless otherwise stated, the costs reported here are costs per capita, computed by dividing total program 
costs by the total population in the area of implementation. 
b These costs represent the costs for detecting and treating cases and may not include prevention costs. 
c These costs reflect the cost of selected interventions and not the entire program. 
 
4.4.3 Health system costs of malaria control 
Of the 32 studies on costs of malaria control, only 24 (45%) used empirical data such as public and 
private expenditure reports or survey data. Eight studies used historical expenditures and budgets 
to extrapolate the costs of intensive control in Africa [29, 32, 33, 61], India [62], Thailand [48], 
Nepal [41], and globally using varying time periods [63]. 
 
The median annual cost per capita for malaria control across all studies was USD 2.21 (range USD 
0.11–USD 234.17). Sabot et al. (China), Some et al. (Kenya), Ramaiah (India), and Haque et al. 
(Bangladesh) reported some of the lowest per capita costs at USD 0.12–USD 0.21, USD 0.28, USD 
0.36, and USD 0.40, respectively (Table 2; Fig. 2) [13, 30, 37, 39]. Two studies by Mills showed 
comparatively low per capita costs for malaria control in Nepal across several districts, ranging USD 
0.11–USD 1.36 [41, 42]. Control costs ranged from USD 0.11 in Nepal [38] to USD 9.39 in India [40], 
USD 32 in Palestine [43] to USD 39.06 in Liberia [31]. In Nepal and India, the costs included 
interventions such as testing and treatment, indoor residual spraying (IRS), and bed nets, while in 
Palestine and Liberia they included community education, environmental management and 
chemoprophylaxis. Costs also varied within countries over time, partly due to the mix of 
interventions that were included in the costing. For example, in India, control costs were reported 
at USD 0.36–USD 0.58 during the GMEP era. Costs were generally lower in Asia compared to Africa. 
 
In a subset of 13 studies conducted after 2000, of which only ten were conducted in Africa, control 
costs ranged from USD 0.94 in Swaziland and USD 4.75 per capita in Rwanda (median USD 2.30 per 
capita). In Asia costs ranged from 0.40 per capita in Bangladesh and USD 2.06 per capita in Sri Lanka 
(median USD 0.64). Most of these studies did not use the full package of WHO recommendations 
for malaria control at scale. None of the studies in the Americas has been conducted since 2000. 
Stuckey et al. [61] modeled the cost of implementing distribution of long-lasting insecticidal nets 
(LLINs), IRS, and intermittent screening and treatment among school children twice per year at 80–
90% coverage in Nyanza Province of western Kenya at USD 179.50–USD 234.17 annually per capita. 
However, these costs were based on modeled coverage of interventions rather than actual scales. 
 
With respect to cost per PAR, the overall median cost per PAR for malaria control, across all studies 
was USD 2.15 (range USD 0.02–USD 11.13). Kondrashin reported the lowest cost per PAR at USD 
0.02 in Bangladesh, followed by USD 0.12 in India and USD 0.52 in Nepal (Fig. 2) [38]. Snow et al. 
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[28] also reported low cost per PAR (USD 0.47–USD 0.80) for Plasmodium falciparum infections 
across 87 countries. These two studies used aggregated budget data from WHO, Global Fund and 
the World Bank. Only two studies that used empirical data reported cost per PAR, which ranged 
from USD 0.87 to USD 1.95 in Sri Lanka [44] and USD 6.64 in Rwanda [29]. 
 
Fig. 4.2. Cost per capita and cost per population at risk of malaria control. 
 
 AFG Afghanistan, BDG Bangladesh, BRA Brazil, CHN China, COL Columbia, ETH Ethiopia, IND India, IDN Indonesia, KEN 
Kenya, LBR Liberia, MUS Mauritius, NPL Nepal, PSE Palestine, RWA Rwanda, SEN Senegal, LKA Sri Lanka, sSA Sub-Saharan 
Africa, SWZ Swaziland, TZA Tanzania, THA Thailand, ZMB Zambia  
 
4.4.4 Health system costs of malaria elimination 
Analyses of actual expenditures for programmes that have recently or are currently eliminating 
malaria have been conducted in only a few selected places, primarily in Asia and Africa with some 
work in South America and Europe (Table 4.2; Table S4.1). Of the 21 studies on costs of malaria 
elimination with known data sources, only 11 used empirical data. Eight of the 21 studies looked at 
the prospective costs of elimination and eradication while the rest used retrospective costs. 
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Total programmatic costs of malaria elimination ranged from USD 10,472 in Iran per 500 population 
(or USD 20.95 per capita) [55] to USD 27 million per year in South Africa [64] (or USD 0.52 per 
capita) (Table S1). The median annual cost per capita for malaria elimination across all studies was 
USD 3.00 (range USD 0.10–USD 20.95) In Iran the assumptions for each type of intervention 
included were not uniform. Larviciding and IRS were implemented annually, however it is unclear if 
the costs for insecticide treated nets (ITNs) and treatment were yearly. In terms of cost per capita, 
the range of reported costs was USD 0.18 in Mexico in 1971 [51] to USD 0.27 in China [65], USD 
15.06 in Taiwan [59], USD 20.95 in Iran [66], and USD 27 in Vanuatu [50] (Table 2; Fig. 3). A study in 
the Aneityum Island of Vanuatu reported the second highest cost per capita at USD 18.44 [60]. This 
1991 campaign included weekly mass drug administration (MDA), ITN distribution, and the use of 
larvivorous fish in breeding sites and was successful in ending local transmission. Barring a few 
exceptions, reported elimination costs per capita were generally lowest in the Asian countries (i.e., 
China [13, 50, 53, 54], India [10], Indonesia [10], Philippines [57], Taiwan [10], Thailand [10], Sri 
Lanka [50], and Vanuatu [58]) and Mexico [51, 52]. Costs were generally highest in African nations, 
such as Mauritius [49], São Tomé and Principe [50], Swaziland [13, 50], and Tanzania (Zanzibar) 
[13]. 
 
Assessing a sub-set of 12 studies carried out after 2000, five were carried out in Africa, eight in Asia 
including one carried out in the Philippines between 1998 and 2010 and six with unspecified dates. 
In the eight studies carried out in the Asia Pacific, costs ranged from USD 0.27 per capita in China to 
USD 27 in Vanuatu (median USD 1.30). Elimination costs were higher in Africa, with costs ranged 
from USD 2.65 in Swaziland to USD 4.22 in Tanzania and USD 12 in Sao Tome (median USD 4.22 per 
capita). 
 
In terms of cost per PAR, elimination in China has the lowest average annual cost of USD 0.05 [53] 
(Table 4.2; Fig. 4.3). Similarly, modeled costs per PAR for elimination in China were USD 0.30 in 
Jiangsu and USD 0.50 in Hainan, while POR is estimated to be USD 0.13 per PAR in both provinces 
[13]. Other countries report much higher cost per PAR. For example, the cost of Mauritius’s second 
elimination campaign in 1975–1990 was approximately USD 4.63  per PAR per year, even though 
several economic costs and contributions by external partners were not included [9, 49]. Costs per 
PAR in diﬀerent provinces in the Philippines ranged from USD 2.77 to USD 4.33 (excluding outbreak 
years) [57]. Four countries in the Middle East reported similar costs per PAR in 1970 ranging from 
USD 0.73 to USD 2.96 [56]. 
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Fig. 4.3. Cost per capita and cost per population at risk of malaria elimination. 
 
CHN China, IRN Iran, IRQ Iraq, JOR Jordan, LBN Lebanon, MUS Mauritius, MEX Mexico, NPL Nepal, PHL Philippines, STP 
São Tomé and Principe, SLB Solomon Islands, LKR Sri Lanka, SWZ Swaziland, SYR Syria, TWN Taiwan, TZA Tanzania, VUT 
Vanuatu  
 
4.4.5 Economic benefits 
Several studies explored the other economic benefits of investing in malaria control and elimination 
without a cost component. Two studies found that a reduction in malaria burden was associated 
with increased household spending in India [67] and increased household consumption in Vietnam 
[68]. In the USA and Latin American countries, exposure to malaria elimination programmes was 
associated with less work disability [69] and higher incomes [70] in adulthood. In a widely cited 
study, Gallup et al. [71] found that a 10% reduction in malaria burden was associated with as much 
as 0.3% in gross domestic product (GDP) growth. Finally, Hong found that between 1850 and 1860 
in the USA, people who migrated from one area to another place with less malaria accumulated 
greater real estate wealth compared to those who relocated to a more malarious area [72]. 
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4.4.6 Cost-benefit analyses 
Of the ten CBAs identified (Table 4.4; Table S4.2), three were conducted during the GMEP era [39, 
73, 74] and five were on malaria elimination. Eight were original studies while two articles were 
reviews with overlapping studies included [10, 16] and only two used empirical data [39, 74]. The 
main type of economic benefit identified in the studies was increased labour productivity due to 
reductions in morbidity and absenteeism. Other benefits included reductions in treatment costs 
and gains from the migration of labour into previously malarial areas. 
 
All but one study in Zambia [34] showed a positive BCR, with BCRs for control ranging from 2.4 in 
the Philippines [10], 4.14 and 9.22 in India [39, 75] and 17.09 in Greece [76], to over almost 150 for 
elimination in Sri Lanka [16] (Table 4.3). 
 
Table 4.4. Cost-benefit analyses 
 
Country or setting Study period Focus 
(control or 
elimination) 
Benefit-
cost 
ratio 
Source Quality 
assessment 
score (out 
of 10) 
Global 2010-2030 Elimination 6.11 [73] 7 
Greece 1946-1949 Elimination 17.09a [74] 1 
India 1953-1954, 1976-
1977 
Control 9.27 [39] 6 
2000-2001 Control 4.14a [75] 3 
Iraq 1958-1967 Elimination 6.3a [71] 3 
Paraguay 1965 Elimination 2.6-3.3 [72] 3 
Philippines Unspecified Control 2.4 [15] NA 
Sri Lanka 1947-1955 Control 146.3 [15] NA 
Sub-Saharan 
Africa 
Varies by study Control 1.9-17.1 [10] NA 
Sudan 1977-1984 Control 4.6 [15] NA 
Thailand Unspecified Control 6.5 [15] NA 
West Pakistan 1960 Control 4.9 [15] NA 
Zambia 1929-1949 Control 0.57a [33] 9 
2006-2015 Control 40 [28] 6 
a Calculated by authors based on reported benefits and costs 
 
4.4.7 Quality assessment and critical appraisal 
The results of the quality assessment of CBAs using the Drummond ten-point checklist are in Table 
S4.3. Out of a possible ten points, the average score for CBAs was 4.8 (range 0–9). Several CBA 
studies scored poorly for failing to discount future benefits, identify alternative scenarios and 
conduct incremental analyses, carry out sensitivity analyses, and address key issues related to 
resource allocation in the country or setting where the study was situated. Table S4.4 shows the 
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results of quality evaluation of the cost studies. Over half of studies that evaluated programmatic 
costs described their cost inputs and thus scored high on the scope of costing metric of the Fukuda 
and Imanaka criteria. Although a total of 54 studies were evaluated in this review, strong 
conclusions cannot be drawn and the findings should be interpreted with caution. 
 
4.5. Discussion 
 
Summarizing evidence on economics of malaria from heterogeneous studies, sources, inputs, 
methods, time, and geography is challenging. While total costs were corrected for population size 
by presenting them as cost per capita or cost per PAR, other factors contributed to the magnitude 
of the costs. The methodologies and cost inputs used were not standard and many studies used 
secondary data. In some cases, the cost inputs, cost categories, interventions, and assumptions that 
were included were not stated explicitly. Some studies provided coverage inputs, such as total 
population or PAR, while others presented a simple total programmatic cost. Among the studies 
included in the review, discount rates when specified, ranged from 3 to 16%. Many of the studies 
included used a public sector perspective for economic analysis. However, these costs represent 
only part of the equation. While most malaria control eﬀorts are largely government-led public 
health initiatives, programmatic costs are only part of the picture as individuals, households and 
employers from the private sector may also incur costs for malaria treatment and prevention. It is 
unclear to what extent these direct and indirect costs were included in the literature examined. 
Out-of-pocket expenditures for treatment as well as transport to health facilities, as well as any 
indirect opportunity cost of lost wages and absenteeism may have substantial consequences. Other 
studies have shown that up to 6% of a household’s total spending on health, even when public 
sector primary health care is free and indirect costs can translate to USD 150 in lost earnings per 
malaria episode [77]. 
 
Numerous caveats with respect to the relevance and extrapolation of the results exist and findings 
should be used cautiously. First, programme costs depend largely on the mix and scale of 
interventions, which diﬀer from country to country, or even among districts or provinces in 
countries with decentralized systems. Mauritius, for example, employs a more costly border-
screening programme for visitors from malaria-endemic countries. Some earlier studies did not 
incorporate post-elimination costs of surveillance and other interventions to prevent re-
introduction of the disease, as the expectation at the time was that malaria-related expenditure 
would stop after elimination. In the early studies that did actually demonstrate reductions in post-
elimination expenditures, the value of these savings were diminished due to discounting, 
preventing them from fully oﬀsetting the initial increased investments to reach elimination. 
Second, cost is aﬀected by the size and programme eﬃciency of a health system used to implement 
interventions, as well as the coverage rates employed. Smaller countries such as Swaziland 
potentially due diseconomies of scale appear to have higher costs. Sri Lanka on the other hand, has 
one of the earliest and eﬀective public health systems with generally low levels of health 
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expenditures. Costs also diﬀered by the region (Africa or Asia) with costs in Asia much lower than in 
Africa, possibly due to higher use of vector control in Africa, as well as size and development status 
of the country evaluated. Fourth, timing plays an important role in determining the price of 
consumables, services and labour. Estimates from earlier years were generally lower than that from 
the contemporary studies due to the diﬀerence between the relative prices of physical and human 
inputs to malaria control. In addition, the current menu of tools and interventions for malaria is 
broader and more costly, encompassing LLINs, intermittent preventive therapy for pregnant 
women and children, artemisinin-combination therapy, and rapid diagnostic tests, as well as 
innovative delivery models. Lastly, there are wide variations in regional, epidemiological and 
economic contexts. The presence of the more tenacious Plasmodium vivax could have substantial 
cost implications during the elimination phase. Barring a few studies based on mathematical 
models, few measured the cost of the full spectrum of WHO recommendations for the control of 
malaria. For elimination, there is currently no recommended optimal package as the interventions 
are often context specific and tailored to the particular landscape of the country. While some of 
these programmatic, temporal, spatial, and methodological diﬀerences are expected in costing 
studies; future studies should attempt to standardize methodologies to facilitate meaningful 
comparisons of cost estimates. 
 
Despite the challenges in directly comparing costs in the studies reviewed, some trends can be 
observed. While the investment needed to achieve elimination varied greatly between countries 
and contexts, it is likely that the immediate costs for elimination will initially be equal to, or higher 
than those of a control programme, as indicated by data from Swaziland [13], due to initial 
investments in programme re- orientation to strengthen surveillance systems. This cost however 
tend to decrease as the focus progresses to the POR phase [42–44] due to streamlining of 
surveillance activities, reductions in commodity expenditures and in some cases, integration of 
supporting health system activities [13, 78]. Two studies that collected empirical data on actual 
expenditures over multiple programmatic phases support this claim. In Sri Lanka, expenditures per 
PAR declined when moving from a high level of control to controlled low-endemic malaria [44]. In 
the Philippines declining marginal expenditures were observed from control to POR, where costs 
per PAR were more than halved [57]. Similar findings have been reported in three Namibian regions 
in a recent study published after the initial search was conducted [79]. In contrast, Ruberu’s 
analysis in Sri Lanka suggested that the high short-term cost of elimination is exceeded by long-
term investments in control and the resulting consequences of productivity losses [46]. This is 
supported by the Eighth Report of the Expert Committee on Malaria which suggested that the cost 
of a well-operated programme to consolidate and sustain elimination would be only 65–75% that of 
operating an ‘all-out’ or intensive malaria control programme [80]. 
 
The bulk of the CBAs dated from the GMEP era. Several of these studies focused on periods of 
relatively high transmission (i.e., control), even though elimination or eradication was mentioned in 
the title or body of articles, emphasizing the need to standardize the use of malaria terminology. 
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Most of these studies were prospective in design and suggest that the benefits of intensive control 
and elimination exceed costs. However, these studies have not been followed up subsequently to 
assess the validity of their conclusions. The main type of economic benefit identified in the studies 
was increased labour productivity due to reductions in morbidity and absenteeism. Other benefits 
included reductions in treatment costs and gains from the migration of labour into previously 
malarial areas. Factors such as school absenteeism due to malaria and its eﬀect on cognitive 
development and educational outcomes have also been reported by several studies, for example, 
Lucas reported that in Sri Lanka ending malaria in the most heavily aﬀected region led to an 
estimated 17% increase in literacy [81]. Similarly, Bleakley et al. [82] examined the eﬀects of 
malaria on female educational attainment in Paraguay and found that every 10% decrease in 
malaria incidence led to 0.1 years of additional schooling, and increased the chance of being 
literate by one to two percentage points. While an important factor on human capital 
accumulation, these were not included in this review as they did not present costs in economic 
terms, an important element in order to be comparable and used in economic analyses. 
 
As with cost estimates, the heterogeneity in cost-benefit estimates can be explained largely by the 
lack of standardization in calculating BCRs, particularly on how benefits were defined, categorized 
or estimated. Some studies used a broad definition of benefits from a societal perspective, while 
others used a narrow definition of outputs. Some studies also made wide-ranging assumptions 
about the eﬀect of malaria on labour, tourism and the larger economy and attempted to include 
their eﬀect into their metric. The studies also use varying time periods of analysis and a variety of 
discount rates ranging from 3 to 10% to obtain present values. A complete economic assessment of 
elimination should include direct and indirect benefits, some of which are diﬃcult to measure. The 
economics of malaria elimination are complicated because most of the benefits of elimination are 
typically realized only when an absolute threshold of malaria-free status is achieved, by conferring 
indirect benefits such as economic development [83]. While it is expected that one of the benefits 
of malaria is likely to be a positive eﬀect on tourism, two studies carried out in an area of South 
Africa and Mauritius [84, 66] reported that tourists’ perceptions of risk were highly unresponsive to 
actual changes in malaria transmission. A comprehensive CBA should compare the potential net 
benefits of elimination with those of control. Ideally, such as exercise should begin with cost-
minimization analysis to establish the optimum package of interventions with which to achieve 
control and elimination. Nevertheless, the overall favourable BCR of investing in malaria supports 
the case for continued investment in malaria elimination within individual countries and globally. 
 
Few studies have looked at the relative returns to elimination versus long-term control. The Eighth 
Report of the Expert Committee on Malaria (1961) suggested that experience indicated that a well-
operated consolidation mechanism costs per annum 65–75% of an attack mechanism [80], and 
there is some evidence that the costs for elimination are likely to be equal to or higher than those 
of a control programme [50, 85]. Indeed, one of the strongest arguments against elimination is the 
increasing cost associated with finding and treating decreasing numbers of cases, since the final few 
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cases require an enormous outlay of resources that may be considered disproportionate to the 
marginal return [86]. This discussion around the financing of malaria elimination is no diﬀerent to 
that of other elimination and eradications programmes. Since the start of the Global Polio 
Eradication Initiative (GPEI), the burden has been reduced by over 99%. Twenty-seven cases of wild 
polio have been diagnosed this year, all in Afghanistan, Pakistan and Nigeria. Finishing the job of 
eradicating polio will cost an additional USD 1.5 billion to enhance vaccination and surveillance 
eﬀorts in hard to-reach places. This translates into a cost of about USD 0.5 billion a year or USD 18 
million per case averted. However, eradicating polio will have saved at least USD 40–50 billion 
between 1988 and 2035. In the USA alone, eradicating polio is estimated to have saved about USD 
220 billion since 1955. Nevertheless, some public health advocates continue to question whether 
polio should be merely managed rather than eliminated and the money be allocated to fighting 
other diseases. However, withdrawing support will have devastating health, social and economic 
eﬀects. In 2003, certain states in Nigeria briefly stopped delivering vaccines in 2003 and as a result, 
GPEI spent USD 220 million dealing with the resultant outbreak. Equatorial Guinea also recently 
saw its first reported polio case since 1999, when a virus from Cameroon exploited a drop in the 
routine vaccination of children [87, 88]. 
 
Similarly, while the literature supports the claim that investment in malaria elimination provides 
generous benefits, the challenge is sustaining financial support. Donor funding is on the decline in 
favour of programmes with seemingly greater potential impact on mortality and morbidly. 
Although many of the countries currently attempting to eliminate malaria are middle-income 
countries and will eventually be able to fund their programmes domestically, they are faced with 
competing priorities for finite amounts of financing. In addition, the long-term nature of elimination 
programmes contrasts with governments’ and donors’ typical short-term funding cycles and goals. 
As a result, elimination programmes become victims of their own success and risk the withdrawal 
of funding at a critical time in their malaria epidemiology. 
 
The review identified several gaps in the literature on the economics of malaria elimination. Firstly, 
there is no standard methodology or guidance for computing the cost of malaria control and 
elimination. The studies in this review employed a wide range of inputs to compute the cost of 
malaria control and elimination to arrive at the costs, making meaningful comparisons diﬃcult. For 
elimination, this standardization needs to include the cost likely to be incurred in a post-elimination 
scenario to allow appropriate budgeting and planning. Secondly, while comprehensive WHO 
guidance exists on interventions for the control of malaria, there is little direction on the 
epidemiological and economic eﬃciencies of various mixes of interventions utilized for malaria 
elimination. The start-up costs of malaria elimination, particularly the cost of strengthening 
surveillance systems for enhanced case identification are also largely unknown. A country 
embarking on elimination will need to plan for the additional resources needed in its transition 
from control to elimination. Most of the studies in this review used financial costs and therefore, 
the true cost of the human resources and programmatic management and health system 
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strengthening are largely unknown. Lastly, malaria elimination confers several non-health benefits 
to the economy. Methods to comprehensively quantify these benefits will greatly enable 
stakeholders to strengthen the elimination argument.  
 
4.6 Conclusion 
 
The evidence documented in this review is important in answering key questions on resource 
allocation and financial planning by malaria programme managers and policymakers serving as an 
interim guide for countries until they are able to undertake more robust economic analyses in their 
own contexts. The investment needed to achieve elimination is likely to initially be equal to or 
higher than that of a control programme, particularly in the short term. As with any disease 
elimination programme, the cost of ‘finishing the job’ is likely to be higher than merely controlling 
the disease. This higher cost must be built into programme budgets with appropriate advocacy 
actions to ensure that financing is maintained well after elimination is achieved. At the same time, 
it should be tacit that, the total benefits of elimination, many immeasurable, vastly outweigh its 
cost. Nevertheless, there is a need for thorough research into the comprehensive benefits of 
elimination to guide relevant policy decisions. At the same time, malaria-related expenditure is not 
likely to stop as soon as elimination is achieved. Malaria interventions need to be viewed as a 
continuous expenditure even when the disease is absent, such as with routine immunization, until 
global eradication is achieved. Elucidating the health and economic costs and comprehensive 
benefits of continuing spending will facilitate such a policy shift. 
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Table S4.1. Cost of malaria to the health system 
Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
Abeyasinghe et 
al. (2012) [1] 
 
Sri Lanka 
(Kurunegala 
and 
Anuradhapura 
districts) 
Retrospective/ 
Cost analysis 
2004 and 
2009 
Literature search, 
public sector 
expenditure 
records, informant 
interviews 
Prevention, diagnosis, 
treatment and 
prophylaxis, 
surveillance and 
response, education 
and communication, 
and program 
management 
No total cost provided No total population 
provided 
Anuradhapura: 
0.87 (2004) and 
1.95 (2009) 
Kurunegala: 2.06 
(2004) and 1.95 
(2009) 
Akhavan et al. 
(1999) [2] 
Brazil (Amazon 
basin) 
Retrospective/ 
Cost analysis 
and CEA 
1989-1996 Literature for 
epidemiological 
data, unclear for 
cost data 
Prevention and 
treatment 
914 M (780 M 
prevention, 134 M 
treatment) 
2.57 (2.18 
prevention, 0.38 
treatment)7 
2.57 (2.18 
prevention, 0.38 
treatment)7 
Clinton Health 
Access Initiative, 
et al. (2011) [3] 
Ethiopia, 
Rwanda, 
Zambia, 
Tanzania 
(Mainland and 
Zanzibar) 
Prospective/ 
Cost analysis 
and CEA 
2011-2015 Malaria specific 
expenditures from 
government and 
active partners 
Diagnosis and 
treatment 
Ethiopia: 148 M 
Rwanda: 55 M  
Senegal: 55.4 M  
Mainland Tanzania: 88-
91 M 
Zanzibar: 4 M 
Ethiopia: 1.677 
Rwanda: 4.787 
Senegal: 4.267 
Mainland Tanzania: 
2.14-2.217 
Zanzibar: 2.877 
Ethiopia: 2.947 
Rwanda: 6.647 
Senegal: 4.267 
Mainland 
Tanzania: 2.14-
2.217 
Zanzibar: 2.877 
Dua et al. (1997) 
[4] 
India (one 
industrial 
setting) 
Prospective and 
retrospective/ 
Cost analysis 
1987-1995 Entomological and 
parasitological 
surveys, hospital 
budgets 
Direct cost to health 
facilities 
112,000 (1985) 
684,000 (1986-1995) 
No total population 
provided 
No PAR provided 
Dy (1954) [5] Various Retrospective/ 1953 Public sector Personnel, supplies, Afghanistan: 726,000 Afghanistan: 1.34 No PAR provided 
                                                        
3 Asterisks in this column describe whether a study explicitly considered malaria severity, where * = uncomplicated and ** = uncomplicated and severe.   
4 Unless otherwise stated, the total costs are based on the study period. 
5 Unless otherwise stated, the costs reported here are the annual costs per capita (i.e., annual total costs of program divided by total population in area of implementation). 
6 Unless otherwise stated, the costs reported here are the annual costs per PAR (i.e., annual total costs of program divided by PAR in area of implementation). For many studies, the cost per PAR is the same as the cost per 
capita because the entire population is deemed at risk for malaria. 
7 Calculated by authors based on total population or PAR reported in the original study. 
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Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
countries in 
Asia 
Cost analysis expenditure 
records  
equipment, transport, 
and other 
miscellaneous expenses 
Burma: 284,000 
Ceylon: 6.1 M 
China: 205,000 
India: 10.9 M 
Indonesia: 160,401 
Malaya: 24,900 
Portuguese India (Goa): 
64,700  
Thailand: 1.8 M 
Vietnam: 3.2 M 
Ceylon: 0.80 
India: 0.30 
Cost per person 
protected 
Afghanistan: 1.74 
Burma: 2.74 
Ceylon: 1.98  
China: 1.37  
India: 0.61 Indonesia: 
1.88 
Malaya: 5.80 
Portuguese India 
(Goa): 2.32 
Philippines: 4.25 
Thailand: 9.71 
Vietnam: 1.06 
Ebi (2008) [6] Global Prospective/ 
Cost analysis 
2000-2030 WHO database, 
Disease Control 
Priorities II project 
cost data 
ITNs, case management 
with ACT, IPTp, and IRS 
1.701 M-9.503 M8 No total population 
provided 
No PAR provided 
Giron et al. 
(2006) [7] 
Colombia Retrospective/ 
Cost analysis 
and CEA 
1993-1998 Public sector 
expenditure 
records, 
household 
interviews 
Fumigation, spraying, 
bednet treatment, 
elimination of breeding 
sites, IEC on 
environmental factors, 
and malaria tests 
National program: 
5,380 per 10,000 
persons 
Integrated alternative: 
34,847 per 10,000 
persons 
National program: 
0.54 
Integrated 
alternative: 3.48  
No PAR provided 
Gunaratna 
(1956) [8] 
Ceylon (Sri 
Lanka) 
Retrospective/ 
Cost analysis 
1934-1955 Unspecified Spraying, case 
detection, and 
treatment 
98,000-7.3 M 0.63-5.22 No PAR provided 
Haque et al. 
(2014) [9] 
Bangladesh  Retrospective/ 
Cost analysis 
2008-2012 Public sector 
expenditure 
Equipment, 
infrastructure, training, 
No total cost provided 0.40 No PAR provided 
                                                        
8 Estimated under different scenarios 
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Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
record  operational research, 
transportation, and 
supplies such as drugs, 
diagnostics, LLINs, and 
insecticides for 
retreatment of nets 
Hedman et al. 
(1979) [10] 
Liberia 
(Yekepa, 
Nimba County) 
Retrospective/ 
Cost analysis 
1953-1961 Unspecified Vector control 
measures (including 
personnel, chemicals, 
equipment) and 
chemoprophylaxis with 
amodiaquine 
504,969 31.25-39.06 No PAR provided 
James (1903) 
[11] 
India (Mian Mir 
cantonment) 
Retrospective/ 
Cost analysis 
1901-1903 Unspecified  Personnel, 
environmental 
management for vector 
control, and 
miscellaneous expenses 
7,217 rupees9 (1901-
1902) 
4.70 rupees9 No PAR provided 
Jowett et al. 
(2005)** [12] 
Tanzania Retrospective/ 
Cost analysis 
1998 Literature, donor 
and public sector 
expenditure 
records, 
manufacturer’s 
pricing for drug 
prices  
Prevention and 
treatment activities 
93 M 3.14 (government 
0.63, donors 0.30, 
private 2.21) 
No PAR provided 
Kaewsonthi et 
al. (1989) [13] 
Thailand  Unclear/ 
Cost analysis 
Unspecified Unspecified Surveillance, vector 
control, and malaria 
clinics 
123 M (24.3 M 
government, 98.7 M 
private)  
No total population 
provided 
No PAR provided 
Kamolratanakul 
et al. (1999) [14] 
Thailand  Prospective/ 
Costs analysis 
1995 Unspecified Personnel, materials, 
and capital 
88,737  Cost per Pv case: 
12.94 
Cost per Pf case: 
15.40 
No PAR provided 
                                                        
9 No reliable exchange rate could be found for Indian rupees for the years 1901-1902 
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Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
Cost per visit: 2.59, 
Cost per case: 11.48 
Cost per house 
sprayed: 3.13 
Cost per 
impregnated net: 
2.15 
Kiszewski et al. 
(2007)** [15]  
81 high-burden 
malaria 
countries 
Retrospective/ 
Cost analysis 
2006-2015 WHO database, 
UNDP projections, 
public sector 
expenditure 
record 
Commodities and 
distribution, health 
system strengthening 
activities, training, 
communication, 
operational research, 
M&E, and technical 
assistance 
4.4 B-5.2 B per year (2 
B-2.5 B Africa, 2.4 B-2.8 
B rest of the world) 
Africa: 2.81 
Asia and Oceania: 
1.34 
Americas: 0.99 
Global: 2.50  
No PAR provided 
Kligler (1924) 
[16] 
Palestine   Retrospective/ 
Cost analysis 
1921-1922 Unspecified Case detection and 
treatment, vector 
control, prophylaxis, 
and education 
Migdal: 434 
Kinnereth: 677 
Yemma: 812 
Migdal: 24 
Kinnereth: 32 
Yemma: 22 
Menachamia: 19 
Um-Ul-Alex: 32  
No PAR provided 
Kondrashin 
(1992) [17] 
WHO SEARO 
region 
Retrospective/ 
Cost analysis 
1990 WHO SEARO and 
New Delhi budget 
data 
Unspecified No total cost provided No total population 
provided 
Bangladesh: 0.02 
India: 0.12 
Indonesia: 2.16 
Nepal: 0.52 
Thailand: 1.59 
Konradsen et al. 
(1999) [18] 
Sri Lanka (one 
area in 
Anuradhapura 
district) 
Retrospective/ 
Cost analysis 
1994-1995 MOH, Anti Malaria 
Campaign, 
Kekirawa 
government 
hospital, survey 
data 
Salaries, transport and 
storage, chemicals, 
capital investments and 
maintenance for IRS, 
bednet impregnation, 
larviciding, water 
management, and 
diagnosis and 
No total cost provided Cost per person 
protected per year 
Spraying: 3.13-4.26 
Bednet 
impregnation: 1.29 
Larviciding: 0.73 
Water management: 
0.36 
No PAR provided 
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Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
treatment Cost per positive case 
Diagnosis: 1.45-2.39 
Treatment: 1.91-4.12 
Korenromp et 
al. (2013)* [19] 
90 countries Retrospective/ 
Cost analysis 
2003-2009 Disbursement 
reports from 
donors, WHO 
database, 
household 
surveys, 
manufacturer cost 
reports  
Unspecified No total cost provided 78-5,749 per case 
prevented10  
57,654-3,903,107 per 
death prevented10  
1.42-11.137 
Mills (1992)* 
[20] 
Nepal (5 
districts) 
Prospective/ 
Cost analysis 
and CEA 
Unspecified Surveys, 
government 
control program 
Diagnosis and 
prevention 
No total cost provided 0.11-1.21 No PAR provided 
Mills (1993b) 
[21] 
Nepal Retrospective/ 
Cost analysis 
and CEA 
1984-1985 Survey data, 
malaria program 
budgets and 
accounts, 
surveillance data  
NMCP costs Morang: 174,877 and 
112,56711 
Ilam: 57,938 and 
31,134 
Rupandehi: 186,546 
and 139,037 
Morang: 0.45 and 
0.97 
Ilam: 1.35 and 1.36 
Rupandehi: 0.81 and 
0.877 
No PAR provided 
Morel et al. 
(2005) [22] 
Sub-Saharan 
Africa  
Prospective/ 
CEA 
2003 
population 
data as 
baseline, 
modeled over 
10 years 
Literature review, 
expert opinion, 
WHO-CHOICE 
database  
Unspecified Southern and Eastern 
Africa: 597,045,946-
598,568,437 
Western Africa: 
426,990,689-
632,846,172 
Southern and Eastern 
Africa:  
2.22 
Western Africa: 
1.21-1.80 
Southern and 
Eastern Africa:  
2.26-2.27 
Western Africa: 
1.76-2.61 
Prakash et al. 
(2003)** [23] 
India (Jorajan 
camp of Oil 
India, upper 
Retrospective/ 
Cost analysis 
and CBA 
April 2000-
May 2001 
Oil India Limited 
records 
Personnel, 
transportation, and 
antimalarial measures 
2,746  Cost of 
hospitalization per 
case: 264.89  
No PAR provided 
                                                        
10 Cost analyses limited to 49 countries outside Africa 
11 Higher costs are from lower receptive areas (API of 10 and 40 per 1000) while lower costs are from moderate receptive areas (API of 50 and 250 per 1000). 
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Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
Assam) 
Ramaiah (1980) 
[24] 
India Retrospective/ 
Cost analysis 
and CBA 
1953-1977 Literature, public 
sector expenditure 
reports 
Treatment and 
transportation 
4.274 M 0.367 No PAR provided 
Ruberu (1977) 
[25] 
Sri Lanka Retrospective/ 
Cost analysis 
1977-1981 Malaria program 
expenditures and 
reports, source of 
historical 
epidemiological 
data unclear 
NMCP costs  7.2 M-13.2 M (1977-
1986) 
Attack phase (1977-
1981): 120.5 M 
Attack phase: 1.71   No PAR provided 
Sharma (1996) 
[26] 
India Retrospective/ 
Cost analysis 
1991 Literature, public 
sector expenditure 
reports 
NMCP expenditures, 
transportation, 
personal protection 
methods, and 
treatment 
330,464,252-
542,423,009 
No total population 
provided 
No PAR provided 
Snow et al. 
(2008)* [27] 
87 countries Retrospective/ 
Cost analysis 
2002-2007 GFATM, WHO, 
World Bank, 
unilateral and 
bilateral 
organizations 
Approved fund 
distributions 
1,114,044,944 No total population 
provided 
Any risk for Pf: 
0.47 
Stable risk for Pf: 
0.80 
Some (1994)** 
[28] 
Kenya (Uasin 
Gishu district) 
Retrospective/ 
Cost analysis 
Jan-Sep 1990 Hospital record, 
absenteeism data 
from 6 primary 
schools, routine 
and verbal reports 
Accommodations, 
vehicle use and 
maintenance, supplies, 
printing, equipment 
and maintenance, and 
miscellaneous expenses 
Additional cost of 
controlling the malaria 
epidemic (June 1990): 
142,665 
0.287 No PAR provided 
Stuckey et al. 
(2014) [29] 
Kenya 
(Rachuonyo 
South district, 
Homa Bay 
county, Nyanza 
Prospective and 
retrospective/ 
Cost analysis 
and CEA 
2011-2012 
data as 
baseline, 
modeled over 
5 years 
GFATM, WHO-
CHOICE, and 
Malaria 
Transmission 
Consortium 
Health system 
resources, treatment, 
supplies, personnel, 
and direct patient costs 
(travel and 
89,749,493-
117,078,093 
897.49-1170.78 over 
five years (179.50-
234.17 per year5) 
No PAR provided 
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Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
province)  databases, 
literature review, 
demographic and 
health survey 
consumables) 
Teklehaimanot 
et al. (2007)** 
[30] 
Africa Prospective/ 
Cost analysis 
2006-2015 
 
Literature, UNDP 
database, UN data 
on malaria 
Prevention, diagnosis, 
treatment, M&E, and 
overhead 
3.5 B 3.47  4.65  
Utzinger et al. 
(2002) [31] 
Zambia (four 
communities)  
Retrospective/ 
Cost analysis 
1929-1949 Census data, life 
tables, literature 
search, program 
budgets for 
control 
Prevention, diagnosis, 
and treatment 
17,078,703 11.867 No PAR provided 
Yadav et al. 
(1991) [32] 
India (two 
mining 
settlements in 
Orissa)  
Retrospective/ 
Cost analysis 
May 1989 Hospital records, 
survey, 
expenditure data 
from mining 
companies 
Treatment, antilarvals, 
and IRS 
128,109 9.397  No PAR provided 
Beaver (2011) 
[33] 
Solomon 
Islands, 
Vanuatu 
Retrospective/ 
Cost analysis 
2008 Government 
budget projection 
reports, GFATM, 
AusAID, WHO, and 
Rotary Against 
Malaria data 
Projected budgets for 
case management, 
diagnosis, prevention, 
and M&E 
No total cost provided Vanuatu: 1.60 
Solomon Islands: 
3.3412 
No PAR provided 
Cohn (1973) 
[34] 
India Retrospective/ 
Cost analysis 
1952-1971 National malaria 
program 
expenditure data 
Materials, equipment, 
and operations 
Control (1951-1958): 
150 M 
Elimination (1958-
1971): 1.3 B 
No total population 
provided 
No PAR provided 
de Zulueta et al. 
(1972) [35] 
Iraq, Lebanon, 
Syria, Jordan 
Retrospective/ 
Cost analysis 
1964-1970 Unspecified NMCP costs Iraq: 77,083,000 
Jordan: 17,699,000 
Lebanon: 5,174,000 
Syria: 22,067,000 
No total population 
provided 
Iraq (1970): 2.96 
Jordan (1970): 
1.68 
Lebanon (1970): 
                                                        
12 Values deflated by remoteness and incapacity indices 
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Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
0.73 
Syria (1970): 0.95 
Jackson et al. 
(2002) [36] 
China (Gushi 
and 
Shangcheng, in 
Henan 
province) 
Prospective/ 
Cost analysis 
1994-1995 Budget for 
administrative 
costs, community 
costs based on 
sample of 
suspected cases, 
government health 
records 
Vector surveillance, 
population blood 
surveys, case 
management, 
personnel, 
administration, 
training, drugs, blood 
testing, and 
miscellaneous expenses 
175,340 1.23 per suspected 
case  
0.05  
Kahn et al. 
(2009a) [37] 
China (Jiangsu, 
and Hainan 
Island), Sao 
Tome and 
Principe, 
Solomon 
Islands, Sri 
Lanka, 
Swaziland, 
Vanuatu 
Prospective/ 
Cost analysis 
and CEA 
2007 
(modeled 
over 20 years) 
Public sector 
expenditure 
reports and 
budgets, GFATM 
proposals, expert 
opinions 
NMCP costs Jiangsu, China 
Control: 9.9 M 
Elimination: 6.66 M 
Hainan, China 
Control: 3.2 M 
Elimination: 2.6 M 
Swaziland 
Control: 0.8 M 
Elimination 1.36 M 
Using GMAP figures 
(1950s-1960s): 3-14 
Hainan, China: 0.27 
Sao Tome and 
Principe: 12 
Solomon Islands: 20 
Vanuatu: 27 
Sri Lanka: 1 
Swaziland: 3  
Hainan, China: 2 
Sri Lanka: 5 
Swaziland: 8  
Kahn et al. 
(2009b) [38] 
China (Jiangsu, 
and Hainan 
Island), 
Swaziland 
Prospective/ 
Cost analysis 
and CEA 
2007 
(modeled 
over 20 years) 
China: MOH 
expenditures and 
budgets, GFATM 
proposals, expert 
opinion 
Swaziland:  
government 
budgets and 
GFATM proposals 
NMCP costs  Jiangsu, China 
Control: 9.9 M 
Elimination: 6.66 M 
Hainan, China 
Control: 3.2 M 
Swaziland 
Annual cost: 430,000 
Budgeted amount for 
elimination: 2.6 M 
Hainan, China 
Elimination: 0.27  
Hainan, China 
Elimination: 2.17  
Kaneko et al. 
(2000)* [39] 
Vanuatu 
(Aneityum) 
Retrospective/ 
Cost analysis 
Sept-Nov 
1991 
Unspecified  ITNs, antimalarials, 
microscopy, 
transportation, and 
No total cost provided 18.44  No PAR provided  
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Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
travel allowances 
Liu et al. (2013) 
[40] 
Philippines (4 
provinces) 
Retrospective/ 
Cost analysis 
1998-2010 
(varies by 
province) 
Subnational 
historical records, 
key interviews, 
Public sector 
expenditure 
reports 
Diagnosis, treatment, 
prevention, 
surveillance, and M&E 
Apayao: 384,737-
798,470  
Laguna: 29,748-117,621 
Cavite: 7,464-45,389 
Benguet: 17,020-17, 
292 
No total population 
provided 
Apayao: 3.50-7.70 
Laguna: 3.48-13.08 
Cavite: 0.67-4.63 
Benguet: 2.69-2.96 
Livadas et al. 
(1963) [41] 
Greece Retrospective/ 
Cost analysis 
1946-1949 Unspecified Direct and indirect cost 11 M No total population 
provided 
No PAR provided 
Lok (1979)* [42] Singapore Retrospective/ 
Cost analyses 
1974-1978 Unspecified Program 
implementation, drugs, 
and medical care 
3.5 M  No total population 
provided 
No PAR provided 
Mills (2008) [43] Multiple 
countries 
Retrospective 
and 
prospective/ 
Cost analysis 
Varies by 
country 
 
Literature  Various No total cost provided Cost per person 
protected13 
Taiwan:  0.52 
India: 0.58 
Sri Lanka: 0.86 
Indonesia: 0.97 
Thailand: 1.54 
No PAR provided 
Moonasar et al. 
(2013) [44] 
South Africa Prospective/ 
Cost analysis 
2012-2018 
 
Public sector 
expenditure 
reports and 
budgets 
Surveillance, vector 
control, health 
promotion, case 
management, and 
program management 
190 M (2012-2018) No total population 
provided 
No PAR provided 
Niazi (1969) [45] Iraq Retrospective/ 
Cost analysis 
and CBA 
1958-1967 Unspecified  Treatment and medical 
care, antilarval 
measures, and 
insecticidal spraying 
86,653,366 No total population 
provided  
No PAR provided 
                                                        
13 Updated costs from (1) Griffith ME. Financial implications of surveillance in India and other countries. Bulletin of the National Society of India for Malaria and Other Mosquito-borne Diseases 1961;9:385-411 and (2) 
Kaewsonthi S, Harding AG. Cost and performance of malaria surveillance in Thailand. Soc Sci Med 1992;34(9):1081-1097.  
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Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
Ortiz (1968) [46] Paraguay 
(agricultural, 
cattle farming, 
and forestry 
industries) 
Retrospective/ 
Cost analysis 
and CBA 
1965 
 
Servicio Nacional 
de Erradicación del 
Paludismo  
NMCP costs  Actual value: 
38,414,815  
Annual disbursement: 
51,466,667 
No total population 
provided 
No PAR provided 
Purdy et al. 
(2013) [47] 
WHO regions Prospective/ 
Cost analysis 
and CBA 
2013-2035 GMAP GMAP costs 7.534 M (2010) 
7.163 M (2015) 
6.338 M (2020) 
6.036 M (2025) 
4.167 M (2030) 
2.877 M (2035) 
No total population 
provided 
No PAR provided 
Rezaei-Hemami 
et al. (2014)* 
[48] 
Iran  Retrospective/ 
Cost analysis 
and CEA 
Unspecified 
(pre-
elimination to 
elimination 
phases) 
Iranian Ministry of 
Health and 
Medical Education 
Utilities, capital, 
operations, personnel, 
and transportation 
10,472 20.95 No PAR provided 
Sabot et al. 
(2010) [49] 
China (Hainan 
and Jiangsu), 
Mauritius, 
Swaziland, and 
Tanzania 
(Zanzibar) 
Retrospective 
and 
prospective/ 
Cost analysis 
Varies by 
country (10-
year time 
horizon for 
elimination 
plus 15 years 
post-
elimination) 
Public sector 
expenditure 
reports and annual 
health reports, 
yearly country 
program data, 
national health 
accounts, donor 
proposals, 
informant 
interviews 
NMCP costs  Hainan, China: 
Control (2007-2009): 
1.766 M 
Elimination (2010-
2014): 4.72 M 
POR (2020-2029): 1.197 
M  
Jiangsu, China 
Control (2007-2009): 
9.169 M 
Elimination (2010-
2014): 17.966 M 
POR (2020-2029): 8.218 
M 
Mauritius 
Control (1982): 2.673 M 
Elimination (1983-
Hainan, China 
Control: 0.21 
Elimination: 0.54 
POR: 0.13 
Jiangsu, China 
Control: 0.12 
Elimination: 0.23 
POR: 0.10 
Mauritius 
Control: 2.37 
Elimination: 4.63 
POR: 2.62  
Swaziland 
Control: 0.94 
Elimination: 2.65 
POR: 1.67 
Tanzania 
Hainan, China 
Control: 0.22 
Elimination: 0.55 
POR: 0.13 
Jiangsu, China: 
Control 0.16 
Elimination 0.30 
POR: 0.13 
Mauritius 
Control: 2.37 
Elimination: 4.63 
POR: 4.63 
Swaziland 
Control: 4.88 
Elimination: 13.77 
POR: 8.65 
Tanzania 
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Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
1988): 4.71 M 
POR (1990-2008): 2.999 
M 
Swaziland 
Control (2004-2008): 
1.068 M 
Elimination (2009-
2013): 3.22 M 
POR (2020-2029): 2.452 
M 
Tanzania: 
Control (2009) 4.229 M 
Elimination (2010-
2019): 5.31 M 
POR (2020-2029): 4.220 
M 
Control: 3.26 
Elimination: 4.22 
POR: 2.18 
Control: 3.26 
Elimination: 4.22 
POR: 2.18 
Suarez Torres 
(1970a)** [50] 
Mexico Prospective/ 
Cost analysis 
1971-1976 
 
Unspecified IRS, surveillance, case 
investigation and 
management, 
education campaign, 
entomological 
surveillance, research, 
program management, 
public relations, 
logistics, and 
administration 
National plan (1971): 
856,874 
National plan with 
regional expansion 
(1971): 1,578,216 
National plan with 
implementation in all 
malarious areas (1971): 
4,057,006  
Six-year plan: 
21,608,204 
Cost of national plan 
with implementation 
in all malarious areas 
(1971): 0.18  
No PAR provided 
Suarez Torres 
(1970b) [51] 
Mexico (Gulf of 
Mexico, 
Yucatan 
Peninsula) 
Prospective/ 
Cost analysis 
July to Dec 
1970 
National 
Commission for 
the Eradication of 
Malaria and 
federal 
government 
Personnel, supplies, 
communication, 
transportation, 
maintenance, spraying, 
and vehicles 
537,425 0.54 No PAR provided 
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Source3 Country or 
region 
Study type/ 
Study method 
Study period Data source Costs and interventions 
included 
Total cost of program 
(2013 USD)4 
Cost per capita per 
year (2013 USD)5 
Cost per PAR per 
year (2013 USD)6 
Taiwan 
Provincial 
Malaria 
Research 
Institute et al. 
(1958)** [52] 
Taiwan Retrospective/ 
Cost analysis 
1952-1957 
 
 
Taiwan Provincial 
Malaria Research 
Institute  
NMCP costs Total funds for malaria 
(1952-1956) 14: 
242,705,049 
15.067 (1956) No PAR provided 
Tatarsky et al. 
(2011) [53] 
Mauritius Retrospective/ 
Cost analysis 
1855-2008 Peer-reviewed 
literature, WHO 
and government 
reports, gray 
literature, expert 
interviews, 
budgets, technical 
reports, program 
reviews, 
expenditure data 
Surveillance, diagnosis, 
treatment, prevention, 
and program 
management 
First elimination (1948-
1951): 2.3 M-2.7 M 
First POR program 
(1969-1974): 2 M 
Second elimination 
(1982-1991): 3 M-5.6M 
Current program 
(2008): 2.7M  
First elimination: 
4.83 and 6.22  
First POR: 3.24  
Second elimination: 
3.03-5.83 
Current POR: 2.23 
No PAR provided 
Note: The color scheme in the table represents the focus of each study, where intensive malaria control is white and malaria elimination and eradication are in grey. 
 
 
                                                        
14 2013 costs are based on the exchange rate for New Taiwan dollars (TWD) in the 1950s, which was 5 TWD to 1 USD (see Li K-T. The evolution of policy behind Taiwan’s development success. Singapore: World Scientific 
Publishing Co. Pte. Ltd.) 
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Acronyms used in Table S4.1 
 
ACT – Artemisinin combination therapy 
API – annual parasite index 
AusAID – Australian Agency for International Development (now under the Department of Foreign 
Affairs and Trade) 
B – Billion 
CBA – Cost-benefit analysis 
CEA – Cost-effectiveness analysis 
IEC – Information, education and communication 
IPTp – Intermittent preventive treatment in pregnancy  
IRS – Indoor residual spraying 
ITN – Insecticide-treated bednet 
GFATM – Global Fund to Fight AIDS, Tuberculosis and Malaria 
GMAP – Global Malaria Action Plan 
LLIN – Long-lasting insecticidal bednet 
M – Million 
M&E – Monitoring and evaluation 
MOH – Ministry of Health 
NMCP – National malaria control program 
PAR – population at risk 
Pf – Plasmodium facliparum 
POR – Prevention of reintroduction 
Pv – Plasmodium vivax 
SEARO – Southeast Asia Regional Office 
TWD – New Taiwan dollars 
UN – United Nations 
UNDP – United Nations Development Programme 
WHO – World Health Organization 
WHO-CHOICE – WHO cost-effectiveness and strategic planning 
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Table S4.2. Cost-benefit analyses of malaria control and elimination 
Source15 Country or 
region 
Study period Perspective/ 
Data sources 
Costs included Benefits included Total cost (2013 USD) Total benefits (2013 
USD) 
Net benefits (NB, in 
2013 USD) or benefit to 
cost ratio (BCR)  
Barlow et al. 
(1986)**16 [1] 
Multiple 
countries 
Varies by 
country 
Societal/ 
Published 
literature 
 
Direct cost of control 
interventions 
Economic benefit of 
increased labor 
productivity 
None None BCR 
Pakistan: 4.9 
Philippines: 2.4 
Sri Lanka: 146.3 
Sudan: 4.6 
Thailand: 6.5 
Clinton Health 
Access Initiative, 
et al. (2011) [2] 
Zambia 
(Konkola copper 
industry) 
2006-2015 Societal/ 
Published 
data  
Direct cost of control 
interventions 
Cost savings 4,180,249  167,733,891 NB: 163,653,642 
BCR: 40 
Prakash et al. 
(2003)** [3] 
India (Jorajan 
camp of Oil 
India, upper 
Assam) 
April 2000-
May 2001 
Societal/ 
Oil India data 
Direct cost of control 
interventions 
Cases averted  2,746 11,387  NB: 8,644 
BCR: 4.1417 
Ramaiah (1980) 
[4] 
India 1953-1954, 
1976-1977 
Societal/ 
Literature, 
public sector 
expenditure 
reports 
Direct and indirect costs 
of control interventions 
Cost savings 4.274 M 
  
NPV: 39.628 M BCR: 9.27 
Utzinger et al. 
(2002) [5] 
Zambia (4 
communities) 
1929-1949 Societal/ 
Census data, 
life tables, 
literature 
search, 
program 
budgets for 
Direct and indirect costs 
of control interventions 
DALYs averted 17.1 M  9.9 M 
 
 
BCR: 0.5717 
                                                        
15 Asterisks in this column describe whether a study considered malaria severity, where * = uncomplicated and ** = uncomplicated and severe.   
16 Review article – only selected studies or findings were extracted and included here 
17 Calculated by authors based on reported benefits and costs 
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Source15 Country or 
region 
Study period Perspective/ 
Data sources 
Costs included Benefits included Total cost (2013 USD) Total benefits (2013 
USD) 
Net benefits (NB, in 
2013 USD) or benefit to 
cost ratio (BCR)  
control 
Livadas et al. 
(1963) [6] 
Greece 1946-1949  Societal/ 
Unspecified 
Direct cost of 
elimination 
interventions 
Cost savings 11 M 199 M  NB: 188 M 
BCR: 17.0917 
Mills (2008)16 [7] Sub-Saharan 
Africa18 
Varies Societal/ 
Published 
literature 
Direct cost of intensified 
control interventions 
Macro-economic 
benefits and monetized 
value of averted DALYs 
None None BCR 
Based on 
macroeconomic 
benefit: 1.9-4.7 
Based on averted 
DALYs: 17.1 
Niazi (1969) [8] Iraq 1958-1967 Societal/ 
Unspecified 
Direct cost of 
elimination 
interventions 
Cost savings  86,653,366 548,383,410 NB: 461,425,993 
BCR: 6.317 
Ortiz (1968) [9] Paraguay 
(agricultural and 
forestry 
industries) 
1965 Societal/ 
Data from 
Servicio 
Nacional de 
Erradicación 
del Paludismo 
Direct and indirect costs 
of elimination 
interventions 
Increased productivity 48 M 139.7 M-220.8 M BCR: 2.6-3.317 
Purdy et al. (2013) 
[10] 
WHO regions 2010-2030 Societal/ 
GMAP 
GMAP costs including 
prevention, case 
management, program, 
and R&D 
DALYs averted, work 
years saved, and 
projected productivity 
growth  
7.534 M (2010) 
7.163 M (2015) 
6.338 M (2020) 
6.036 M (2025) 
Several reported based 
on GDP per person and 
projected productivity 
growth 
NB (2013-2035): 208.6 
B 
BCR (2035): 6.1117 
                                                        
18 More studies conducted in other studies are included in the original review article, but only the BCRs from Sub-Saharan Africa are reported here. Findings from other studies in Sudan, Thailand, Pakistan, Greece, Sri Lanka, Iraq, 
Paraguay, and India are reported separately in this table or are included in the Barlow et al. (1986) entry. 
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Source15 Country or 
region 
Study period Perspective/ 
Data sources 
Costs included Benefits included Total cost (2013 USD) Total benefits (2013 
USD) 
Net benefits (NB, in 
2013 USD) or benefit to 
cost ratio (BCR)  
4.167 M (2030) 
2.877 M (2035) 
Note: The color scheme in the table represents the focus of each study, where intensive malaria control is white and malaria elimination and eradication are in grey. 
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Acronyms used in Table S4.2 
 
B – Billion 
BCR – Benefit-cost ratio 
DALY – Disability-adjusted life year 
M – Million 
NB – Net benefit 
NPV – Net present value 
GDP – Gross domestic product 
GMAP – Global Malaria Action Plan 
R&D – Research and development 
WHO – World Health Organization 
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Table S4.3. Quality assessment of cost-benefit analyses using the 10-point Drummond checklist 
Article 
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10  
Was a well-
defined 
question 
posed in 
answerable 
form? 
Was a 
comprehensi
ve 
description 
of the 
competing 
alternatives 
given? 
Was the 
effectiveness 
of the 
programmes 
or services 
established? 
Were all the 
important 
and relevant 
costs and 
consequence
s for each 
alternative 
identified? 
Were costs 
and 
consequence
s measured 
accurately in 
appropriate 
physical 
units? 
Were costs 
and 
consequence
s valued 
credibly? 
Were costs 
and 
consequence
s adjusted 
for 
differential 
timing? 
Was an 
incremental 
analysis of 
costs and 
consequence
s of 
alternatives 
performed? 
Was 
allowance 
made for 
uncertainty 
in the 
estimates of 
costs and 
consequence
s? 
Did the 
presentation 
and 
discussion of 
study results 
include all 
issues of 
concern to 
users? 
TOTAL 
SCORE 
Barlow et al. (1986)* [1] NA NA NA NA NA NA NA NA NA NA NA 
Clinton Health Access 
Initiative, et al. (2011) [2] Y Y Y N Y Y N Y N N 6 
Prakash et al. (2003) [3] Y Y Y N N N N N N N 3 
Ramaiah (1980) [4] Y Y Y N Y Y N Y N N 6 
Utzinger et al. (2002) [5] Y Y Y Y Y Y Y N Y Y 9 
Livadas et al. (1963) [6] N Y N N N N N N N N 1 
Mills (2008)* [7] NA NA NA NA NA NA NA NA NA NA NA 
Niazi (1969) [8] Y Y N N N N N Y N N 3 
Ortiz (1968) [9] N Y Y N N Y N N N N 3 
Purdy et al. (2013) [10] Y Y Y N Y Y Y Y N N 7 
Note: The color scheme in the table represents the focus of each study, where intensive malaria control is white and malaria elimination and eradication are in grey.   
* These articles are reviews, which could not be assessed for quality using the Drummond checklist. 
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Table S4.4. Quality assessment of costing studies 
Reference Scope of costing  Accuracy of method evaluating cost 
Abeyasinghe et al. 
(2012) [1] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
α 
Micro-costing estimates based on 
individual item expenses and/or detailed 
data sets 
Akhavan et al. 
(1999) [2] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
γ 
Use of charge data as a proxy  
Beaver (2011) [3] D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Clinton Health 
Access Initiative, 
et al. (2011) [4] 
A 
All components of costs were described 
and data for both quantity and unit price 
of resources were reported for each 
component. 
γ 
Use of charge data as a proxy  
Cohn (1973) [5] D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
de Zulueta et al. 
(1972) [6] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Dua et al. (1997) 
[7] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Dy (1954) [8] B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Ebi (2008) [9] C 
All components of costs were described 
but costs in each component were not 
reported. 
γ 
Use of charge data as a proxy  
Giron et al. (2006) 
[10] 
C 
All components of costs were described 
but costs in each component were not 
reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
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budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Gunaratna (1956) 
[11] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Haque et al. 
(2014) [12] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Hedman et al. 
(1979) [13] 
A 
All components of costs were described 
and data for both quantity and unit price 
of resources were reported for each 
component. 
β 
Estimates based on relative value units 
(RVUs) or ratio of costs to charges (RCCs) 
Jackson et al. 
(2002) [14] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
α 
Micro-costing estimates based on 
individual item expenses and/or detailed 
data sets 
James (1903) [15] B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Jowett et al. 
(2005) [16] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
γ 
Use of charge data as a proxy  
Kaewsonthi et al. 
(1989) [17] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Kahn et al. 
(2009a) [18] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Kahn et al. 
(2009b) [19] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
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unpublished literature, personal 
communication, and other secondary 
sources) 
Kamolratanakul 
et al. (1999) [20] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Kaneko et al. 
(2000) [21] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Kiszewski et al. 
(2007) [22] 
A 
All components of costs were described 
and data for both quantity and unit price 
of resources were reported for each 
component. 
γ 
Use of charge data as a proxy  
Kligler (1924) [23] B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Kondrashin (1992) 
[24] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Konradsen et al. 
(1999) [25] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
α 
Micro-costing estimates based on 
individual item expenses and/or detailed 
data sets 
Korenromp et al. 
(2013) [26] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Liu et al. (2013) 
[27] 
A 
All components of costs were described 
and data for both quantity and unit price 
of resources were reported for each 
component. 
α 
Micro-costing estimates based on 
individual item expenses and/or detailed 
data sets 
Livadas et al. 
(1963) [28] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
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unpublished literature, personal 
communication, and other secondary 
sources) 
Lok (1979) [29] B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Mills (1992) [30] D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Mills (1993b) [31] B 
All components of costs were described 
and data for costs in each component 
were reported. 
β Estimates based on relative value units 
(RVUs) or ratio of costs to charges (RCCs) 
Mills (2008)* [32] NA Assessment not applicable NA Assessment not applicable 
Moonasar et al. 
(2013) [33] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Morel et al. 
(2005) [34] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
β Estimates based on relative value units 
(RVUs) or ratio of costs to charges (RCCs) 
Niazi (1969) [35] A All components of costs were described 
and data for both quantity and unit price 
of resources were reported for each 
component. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Ortiz (1968) [36] D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Prakash et al. 
(2003) [37] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Purdy et al. D Only scope of costing was described but δ No clear description of cost accounting 
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(2013) [38] components of costs were not described. methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Ramaiah (1980) 
[39] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Rezaei-Hemami et 
al. (2014) [40] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Ruberu (1977) 
[41] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
γ 
Use of charge data as a proxy  
Sabot et al. (2010) 
[42] 
A 
All components of costs were described 
and data for both quantity and unit price 
of resources were reported for each 
component. 
α 
Micro-costing estimates based on 
individual item expenses and/or detailed 
data sets 
Sharma (1996) 
[43] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Snow et al. (2008) 
[44] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Some (1994) [45] B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Stuckey et al. 
(2014) [46] 
A 
All components of costs were described 
and data for both quantity and unit price 
of resources were reported for each 
component. 
γ 
Use of charge data as a proxy  
Suarez Torres B All components of costs were described δ No clear description of cost accounting 
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(1970a) [47] and data for costs in each component 
were reported. 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Suarez Torres 
(1970b) [48] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Taiwan Provincial 
Malaria Research 
Institute et al. 
(1958) [49] 
D 
Only scope of costing was described but 
components of costs were not described. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Tatarsky et al. 
(2011) [50] 
A 
All components of costs were described 
and data for both quantity and unit price 
of resources were reported for each 
component. 
α 
Micro-costing estimates based on 
individual item expenses and/or detailed 
data sets 
Teklehaimanot et 
al. (2007) [51] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Utzinger et al. 
(2002) [52] 
C 
All components of costs were described 
but costs in each component were not 
reported. 
δ 
No clear description of cost accounting 
methods or inability to confirm the 
method easily (i.e., data are taken from 
budget or financial reports, published or 
unpublished literature, personal 
communication, and other secondary 
sources) 
Yadav et al. 
(1991) [53] 
B 
All components of costs were described 
and data for costs in each component 
were reported. 
γ 
Use of charge data as a proxy  
Note: References in RED are in Spanish or French. 
* These articles are reviews, which could not be assessed for quality using the Fukuda and Imanaka checklist. 
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5.1 Abstract 
 
Sri Lanka has made remarkable gains in reducing the burden of malaria, recording no locally 
transmitted malaria cases since November 2012 and zero deaths since 2007. The country 
was recently certified as malaria free by World Health Organization in September 2016. Sri 
Lanka, however, continues to face a risk of resurgence due to persistent receptivity and 
vulnerability to malaria transmission. Maintaining the gains will require continued financing 
to the malaria program to maintain the activities aimed at preventing reintroduction.  This 
article presents an investment case for malaria in Sri Lanka by estimating the costs and 
benefits of sustaining investments to prevent the reintroduction of the disease. An 
ingredient-based approach was used to estimate cost of the existing program. The cost of 
potential resurgence was estimated using a hypothetical scenario in which resurgence 
Chapter 5: An Investment Case to Prevent the Reintroduction of Malaria in Sri Lanka 
 
101 
 
 
assumed to occur, if all prevention of reintroduction activities were halted. These estimates 
were used to compute a benefit–cost ratio and a return on investment. The total economic 
cost of the malaria program in 2014 was estimated at U.S. dollars (USD) 0.57 per capita per 
year with a financial cost of USD 0.37 per capita. The cost of potential malaria resurgence 
was, however, much higher estimated at 13 times the cost of maintaining existing activities 
or 21 times based on financial costs alone. This evidence suggests a substantial return on 
investment providing a compelling argument for advocacy for continued prioritization of 
funding for the prevention of reintroduction of malaria in Sri Lanka. 
 
5.2 Introduction 
 
Sri Lanka has made extraordinary gains in reducing the burden of malaria in the last decade. 
Between 2000 and 2011, the number of malaria cases declined by more than 99% [1,2]. 
With zero locally transmitted malaria cases recorded since November 2012 and no 
indigenous deaths since 2007, Sri Lanka received the World Health Organization (WHO) 
certification of elimination in September 2016, an official recognition of its malaria-free 
status [1,3,4]. This period of progress coincided with increased political and financial 
commitment from the government and external donors, particularly the Global Fund to 
Fight AIDS, Tuberculosis and Malaria (Global Fund). 
 
As Sri Lanka’s national malaria program, the Anti Malaria Campaign (AMC), shifts its 
programmatic focus toward prevention of reintroduction (POR), it faces a new set of 
strategic and financial challenges [5]. Funding for malaria from the Global Fund is declining 
and being prioritized for high- burden, low-income countries [6]. At the same time, there is 
waning political interest and a rising disinterest toward malaria among health workers 
within the country as the disease is no longer considered a major public health threat and 
other health issues such as dengue fever and non- communicable diseases have become 
more pressing national health priorities [5]. 
 
Abruptly shifting focus away from the malaria program at this critical juncture is a 
conceivable risk to malaria resurgence in Sri Lanka. Scaling down of malaria efforts due to 
funding withdrawal in Sri Lanka in the 1960s is arguably the most cited resurgence story in 
history [7]. In 1963, malaria elimination was on the horizon with only 17 cases recorded in 
public facilities, of which only six were autochthonous (locally transmitted) [2, 8]. Following 
this success, there was a severe cutback in political and financial support for malaria control, 
leading to the withdrawal of malaria control measures, weakened surveillance and 
programmatic support, and growing insecticide resistance. Rapid resurgence of malaria 
soon followed with confirmed malaria cases rising to more than half a million in 1969 [8].  
Between 1970 and 1999, malaria control interventions were resumed; however, frequent 
epidemics continued to occur during the 1980s and early 1990s. 
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The country continues to face a significant risk of resurgence especially in areas of high 
receptivity and vulnerability. Increased levels of tourism, migration, poor infrastructure in 
some areas, and the presence of vectors contribute to vulnerability to autochthonous 
transmission triggered by imported malaria [9,10]. In 2013, 95 imported cases of malaria 
were reported throughout the year. 60 % of the imported cases occurred among Sri Lankans 
returning from travel overseas, most being diagnosed and reported by public sector 
hospitals in the Western Province, an area not traditionally endemic for malaria. 
 
To counter these challenges, Sri Lanka embarked on a new national strategic plan (NSP) for 
the elimination and POR of malaria for 2014–2018 [5]. The key focus of this strategy was to 
reorient and focus the program to strengthen surveillance systems for malaria, to facilitate 
rapid detection and response to emergent cases, and to eliminate parasite reservoirs and 
transmission foci. To implement this strategy, the AMC needs continued resources 
particularly in the short- to medium-term until the intrinsic transmission potential is 
sufficiently altered to make elimination stable. 
 
The purpose of this study was to develop an investment case for malaria POR in Sri Lanka. In 
addition, it reviews the funding landscape for malaria in the country and identifies 
anticipated gaps in the near future. The findings will provide the AMC with an estimate of 
the resources required to prevent the reintroduction of malaria, as well as robust evidence 
to advocate for sustained funding from both domestic and external sources. 
 
5.3 Methods 
 
5.3.1 Study design 
This study used a cost–benefit approach in which the cost of current malaria program 
activities was computed against the economic benefits of maintaining the program. A 
comprehensive literature review was initially conducted to gain an understanding of the 
current and historical structure, activities, and financing of the malaria program. 
 
A micro-costing approach was used to obtain data on the costs of POR. A detailed cost 
analysis was conducted for ongoing program activities from expenditure and financial 
records, historical record reviews as well as extraction from existing reports and key 
informant interviews. Available information was obtained from existing reports and grey 
and published literature, including AMC records at the national and regional levels. 
 
All fixed and recurrent costs incurred by the health system for malaria activities including 
resources received as donations and other in-kind or indirect expenditures were captured. 
Costs were categorized by source of funding, type of cost input, and by activity or 
intervention. Benefits were measured as the averted costs of resurgence were estimated 
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under a hypothetical scenario of resurgence, which was constructed based on historical 
data and expert opinion in the country. Under this counterfactual scenario, it was assumed 
that all POR activities would be halted in 2014 resulting in an increase in malaria cases 
between 2015 and 2020 with a peak in 2017, mimicking the magnitude and trend of the 
malaria epidemic between 1997 and 2002, adjusted for population growth. The cost of 
resurgence was estimated as the direct and indirect cost incurred by the health system to 
prevent and treat the increased cases as well as the direct and indirect cost incurred by 
individual households and the society. 
 
The framework presented in Figure 5.1 was used to develop the cost–benefit analysis using 
an ingredient-based micro- costing analysis for estimating cost and a corresponding 
counterfactual scenario analysis for estimating benefits. 
 
5.3.2 Study setting and sampling 
Sri Lanka is divided into nine provinces and 25 administrative districts. We purposively 
sampled five districts in five different provinces to collect data on the cost of the malaria 
activities for POR: Hambantota (Southern Province), Ampara (Eastern Province), 
Anuradhapura (North Central Province), Puttalam (North Western Province), and Jaffna 
(Northern Province). The sampled districts represented regions where recent cases had 
been identified and included a range of previously endemic regions that used different 
mixes of interventions. Based on input from the AMC and other in-country experts, these 
sampled districts were deemed to be representative of the remaining 20 districts with 
respect to programmatic costs and levels of receptivity and vulnerability to malaria 
transmission. In addition, cost data were also collected from the AMC at the national level. 
 
5.3.3 Data collection 
Data collection for this study took place between February and July 2015. Data on the costs 
of malaria POR activities for 2014 were obtained from interviews and a review of the most 
recent budget and expenditure records. Staff at the regional malaria offices (RMOs) in each 
of the sampled districts was interviewed in a semi- structured format. The time spent on 
each activity was recorded based on self-reporting by the RMOs and other interviewees 
triangulated with interviews with the AMC director. At the central level, officers at the AMC 
including the AMC director, director of finance and accounting, surveillance, and monitoring 
and evaluation unit staff, and the Global Fund project finance manager were interviewed. 
 
Data for the cost of resurgence were retrieved from published and unpublished literature 
and described in detail under “data analysis” below. Key informant interviews with AMC 
staff were also conducted to obtain consensus on the assumptions used and to fill any 
outstanding data gaps. The data on financing for malaria were extracted from existing 
Chapter 5: An Investment Case to Prevent the Reintroduction of Malaria in Sri Lanka 
 
104 
 
 
reports and grey and published literature including, but not limited to, Internet-based 
searches and AMC records at the national and regional levels. 
 
This study was approved by the institutional review boards of the University of California, 
San Francisco Committee on Human Research (Study no. 14-14546, Reference no. 093635) 
and the Ethics Review Committee of the Faculty of Medicine, University of Kelaniya, Sri 
Lanka (Reference no. P/209/10/2014). Verbal informed consent procedures were conducted 
before each interview. 
 
5.3.4 Data analysis 
Estimating cost of POR. Primary data on costs collected from each sample district and the 
AMC were aggregated based on three dimensions—funding source, activity or intervention, 
and input type—to identify the cost drivers for malaria POR activities. All costs were 
expressed in 2013 U.S. dollars (USD), using a mid-year exchange rate of 131.5 Sri Lankan 
rupees per USD. 
 
Cost by source. The two main sources of funding for malaria activities in Sri Lanka were 1) 
domestic funding, in the form of direct government allocations from the national health 
budget to the AMC and to the provinces, and 2) external funding, primarily from the Global 
Fund provided to the government for malaria activities. Government resources were 
disbursed to provinces and districts for all integrated health activities including malaria 
prevention and control separately from the resources provided to the AMC specifically for 
malaria activities. The explicit source of funding for malaria activities for each line item was 
identified to the extent possible. 
 
Cost by input. Costs were categorized by four major inputs of production: capital, personnel, 
consumables, and services. Capital costs included vehicles, buildings and office space, 
furniture, computers, and other durable sup- plies. Personnel costs included salaries, 
allowances, and any other compensation to staff involved in malaria activities. Consumable 
costs included office and laboratory sup- plies, medicines, insecticides, and other products. 
Service costs included utilities, transport (domestic and international), training, 
maintenance, and security. 
 
Capital goods were annualized based on their useful life years and a standard discount rate 
of 3%.  Maintenance costs for equipment, vehicles, or buildings were calculated using actual 
information on the expenditure of maintaining these resources. No replacement costs were 
used for capital resources when their current value had already depreciated to zero, 
assuming that replacement would not occur in the near future. For all inputs shared across 
multiple programs, only the cost attributed to malaria activities was included based on the 
%age of time spent on malaria-specific activities. Shared resources such as staff time spent 
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on each activity were self-reported and determined through interviews and triangulated 
using multiple sources. 
 
Cost by activity or intervention. All costs were divided across seven different activity groups 
for malaria: vector control (VC); diagnosis (D); treatment and prophylaxis (TP); surveillance 
and epidemic management (SEM); monitoring and evaluation (ME); information, education, 
and communication (IEC); and program management (PM). Although the implementation of 
most of these activities was integrated, the activity groups were created to facilitate analysis 
for the purpose of this study. Resources were apportioned across the activities based on 
self-reporting during interviews. Table 5.1 details the inputs for each of these interventions. 
 
Estimating cost of POR at the national level. To obtain national-level estimates of cost of 
POR, data from the five sampled districts were extrapolated to the entire country by 
matching each non-sampled district to a representative sampled district. District matching 
was based on the size of the malaria program and the mix of activities implemented by the 
sampled and non-sampled districts. The number of staff and the size of the district 
measured by area in square kilometers were used as proxies for the size of the malaria 
program for the purpose of matching for cost extrapolation. Districts in the Western 
Province (i.e., Colombo, Gampaha, and Kalutara) were not matched in the same way 
because the AMC serves as the RMO for this region and their costs were already 
incorporated into AMC costs. 
 
To estimate the national cost of POR, the total cost incurred by each sample district in 2014 
was divided by its respective population to get the average cost per capita. The population 
of each non-sampled district was multiplied by the average cost per capita from the 
corresponding matched sample district. Costs across all districts were then summed 
together with the central level costs from the AMC to estimate the total cost of POR for the 
country for 2014. The AMC anticipated that the activities and, therefore, the cost of 
continuing POR over the next 3–5 years is likely to be similar to the cost of the program in 
2014. The NSP (2014–2018) prioritizes strengthening of the existing interventions for 
malaria, particularly surveillance and response for the early detection of cases and their 
effective treatment, maintaining skills for diagnosis and treatment, strengthening 
preparedness for epidemic and outbreak response, and entomological surveillance through 
integrated vector management. The cost data estimated for 2014 were thus projected 
linearly to obtain cost estimates for 2015–2020, assuming a steady economic growth rate 
[11]. 
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Figure 5.1. Framework for cost and benefit analysis 
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Table 5.1. Detailed explanation of cost categories 
 
Vector control (VC)  
 
Environmental management 
Targeted biological control  
Personal and community protection (LLINs and 
IRS) 
Chemical larviciding 
Diagnosis (D) Rapid diagnostic test  
Molecular diagnosis and confirmation  
Quality assurance 
Treatment and prophylaxis (TP) Chemoprophylaxis 
Passive case detection and treatment 
Provider training 
Surveillance and epidemic management (SEM) Active case detection 
Activated passive case detection 
Entomological surveillance 
Case investigation and response 
Epidemic response 
Surveillance training 
Private sector surveillance  
Monitoring and evaluation (ME) Internal ME 
External ME  
Health information system 
Periodic surveys  
Information, education, and communication 
(IEC) 
Private sector engagement 
Partnership development 
Behavior change communication programs 
Policy advocacy 
School-based education 
Operational research 
Program management (PM) 
 
Administrative training  
Capacity building 
Staff placement and recruitment 
Meetings 
Supervision and monitoring 
General administration 
* Each of the categories above includes the human resources, consumables and utility costs associated with 
implementing the activit
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5.4 Estimating cost of resurgence 
 
The benefit of sustained investments in malaria and hence the corresponding cost saving from POR 
activities was obtained by estimating the cost of potential malaria resurgence. A hypothetical 
resurgence scenario was constructed based on the assumption that all POR activities would have 
been halted in 2014, resulting in an increase in malaria cases between 2015 and 2020 similar to 
that observed during the epidemic between 1997 and 2002, after adjusting for population growth. 
In this scenario, the peak number of malaria cases was assumed to be 324,371 with 122 deaths 
with a total epidemic size of 1,241,776 cases. The detailed parameters used to estimate the cost of 
resurgence and their data sources are listed in Table 5.2. As shown in Figure 5.1, the costs of 
resurgence were categorized based on three broad dimensions: 1) cost to the health system, 2) 
cost to the individual households, and 3) cost to the society. 
 
Cost to the health system. Cost due to increased health service utilization. The potential cost of 
malaria resurgence to the health system was calculated separately for uncomplicated malaria (UM) 
and severe malaria (SM). Of the UM cases, Plasmodium vivax cases were presumed to be treated 
with primaquine for 14 days and chloroquine for 3 days according to the national treatment 
guidelines, and Plasmodium falciparum cases with artemether–lumefantrine as inpatients. Table 
5.3 outlines the malaria treatment guidelines in Sri Lanka. 
 
Table 5.2. Input parameters, and the data sources 
 
Parameter Values Sour
ce 
Comments 
Population 18.75 million  (year 1999) 
20.96 million (year 2015) 
[15] Projected for 2015 
based on population 
growth rates from 
UN[20] 
GDP per capita Year 1999: 2135.7 (in 2005 
USD) 
Year 2015: 3839 
  
GDP growth rate Year 2015: 7.4% [11]  
Malaria    
Number of cases 264,549 (year 1999) 
324,371 (year 2017) 
 
[11] Projected for 2015 
based on population 
growth rates from 
UN 
Distribution of cases by gender Male: 54% (1999); 90%(2015) 
Female: 46% (1999); 
10%(2015) 
AMC Distribution for year 
2015 based on that 
for 2011 
Distribution of cases by age <15 years: 41% (1999): 6% AMC Distribution for year 
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Parameter Values Sour
ce 
Comments 
(2015) 
>15 Years: 59% (1999): 94% 
(2015) 
2015 based on that 
for 2011 
Number of deaths 102 (1999) 
122.3 (2015) 
AMC Projected for 2015 
Proportion of uncomplicated cases  75% AMC  
Proportion of severe cases 25% AMC  
Proportion vivax 76% AMC  
Proportion falciparum 24% AMC  
Slide positivity rate 16.72% AMC  
Total blood films 1.58 million AMC  
% population protected by IRS 4% twice a year AMC   
# of LLINs needed 1 LLIN per 1.8 population in 
“at risk areas” 
[16]  
Cost and related parameters    
# days lost due to a malaria illness 9.3 days [17]  
Cost of OP illness USD 1.68 [12]  
Cost of IP admittance USD 24.49 [12]  
Cost of malaria medicines (OP) USD 1.00 AMC  
Cost of malaria medicines (IP) USD 8.5 AMC  
Cost of IRS per person protected USD 4.37 [17]  
Cost of LLIN distributed USD 6.87 AMC  
Cost of testing non-malaria fevers USD 1.12 per RDT  
USD 0.86 per microscopy 
slide 
[12]  
Cost for SP during pregnancy USD 0.5 AMC  
Cost of household consumption 
goods for malaria  
USD 7.31 [17]  
Tourism    
Number of tourists (in million) 0.44 million (1999) 
1.89 million (2015) 
[18]  
Average nights spent by tourist 8.6 (1999) 
9.25 (2015) 
[18] 2015 data is based 
on author’s 
projection based on 
previous trends 
Average revenue per tourist per 
day 
USD 158.65 [18]  
%age of tourists from Europe and 
North America 
67 [18]  
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Table 5.3. Treatment guidelines for malaria treatment in Sri Lanka 
 
Uncomplicated malaria (P. falciparum) Hospitalization for 3 days with immediate dose of 
primaquine (0.75 mg/kg body weight) plus 
artemether-lumefantrine (20/120 mg) 
Severe malaria (P. falciparum) Hospitalization with injectable artesunate until 
patient can take medication orally (usually 3 days) 
after which a complete course of artemether-
lumefantrine (20/120 mg) is given 
Military P. vivax patients hospitalized for 3 days in military 
medical facilities; patients are kept within their 
barracks for two weeks for 14- day primaquine 
regimen (0.25 mg/kg body weight) in addition to 
chloroquine for 3 days 
Non-military Primaquine for 14 days (0.25 mg/kg body weight) 
plus chloroquine for 3 days 
Mixed infections Artemether-lumefantrine (20/120 mg) for 3 days 
plus primaquine for 14 days as an inpatient for 3 
days 
 
The unit costs of malaria treatment were multiplied by the number of potential cases to estimate 
the total cost of treatment to the health system. Actual health system costs for both inpatient and 
outpatient treatment of malaria were not available as malaria services are integrated with general 
health services. Therefore, secondary data from a separate micro-costing database from a teaching 
hospital in Kurunegala, Sri Lanka, were used to approximate service delivery costs, which included 
the average cost of out- patient care  (including consultation and diagnostic tests) and the average 
cost of hospital admission for all patients regardless of original complaint or final diagnosis [12]. 
The cost of inpatient care thus includes the length of a hospital stay multiplied by the average cost 
of a hospital bed per day. The cost of an average course of antimalarials as reported by the AMC 
was added to this to obtain the total cost of malaria treatment (AMC, personal communication). 
Supply chain costs were estimated as 25% of the acquisition cost of the product and added to the 
unit cost of the medicine [13]. 
 
Cost of vector control. The cost of indoor residual spraying (IRS) and distribution of long-lasting 
insecticidal nets (LLINs) were used to estimate the cost of vector control under the resurgence 
scenario.  Under this scenario, we assumed that the country would resume IRS at a coverage rate of 
4 % of the total population, similar to the coverage rate during the 1999 resurgence (AMC, personal 
communication). 
 
In addition, LLIN coverage of 1 net per 1.8 people was assumed based on WHO recommendations 
for the population at risk [14]. The total population at risk was identified in collaboration with the 
AMC based on the receptivity and vulnerability for malaria transmission in the country. Costs for 
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procurement, distribution, and delivery of LLINs and IRS were obtained from WHO Global Malaria 
Program and added to the cost of vector control as these costs were not available in country 
(Patouillard, E., personal communication). 
 
Cost of increased diagnosis of fever cases for malaria. Under the resurgence scenario, it was 
assumed that more fever cases would be tested for malaria, leading to increased spending on rapid 
diagnostic tests (RDTs) and microscopy. Using the slide positivity rates from 1999 of 16.72% and the 
expected number of positive malaria cases in 2015, we estimated the total number of potential 
non-malaria cases assuming that 83.28% of the cases would be non-malarial fevers. The excess cost 
of diagnosing non-malaria fever cases was obtained by multiplying the number of potential non-
malarial fevers by the average cost of diagnosis (average of RDT and microscopy) plus the cost of 
administering the test (AMC, personal communication). 
 
Cost of training and IEC. In the event of malaria resurgence, it was assumed that there will be 
additional training for providers of all cadres, as well as additional IEC-related activities directed at 
the community. 
 
Cost to the individual household. Out-of-pocket (OOP) expenditures incurred due to malaria. All 
malaria cases are treated in the public sector free of charge. They do not incur any user fees and 
there are no social health insurance schemes covering malaria. OOP expenditures due to malaria 
include both direct and indirect cost incurred by the house- hold for preventing or seeking care for 
malaria. These included transport costs as well as expenditures on other products for prevention, 
such as LLINs, mosquito coils, and repellents. These expenditures were extrapolated from 
secondary data from a study done in Sri Lanka in 1994 and inflated to reflect current costs [17]. 
 
Cost to society. Cost due to loss of life to malaria. The full income approach (see equation below) 
was used to estimate the potential social value of life lost due to malaria mortality as proposed by 
the Lancet Commission on Investing in Health [19]. This approach combines growth in national 
income with the value of additional life years (VLYs) due to malaria, which accounts for an 
individual’s willingness to trade off income, pleasure, or convenience for an increase in life 
expectancy. 
 
𝑰𝒏𝒄𝒐𝒎𝒆 𝑮𝒓𝒐𝒘𝒕𝒉 + 𝑽𝒂𝒍𝒖𝒆  𝒐𝒇 𝒍𝒊𝒇𝒆 𝒚𝒆𝒂𝒓𝒔 𝒈𝒂𝒊𝒏𝒆𝒅 𝒊𝒏 𝒕𝒉𝒂𝒕 𝒑𝒆𝒓𝒊𝒐𝒅 
= 𝑪𝒉𝒂𝒏𝒈𝒆 𝒊𝒏 𝒄𝒐𝒖𝒏𝒕𝒓𝒚′𝒔 𝒇𝒖𝒍𝒍 𝒊𝒏𝒄𝒐𝒎𝒆  𝒐𝒗𝒆𝒓 𝒂 𝒕𝒊𝒎𝒆 𝒑𝒆𝒓𝒊𝒐𝒅 
 
The (potential) number of adult deaths due to malaria in the resurgence scenario was multiplied by 
the remaining life years at death and the VLYs. The number of excess deaths among adults (persons 
age 15 years and above) in the hypothetical scenario was projected based on deaths between 1997 
and 2002. The average life expectancy at age 40 years (separately for male and female) obtained 
from World Bank data was used as a proxy for the remaining life years at death due to malaria [11]. 
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The Lancet Commission estimates the VLY average across low- and middle-income countries to be 
2.3 times the income per capita at a 3% discount rate [19]. Sri Lanka’s gross domestic product (GDP) 
per capita at 7.4%for 2015 was obtained from the World Bank database [11,17]. 
 
Cost due to loss of productivity to malaria morbidity. The reduced productivity or lost earnings due 
to malaria morbidity in adults was estimated by multiplying the potential malaria cases among the 
adult population, average days lost to one malaria episode (estimated at 9.3 days from previous 
research), and the average income (GDP) per capita per day obtained from World Bank data 
[14,16]. 
 
Estimating the return on investment. The return on investment (ROI) to the health system was 
calculated as the difference in total cost of POR and total cost of potential resurgence, also known 
as the net gain, divided by the total cost of POR. The cost of POR was computed from an input 
perspective using data from the costing portion of this study, whereas the cost of resurgence was 
computed from an output perspective, where the output costs were multi- plied by the potential 
number of cases under resurgence. 
 
Uncertainty analysis. As with any cost and benefit estimation, our estimates relied on various 
assumptions about the input parameters, such as discount rates. To test the sensitivity of the cost 
of POR to discounting, the discount rate used for capital goods was varied between 1% and 7%. 
Another key underlying assumption in this analysis is that withdrawal of all malaria interventions 
will result in resurgence. The risk of resurgence in the future primarily hinges on two key 
parameters: the probability of resurgence and the severity of resurgence. In our construction, we 
assumed that future resurgence would be as severe as that experienced during the most recent 
epidemic between 1997 and 2002 (with a peak in year 1999). We also assumed that the resurgence 
would follow a similar distribution pattern and that a resurgence of this severity would occur with 
100% probability. 
 
To assess the robustness of our estimates with regard to the uncertain risk of resurgence, we 
conducted a sensitivity analysis by generating several alternative scenarios of resurgence with 
varying assumptions of severity and probability based on historical data. Following the application 
in the insurance industry and recent literature on pandemic influenza risk, we used the notion of 
“exceedance probability” to test probability of a resurgence with a certain thresh- old severity. 
Using historical data on malaria incidence, the maximum annual growth rate and the maximum 
total growth rate (between trough years) were used to vary the severity levels. Additional 
probabilities for the risk of resurgence were based on available historical data in the literature. 
Cohen and others (2012) [7] noted that 75 malaria resurgence events occurred over 70 years in 61 
different countries, which translates to a 2% probability of resurgence. We used this as a lower 
bound estimate to analyze the sensitivity of the ROI to varying probabilities of resurgence between 
2 and 100%. 
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Table 5.4 includes the various parameters that were varied and scenarios that were generated to 
assess the uncertainty of the cost and ROI estimates. Figure 5.2 illustrates the scenarios that were 
as translated into incidence projections. Financial costs of malaria. The financial costs of malaria 
POR were obtained from the estimates of economic costs without accounting for capital costs or 
the cost of the general health system or personnel that are financed through integrated national 
and provincial health budgets not specific to malaria. 
 
Table 5.4. Scenarios for uncertainty analysis  
 
Severity of resurgence Scenarios 
Incidence rate similar to historical rates between 1997-2002 Baseline 
Maximum annual growth rate observed between two peak years I 
Maximum total growth rate observed between two peak years II 
Growth rate in 1975 from previous trough year  III 
Growth rate in 1987 from previous trough year IV 
Growth rate in 1991 from previous trough year V 
Growth rate in 1999 from previous trough year VI 
Growth rate required to reach number of cases in year 1968 from 2012 level VII 
Growth rate required to reach number of cases in year 1975 from 2012 level VIII 
Growth rate required to reach number of cases in year 1987 from 2012 level  IX 
Growth rate required to reach number of cases in year 1991 from 2012 level  X 
Growth rate required to reach number of cases in year 1999 from 2012 level  XI 
Probability of resurgence   
100% Severe 
51% Median 
2% Mild 
Note: The severity of resurgence is determined based on a combination of historical growth rates since 1950 in 
order to reach the peak level of resurgence from the base year 2012 (when only 23 cases were observed). The 
distribution of cases during hypothetical resurgence years (2015-2010) followed the actual case distribution 
observed between years 1997-2002.   
 
5.5 Results 
 
5.4.1 Cost of POR 
The total economic cost of the malaria program in Sri Lanka for 2015 was estimated to be USD 
11.85 million (Table 5.5). 58 % of the total cost was incurred by the AMC, whereas the provincial 
level incurred the remaining 42 %. Cost estimates varied widely across the districts from less than 
USD 30,000 to about USD 0.5 million per year with a median cost of USD 197,252. The average 
economic cost per capita for POR was estimated to be USD 0.57 and the corresponding financial 
cost was USD 0.37 for 2015. 
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Figure 5.2. Framework for uncertainty analysis 
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About 80  % of the total cost was funded domestically, of which 8 % was from provincial funds and 
72 % was from national government. The Global Fund financed the remaining 20 %. Funding for the 
AMC was primarily domestic (82 %) and the remaining 18% from the Global Fund. Across the 
districts, the source of funding varied largely with an average of 70 % domestic (of which 9 % was 
national and 62 % was provincial) and 29 % from donors. 
 
Table 5.5. Projected cost for malaria POR 
 
Year Estimated annual cost 
(millions USD) 
Cumulative cost 
(millions USD) 
2015  11.86  11.86 
2016  12.62   24.48 
2017  13.43   37.90 
2018  14.28   52.19  
2019  15.20  67.39 
2020  16.17  83.56  
 
 
Figure 5.3. Distribution of input cost across sample districts 
 
 
Among the inputs, human resources constituted the largest share at about 83% of the total cost, 
followed by capital costs at about 13%. Consumables and services together constituted about 5% of 
total cost of malaria POR. There was considerable heterogeneity in the mix of inputs across the 
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district and the national levels (Figure 5.3). In all instances, however, human resources were the 
main cost driver at 62– 90% of total cost among the districts. The share of capital cost was, on 
average, 22% (range: 8–30%). Consumables constituted < 1% of the total cost (range: < 1–3%), and 
services constituted approximately 3% of the total cost (range: < 1–5%). 
 
Among the activities, the major cost drivers at all levels were project management and surveillance 
and epidemic management, followed by VC and D. Figure 5.4 illustrates the distribution of total 
costs across all activities in Sri Lanka. At a national level, PM consisted of about 63% of the total 
cost, followed by SEM at about 12%, and VC at 9%. 
 
Figure 5.4. Distribution of total cost of POR across interventions 
 
 
 
 
The cost of activities also varied widely across districts (Figure 5.5). At the district level, SEM 
constituted an average of 33% of the cost  (range:  21–44%).  Across the districts, the cost share for 
VC averaged 19% (range: 11–28%). Similarly, the cost share of D ranged between 8% and 24% with 
an average of 16%. The cost share of IEC was fairly stable across districts at approximately 5% of 
the total cost. 
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Figure 5.5. Distribution of cost of POR by intervention across districts    
 
 
Across all activities, human resources constituted the highest share, followed by capital costs. The 
most human resource-intensive interventions were PM, SEM, and ME. IEC was the most capital-
intensive intervention. As expected, TP followed by VC and D constituted relatively higher shares of 
consumable costs than other interventions. These differences in inputs across interventions are 
illustrated in Figure 5.6. 
 
Cost of POR activities over time. The future cost of POR was extrapolated using the costs for 2014 
adjusting for economic growth under the assumption that most of the activities and interventions 
for POR will remain constant over the next 5 years. The estimated cost to sustain the current level 
of activities for malaria between 2015 and 2020 was estimated at USD 83 million (Table 5.4). 
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Figure 5.6. Distribution of input cost across interventions 
 
 
 
5.4.2 Cost of resurgence 
Figure 5.7 illustrates this cost of resurgence between 2015 and 2020 broken down by the cost to 
household, the health system, and society. 
 
Table 5.6. Cost of resurgence of malaria for year 2015   
Cost of resurgence in 2015 Best estimate 
(in millions USD) 
Direct cost to the health system 
 
Cost due to increased health service utilization 14.63 
Cost of vector control to control resurgence 104.08 
Cost of increased diagnosis  1.30 
Cost of training human resources and educating 
community 
1.31 
Direct cost to the individual household 
 
Out of pocket expenditure due to malaria  1.96 
Indirect cost to the society 
 
Cost due to loss of life to malaria  21.13 
Cost due to loss of productivity to malaria morbidity 24.54 
Total cost of resurgence in 2015 168.96 
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The total cost of resurgence was estimated at approximately USD 169 million. Within this cost, the 
direct cost to the health system was USD 121 million, the cost to households was USD1.95 million, 
and the cost to society totaled USD 45.66 million (Table 5.6).  
 
The cost of resurgence was estimated to be the highest for year 2017 when the incident cases peak 
and started declining following the trajectory of malaria incidence. The majority of the cost of 
resurgence is incurred by the health system, followed by the cost to society. As the majority of 
malaria interventions are publicly funded, out-of-pocket expenditures or household did not 
constitute a large portion of the cost. 
 
5.4.3 Return on investment 
The total cost of malaria POR in Sri Lanka for 2015 was estimated to be USD11.86 million, whereas 
the total cost of resurgence for the corresponding year was USD168.96 million yielding a ROI of 
more than 13 to 1. When considering the financial costs only (without capital cost and non-malaria-
specific cost incurred by the integrated health system), the ROI was estimated at more than 21 to 1. 
 
Similarly, when considering only the financial cost to the health system (without individual or 
societal costs), the cost of resurgence is estimated to be about 10 times the cost of maintaining the 
activities yielding a ROI of 10 to 1. 
 
Figure 5.7. Cost of resurgence of malaria in Sri Lanka 
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5.4.4 Uncertainty analysis 
An uncertainty analysis was carried out using a variety of discount rates to test the robust- ness of 
the results. The results did not vary significantly with the discount rates used—the difference in the 
cost estimate between the highest and the lowest discount rates was less than USD 0.2 million in 
2015. A discount rate of 3 % produced the median cost estimates and was retained for this analysis. 
 
In addition, a sensitivity analysis was performed on the cost of resurgence by varying the risk and 
probability of a hypothetical resurgence scenario. Figure 5.8 illustrates the ROI obtained under the 
various scenarios. Under these resurgence scenarios, the cost of resurgence was estimated at 
between USD 78 and 208 million. 
 
The ROI, in turn was found to be between 6 and 16 under various severity and probabilities of 
resurgence. As expected, the cost of resurgence starts declining as the resurgence is contained 
after the peak year in 2017, resulting in a subsequent reduction in ROI. Figure 5.8 illustrates the 
sensitivity of the ROI using economic cost to varying levels of risk and probability of resurgence. 
Eleven scenarios of incidence were used in the sensitivity analysis denoting risk at three levels of 
probability: 100 %, 51 %, and 2 % for a total 33 scenarios (Table 5.4). 
 
Figure 5.9 illustrates the sensitivity of the ROI using financial cost to varying levels of risk and 
probability of resurgence. Eleven scenarios of incidence were used in the sensitivity analysis 
denoting risk at three levels of probability, 100 %, 51 %, and 2 % for a total 33 scenarios (Table 5.4). 
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Figure 5.8. Sensitivity analysis of the estimates of return on investment in malaria using economic 
costs 
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Figure 5.9. Sensitivity analysis of the estimates of return on investment in malaria using financial 
costs 
 
 
 
5.4.5 Financing for malaria 
In 2014, total funding for malaria activities from all sources was USD 8.7 million, which accounted 
for about 1 % of the overall government spending on health in Sri Lanka [5]. Domestic funding 
accounted for about 58 % of the expenditure on malaria in the country in 2014, whereas the 
remaining 42 % of the funding for malaria came from the Global Fund at USD 3.7 million [5]. Table 
5.7 provides the actual and the projected expenditures on malaria from 2012 to 2017. 
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Table 5.7. Actual and projected expenditures for the malaria program in Sri Lanka 2012-2017 
 
Source of Funding Actual funds spent 
(millions USD) 
Projected funds (USD) 
 2012 2013 2014 2015 2016 2017 
Domestic spending [1] 3.26 3.63 5.06 5.49 6.12  6.77 
Global Fund support [2] 2.91 3,.13 3.72 2.47 2.47  2.47  
Total budget for malaria 
control 
6.17 6.76 8.78 7.95 8.58 9.23 
Total domestic spending 
on health 
7.58 8.41 9.34 1,037 1,151 1,277 
% of domestic funding for 
malaria 
53 54 58 69 71 73 
% of domestic health budget 
allocated for malaria 
0.43 0.43 0.54 0.53 0.53 0.53 
Total budget for malaria as a 
%age of total domestic 
spending on health 
0.81 0.80 0.94 0.77 0.75 0.72 
 [1] Based on data published by the Central Bank of Sri Lanka (www.cbsl.gov.lk) 
[2] Global Fund support amounting to USD 9.6 million has been requested for the period 2014-2017. Given that this grant 
was not approved until 2015, it has been allocated to 2015-2017 projected costs and has been split evenly among the 
three years. 
 
The financial cost required to maintain the current level of malaria activities in Sri Lanka in 2015 
was estimated to be on average about USD 7,673,961 million annually. Domestic financing covered 
approximately 53 % at USD 4,054,878. Even with resources from the Global Fund at approximately 
USD 2.3 million, Sri Lanka still faces a financial gap of about USD 1.7 million annually. 
 
5.6 Discussion 
 
This study found that the economic cost of maintaining malaria POR in Sri Lanka was approximately 
USD 0.57 per capita in 2015 and the corresponding financial cost was USD 0.37 per capita. In 
contrast, the cost of resurgence in 2015 was estimated to be USD 169 million or USD 8.07 per 
capita in a single year, yielding an economic ROI of 13.29 to 1 and a financial return of 21 to 1. This 
by far exceeds the threshold on returns that are considered to be high- impact investments [20]. 
 
The estimates of cost of resurgence in this study are likely to be undervalued as they exclude 
several macro- economic costs of malaria far beyond the health system. Studies have shown that 
indirect costs of malaria account for a large share of societal costs due to its debilitating physical 
impact leading to cognitive disability in children and later productivity as adults, as well as impeding 
macro-economic development by limiting foreign investments and tourism [21-27]. These 
macroeconomic impacts have not been included in these estimates, primarily due to the lack of 
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accurate data to quantify these effects and to directly attribute them to malaria.  Other costs to the 
health system such as cost of drug and insecticide resistance, the cost of higher price alternatives, 
the cost associated with their implementation, and the cost of research and development have also 
been omitted.  
 
There are several limitations to the data and methods used in this study. Obtaining accurate data 
on the cost of program operations, particularly in an integrated health system, is challenging. 
Several malaria program resources were shared across other public health programs. Peripheral 
level staff is often designated to perform other public health functions such as dengue surveillance 
following the decline in malaria burden leading to difficulties in attributing specific resources to 
malaria alone. Furthermore, activities for malaria were paid for through a combination of 
government and external resources. Although most provincial level staff was paid using 
government funds, several central AMC staff was funded through the Global Fund grants. In 
addition, resources for malaria control were spread across interventions and activities. Costs for 
malaria in this study were estimated using self-reported hours during the interview process and 
apportioned to the respective malaria activities. While this is a common methodology used in other 
studies, the authors acknowledge the potential reporting bias in the estimates. Ideally, a protracted 
period of time would be spent in the field to closely monitor and record the time and resources 
spent on each activity. However, such an approach would require a considerably more resources 
than those available for this work. 
 
The perspective used for estimating the cost of POR was the public sector provider perspective as 
the majority of costs incurred for malaria are from the public sector with prevention and treatment 
provided free by the government at the time of this analysis. 
 
The findings of this work are based on a hypothetical resurgence scenario. Although the probability 
and magnitude of resurgence are difficult to predict, historical evidence from Sri Lanka and other 
countries suggests that weakening vigilance and waning financing provide a high risk for malaria 
resurgence [7]. In this study, the cost of resurgence was over 14 times the cost of POR with a 
healthy ROI of 13 to 1. Varying the risk and probability of resurgence consistently outweighs the 
cost of investing in POR. 
 
The major cost driver in the resurgence scenario was vector control. The analysis used conservative 
estimates of vector control coverage of 4% for IRS and targeted LLIN coverage to populations at 
risk. The authors recognize that the resulting ROI is based on these assumptions; however, 
historical evidence from Sri Lanka, experience from other countries, and expert consultations on 
the intervention cover- age in a potential resurgence scenario were used to inform these 
assumptions. 
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The total income approach was used to compute income losses from malaria mortality. Although 
this methodology provides more generous estimates of losses than other methods, given the small 
number of deaths in the resurgence scenario, the use of this method is not likely to have resulted in 
a significantly higher than expected ROI. 
 
There are currently no global recommendations on the specific mixes of interventions needed for 
elimination and POR, and little data on the effectiveness and cost-effectiveness of the various 
strategies for POR. The AMC has largely suspended vector control activities in favor of rigorous 
epidemiological and entomological surveillance. Decisions on intervention selection were made by 
experts with in-depth historical knowledge of malaria epidemiology in Sri Lanka, bolstered by 
pragmatic decision-making. These cost estimates are largely founded on the assumption that the 
current strategy in Sri Lanka will continue to succeed in preventing POR. Nevertheless, without a 
transmission model or comparative trial data to assess the epidemiological and economic efficiency 
of the intervention mix, it is difficult to recommend optimal strategies or to judge if further cost 
savings can be accrued through technical and programmatic efficiencies. 
 
When compared with projected “top-down” cost estimates from the NSP, the economic cost is 
approximately 43% higher as our estimates include societal costs to the health system including 
health worker salaries in the integrated health system. Using financial costs only demonstrated 
similar estimates to the NSP projections with a financial cost of 7% less than the top-town budget 
projections. In addition, the NSP projections do not include the savings that the AMC had accrued 
from insecticide procurement from targeting IRS to high-risk areas. 
 
Despite the robust benefits associated with investing in malaria POR, Sri Lanka’s program is likely to 
face a gap in funding in the immediate future. Funding for malaria from government sources met 
only 53% of the total needs in the country, as estimated by this study. This gap is likely to be much 
higher after 2018 when the Global Fund grant ends, which unless bridged by domestic resources 
will result in a severe funding cliff with potential devastating effects on the malaria program. 
 
Despite the waning commitment from donors and shifting of government priorities, there are 
several opportunities within the country to mobilize additional resources for POR. Sri Lanka 
currently allocates only about 0.43% of their total domestic expenditure on health to malaria [5]. A 
recent analysis by Jha and colleagues suggest that if Asian countries were to allocate 2 % of their 
health budgets to malaria, the funding gap would be reduced significantly [28]. Increasing the 
funding domestically or identifying alternative financing mechanisms is imperative to sustaining the 
gains in malaria control and elimination in Sri Lanka. 
 
Sri Lanka’s economy has experienced strong growth rates in recent years. The flourishing economy 
presents an opportunity for the government to increase its domestic allocations for health and 
hence funding for malaria. Tax revenues constitute only around 13.1% of Sri Lanka’s total GDP in 
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2013, although the government of Sri Lanka has recently announced new adjusted tax proposals 
[29,30]. Raising tax revenues to amount to 20% of GDP as recommended by the Addis Ababa 
accord for the Sustainable Development Goals would generate an additional revenue of USD4.35 
million per year—a potential funding source for malaria POR [31]. The private sector is also a major 
player in Sri Lanka’s economy. A total of 40 companies collectively spend about USD 30.5 million 
annually on corporate social responsibility (CSR) covering a wide range of development issues [32]. 
The CSR consortia in Sri Lanka has recently partnered with Sri Lanka’s Public Health Department for 
dengue eradication. Tapping into the resources from CSR programs of large multinational firms 
operating in Sri Lanka to fight malaria may also be a potential resource for POR. Sri Lanka has 
already adopted a policy for discouraging alcohol consumption and smoking by raising taxes on 
both products in recent years providing additional government revenue. Exploration of other 
means of augmenting domestic financing using innovative approaches such as health and diaspora 
bonds and airline and financial transaction taxes have the potential to supplement government 
revenue, which can be used for health including malaria [22]. 
 
High-level advocacy to policy makers and donors is needed to ensure sustained financing for 
malaria. This study provides compelling evidence on the economic benefits of continued 
prioritization of funding for malaria, which can be used to strengthen the advocacy argument for 
increased domestic and external funding to keep Sri Lanka malaria free. 
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6.1 Abstract 
 
Background: The Asia Pacific region has made significant progress against malaria, reducing 
cases and deaths by more than 50% between 2010 and 2015. Multiple factors have 
contributed to these reductions including strong political and financial commitment of 
governments, donors, and partners. However, the region continues to face a high burden of 
malaria. Gains made against the disease are fragile, threatened by declining funding and 
persistent health system challenges, particularly the risk and spread of antimalarial drug 
resistance. To address these challenges, leaders in the region have committed to a goal of 
malaria elimination by 2030, endorsing a detailed plan to accelerate progress as outlined in 
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the Asia Pacific Leaders Malaria Alliance (APLMA) Malaria Elimination Roadmap. Achieving 
this will require an intensification of efforts accompanied by a plan for sustainable financing 
for the region. This article presents an investment case for malaria in Asia Pacific by 
estimating the costs and benefits of sustaining investments until elimination is achieved in 
the region. 
 
Methods: A mathematical transmission model was developed to project rates of decline of 
malaria and determine the associated costs of the interventions that would need to be 
undertaken to reach elimination on or before 2030. 80 scenarios were modeled under 
various assumptions of resistance, MDA and LLIN coverage. The scenario that allowed 
attainment of the elimination threshold was considered the elimination scenario. Using 
outputs from the model, the mortality and morbidity averted from malaria elimination were 
estimated and health benefits were monetized by calculating the averted cost to the health 
system, averted cost to individual households, and averted cost to society. The full-income 
approach was used to estimate the economic impact of lost productivity due to premature 
death and illness and a return on investment was computed. 
 
Findings: The study estimated that by using a variety of interventions, all 22 countries in the 
Asia Pacific region could achieve elimination of Plasmodium falciparum and Plasmodium 
vivax malaria, up to two years before the regional 2030 target and at a cost of USD 29.02 
billion between 2017-2030. Approximately 80 per cent of the cost will be incurred in South 
Asia. Compared to a business as usual scenario, interrupting local transmission can save 
over 400,000 lives and avert 123 million malaria cases, translating to almost USD 90 billion 
in economic benefits. Discontinuing vector control interventions and reducing treatment 
coverage rates to 50% will reverse the gains made, resulting in an additional 845 million 
cases, 3.5 million deaths, and excess costs of USD 7 billion. Malaria elimination in the Asia 
Pacific region has a return on investment of 6:1. Despite this evidence, there remains a 
significant annual gap in funding of about 80% of the estimated cost of elimination between 
2018-2020 in the region, emphasizing the need for sustained financial resources. 
 
Interpretation: This investment case provides compelling evidence for the benefits of 
continued prioritization of funding for malaria and can be used to develop an advocacy 
strategy for increased domestic and external funding for the region to reach its goal to be 
malaria-free by 2030. 
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6.2 Introduction 
 
The Asia Pacific region has achieved significant gains against malaria over the last decade. 
Malaria cases and deaths have declined by more than 50% between 2010 and 2015 in the 
region’s 22 malaria-endemic countries.19 Sri Lanka was declared malaria-free in 2016, 
becoming only the second country in Southeast Asia, after the Maldives, to successfully 
eliminate malaria. Apart from India, Indonesia, Myanmar, and Thailand, malaria-endemic 
countries have reported reductions in malaria incidence of more than 75% since 2000. In 
Bhutan, China, and Timor-Leste, cases have declined by almost 100%, with less than 200 
cases in 2016 [1]. 
 
Progress in driving down malaria may be attributed to a number of factors; strong political 
and financial support from governments and donors like the Global Fund to Fight AIDS, 
Tuberculosis and Malaria (the Global Fund) has enabled the scale-up of effective 
interventions to prevent, diagnose, and treat malaria. Financing for malaria in the Asia 
Pacific region increased from less than USD 100 million in 2000 to about USD 415 million in 
2016. Between 2006-2010, the Asia Pacific region attracted between 12% and 21% of global 
malaria funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) 
[2]. However, there has been a steady decline in external financing for malaria, particularly 
for middle-income status countries that experience relatively lower malaria transmission 
[3].20 Although domestic financing for malaria has increased in many countries in the last 
decade, the need for malaria control and elimination far exceeds the available resources, 
particularly in the context of elimination where malaria is no longer perceived as a priority 
disease. 
 
Despite the progress and opportunities for elimination, malaria remains a major cause of 
death and illness in the region with an estimated 1.72 billion people at risk of the disease in 
2016 [4]. The recent gains made are fragile and investments could be lost if malaria 
resurges. The case for malaria elimination has never been stronger, particularly with the 
growing threat of antimalarial drug resistance arising from the Greater Mekong Subregion 
(GMS) and the risk of it spreading to other regions. Reduced funding or political 
commitment has historically been linked to 75 resurgences of malaria in 61 countries since 
the 1930s [6]. However, in order to achieve a malaria-free Asia Pacific – a goal endorsed by 
                                                        
19 The Asia Pacific region in this report encompasses the 22 malaria-endemic countries as defined by APLMA. Sri 
Lanka has since been declared as malaria free but still implements prevention of reintroduction activities. 
Countries include: Afghanistan, Bangladesh, Bhutan, Cambodia, Democratic People’s Republic of Korea (DPRK), 
India, Indonesia, Lao People’s Democratic Republic  (Lao PDR), Malaysia, Myanmar, Nepal, Pakistan, Papua New 
Guinea (PNG), People’s republic of China, Philippines, Republic of Korea (ROK), Solomon Islands, Sri Lanka, 
Thailand, Timor Leste, Vanuatu and Vietnam. 
20 Low transmission refers to low-burden, pre-elimination, and elimination settings. 
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leaders at the highest levels though the Asia Pacific Leaders Malaria Alliance (APLMA)21 – 
financial resources will need to be sustained [5]. 
 
Countries and partners need better estimates of the resources required to eliminate malaria 
in the long term, as well as evidence on the financial and economic benefits of investing in 
malaria elimination in order to advocate for more resources. The objectives of this study 
were to estimate the cost to achieve malaria elimination in the Asia Pacific region by 2030; 
generate an investment case for malaria by estimating the economic benefits of malaria 
elimination and prevention of reintroduction (POR) and; identify the funding gaps and 
explore the potential opportunities for generating financial resources for achieving malaria 
elimination goals.  
 
6.3 Financing for malaria in the Asia Pacific region 
 
The main sources of financing for malaria in Asia Pacific are domestic government resources 
and external financing from donors. Although domestic financing for malaria has increased 
by over 40% in Asia Pacific between 2015-2017 compared to 2012-2014 [5], most national 
malaria control programs (NMCPs) in the region continue to be highly reliant on external 
financing, particularly from the Global Fund. As Figure 1 illustrates, almost 50% of the total 
funding for malaria in Asia Pacific in 2016 was from the Global Fund. This dependence on 
external financing is projected to continue [7]. 
 
6.4 Methods 
 
We used outputs from a mathematical transmission model to estimate the costs and 
benefits of malaria elimination. The model estimated the impact of several intervention 
scenarios on the transmission of P. falciparum and P. vivax malaria from 2016 to 2030 in 
each of the 22 countries. Data used to calibrate and validate the model were sourced from 
World Malaria Reports [1, 4. 9-15], peer reviewed literature on G6PDd prevalence and the 
Earth System Research Laboratory website for El Niño Southern Oscillation time series [16. 
17]. This data was used to build ranges of plausible estimates of several malaria-related 
indicators including estimated cases [18]. 
 
The model was validated separately against the estimated burden of disease for P. 
falciparum and P. vivax and accumulated case mortality. Several indicators (such as the 
                                                        
21 At the 2013 East Asia Summit (EAS), the Asia Pacific Leaders Malaria Alliance (APLMA) was established to 
accelerate progress towards a reduction in malaria cases and deaths. In 2014 at the ninth EAS, the APLMA Co- 
Chairs (the Prime Ministers of Viet Nam and Australia) tabled a recommendation for the Asia Pacific region to 
become free of malaria by 2030. EAS Heads of Government agreed to the goal, and tasked APLMA Co- Chairs to 
present a plan to reach malaria elimination through a “Leaders Malaria Elimination Roadmap”. The APLMA 
roadmap was presented to Heads of Government during the 10th EAS Meeting in 2015.  
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estimated incidence of all malaria species and reported fatalities) were modeled for each 
country between 2016 and 2030, under scenario-specific assumptions. Eighty (80) scenarios 
were simulated, based on 10 different sets of packages of interventions. These ranged from 
discontinuing most malaria activities to a very substantial scale-up of interventions, which 
could be supplemented by mass drug administration (MDA) or an increase in the coverage 
of Long-lasting Insecticide Treated Nets (LLINs), at either a stable or increasing trajectory of 
drug resistance [19]. The last component was a full costing of each scenario by computing 
the costs of interventions per country, year and component and developing an investment 
case. 
 
While the reported coverage of interventions (particularly long lasting insecticide-treat nets 
(LLINs) and indoor residual spraying (IRS)) were included in the model to inform changes in 
incidence, there was little available data on coverage of other interventions between 2000 
and 2015, such as the introduction of community health workers). These coverage statistics 
were therefore imputed based on observed changes in reported incidence. The mortality 
predicted by the model was validated against reported deaths. A full description of the 
model is available elsewhere [19]. 
 
Figure 6.1.  Financing for malaria in the Asia Pacific region 
 
 
Source: [8] 
 
6.4.1 Elimination scenarios 
A total of 80 (eighty) scenarios were generated. We modeled four counterfactual scenarios 
(Nos. 1-4 in Table 6.1) including one “business as usual scenario” in which coverage 
remained the same as for 2015 (the last data point for which covariate rates were available 
for all 22 countries), and three reverse scenarios that simulated the potential impact of 
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scaling down the malaria program. The six elimination scenarios (No. 5-10 in Table 6.1 were 
modeled sequentially to increase in complexity and in the number of interventions included. 
 
Table 6.1. Modeled scenarios 
 
 Scenario Description 
1 Business as usual • Continue all interventions at 2015 levels from 
2016 through 2030 
2 Reverse scenario 1 • Business as usual 
• IRS activities ceased 
3 Reverse scenario 2 • Reverse scenario 1 
• Distribution of new LLINs ceased 
4 Reverse scenario 3 • Reverse scenario 2 
• Treatment rates reduced by 50% 
5 Universal coverage • Business as usual 
• Coverage of population at risk with test and 
treat increased from 2017 onwards in a linear 
fashion over eight years to 80% by 2025 
• Quinine is switched to injectable artesunate 
for management of severe disease in 2017 
6 IRS • Universal coverage 
• IRS coverage in 2017 doubled in a linear 
fashion over eight years 
7 Effective usage • Universal coverage 
• Effectiveness of LLINs increased 
• Surveillance increased 
8 New P. vivax treatment • Effective usage 
• Replace primaquine with a new P. vivax 
treatment 
9 New LLINs • New P. vivax treatment 
• Life of LLINs doubled 
10 New P. falciparum treatment • New LLINs 
• First-line Artemisinin based Combination 
Therapy (ACT) replaced with new candidate 
for P. falciparum treatment 
 Assumption Description 
A Artemisinin resistance 5% probability of treatment failure from ACTs 
across all countries is constant until 2018 and then 
increased to 30% through 2025 
B MDA Five annual rounds of MDA at 50% coverage from 
2018 starting four months before the peak of the 
transmission season targeted at both species 
C LLINs Scaling up LLINs to 80% effective coverage 
deployed in a 3-year cycle (50%, 25% and 25%) 
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For each country, we determined the minimum package of interventions that would achieve 
malaria elimination, defined here as one year with less than one reported clinical case. This 
was taken to be the minimum elimination scenario for that particular country. Since the 
model did not distinguish between indigenous and imported cases, we assumed that certain 
thresholds of cases are imported, which we subtracted from the model outputs. In addition, 
we simulated the effect of improved targeting of malaria interventions on both costs and 
epidemiological outputs. We did this by reducing intervention coverage by 30% among the 
population at risk (PAR) for all scenarios, with and without the resistance and mass drug 
administration (MDA) assumptions. 
 
The outputs of averted mortality and morbidity under the elimination scenarios were 
expressed as reported cases and deaths (projected from reported cases) and estimated 
cases and deaths projected from a range of estimates. Averted cases and deaths were then 
used to estimate the cost, benefits, and returns on investment (ROIs).  
6.4.2 Additional assumptions 
We applied additional assumptions to simulate various possible outcomes across all 10 
scenarios: (i) the first was around the occurrence of artemisinin resistance; across all 
scenarios, a baseline treatment failure rate of 5% was applied in all countries from 2016-
2030. Under the resistance assumption, the probability of treatment failure was kept 
constant at 5% through 2018 and increased to 30% between 2018 and 2025; (ii) the second 
assumption concerned the use of MDA. MDA was simulated as five annual rounds of 
dihydroartemisinin-piperaquine at 50% coverage of the population at risk from 2018 
onwards, starting four months before the peak of the malaria transmission season; (iii) n a 
third set of simulations, LLIN scale-up was added to all the elimination scenarios in 
accordance with WHO guidelines for vector control, if malaria elimination was not achieved 
by 2030. LLIN scale-up was defined as LLIN coverage of up to 80% coverage achieved 
through three-year distribution cycles from 2017 to 2026. These additional rates of decline 
were projected separately. 
 
These additional scenarios produced a total of 80 scenarios: with and without resistance; 
with and without MDA; and with and without LLIN scale up to 80%. 
 
6.4.3 Population at risk 
For all the scenarios, a declining population at risk (PAR) was assumed in the model. PAR 
values used to estimate costs in the model were adjusted to reflect the decreases in 
incidence predicted from the implementation of elimination-focused interventions. 
Historical incidence and PAR data were analysed statistically to infer a predicted change in 
PAR for a given change in incidence. This relationship was applied to the 2015 PAR data and 
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updated every year until 2030 as interventions were applied in the modeled scenarios. This 
method has limitations, including a non-standardized definition of PAR. 
 
6.4.4 Cost projections 
We built a cost estimation model aligned with the outputs of the transmission model to 
estimate the total costs associated with implementing each of the scenarios above. Program 
costs included the costs of testing and treating uncomplicated or outpatient (OP) and severe 
or inpatient (IP) malaria cases; vector control (i.e., LLIN distribution and IRS); supply chains; 
surveillance through community health workers; information, education, communication; 
training; MDA; new treatments (e.g., tafenoquine for P. vivax); and rollout of new LLINs. 
Unit costs for each activity were obtained using a combination of empirical data collected in 
various Asia Pacific countries by the authors, literature reviews, and proxies when the 
previous options were unavailable (Table S1). 
 
In addition, we simulated the effect of improved targeting of malaria interventions on both 
costs and epidemiological outputs on cost. We did this by reducing intervention coverage by 
30% year-to-year among the PAR for all three scenarios with and without the resistance 
assumption. 
 
The total cost of the elimination scenarios was used to build this investment case. We 
calculated the costs to reach elimination separately for each country and then summed 
them to obtain the total cost for elimination in the Asia Pacific region. To calculate the 
incremental or additional costs of malaria elimination (which were used to calculate ROIs), 
we subtracted the estimated costs of the business as usual and reverse scenarios from the 
elimination scenario. All monetary figures are expressed in 2015 constant USD. 
 
6.4.5 Economic benefits estimation 
Using outputs from the model, we estimated the mortality and morbidity averted from 
malaria elimination by subtracting the estimated cases and deaths of the elimination 
scenario from the corresponding outputs of the “business as usual” and “reverse” scenarios. 
We then monetized these health benefits by looking at the averted cost to the health 
system, averted cost to individual households, and averted cost to society: 
 
• Cost averted to the health system includes costs associated with diagnosis and 
treatment costs of IPs and OPs; 
• Cost averted to the individual households is out-of-pocket (OOP) expenditures for 
seeking care; and 
• Cost averted to the society due to patients’ lost productivity due to premature 
death and morbidity and caregivers’ reduced economic output. 
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The same cost inputs used in the cost estimation were used for calculating the economic 
benefits. Unit costs for case management included costs for OP visits, diagnostic tests, and 
drug treatments for OP malaria cases, as well as hospital hotel costs and drug treatments 
for IP malaria cases. OOP expenditures were estimated by applying country-specific OOP 
expenditure per capita separately for OP and IP cases. We calculated productivity losses 
among patients and caretakers by multiplying an estimate of daily productivity by the 
number of days lost due to illness or care seeking.  
 
We used the full-income approach to estimate the economic impact of lost productivity due 
to premature death from malaria. We multiplied the number of averted deaths for each 
country by the country-specific values of additional life years (VLYs) and life expectancies at 
age 40 among males and females, which was the assumed average age of death due to 
malaria. One VLY was estimated to be 2.2 times the gross domestic product (GDP) per capita 
for each of the countries in South East Asia and the Pacific and 2.8 times the GDP per capita 
for each of the countries in South Asia, as suggested by the Lancet Commission on Investing 
in Health [20]. 
 
All costs and economic benefits were discounted at 3%. 
 
6.4.6 Return on investment  
The ROI was calculated by subtracting the incremental cost of elimination from the 
economic benefits, and dividing the resulting figure by the incremental cost of elimination. 
The ROI is interpreted as the economic return from every additional dollar spent on malaria 
elimination. We performed the analysis for 2017-2030 by comparing the elimination 
scenario with the business as usual and reverse scenarios under the stable and increasing 
resistance assumptions.  
 
6.4.7 Uncertainty analysis 
We performed stochastic sensitivity analysis on the epidemiological and cost outputs of the 
malaria transmission model. The minimum, median, and maximum malaria cases and 
deaths predicted by the model for each scenario were used to calculate the minimum, 
median, and maximum economic benefits. For the costs, we assigned an uncertainty 
interval of +/-25% on the value of the input costs used. Three hundred random samples 
were drawn, which generated a range of costs. From the range of costs generated, we 
determined the minimum, maximum, median, mean, and other percentiles. 
 
6.4.9 Gap analysis and opportunities for resource mobilization 
Using available malaria financing data in the region (donor and domestic), between 2017-
2020, we estimated the potential gap in financing assuming the total funding envelope 
would remain as projected. We also assessed potential opportunities for resource 
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mobilization to fill financing gaps by mapping private sector investors and analysing the 
domestic funding landscape. 
 
Research in context 
 
Evidence before this study: Several attempts have been made to forecast the financing needs for 
countries to reach elimination and to determine the economic benefits of these efforts in the Asia 
Pacific. In 2015, APLMA estimated that just over USD 1 billion per year would need to be spent in the 
first five-year phase of Asia Pacific malaria elimination, and just under USD 2 billion per year in 
subsequent phases leading to over 200 million preventable malaria cases and 1.3 million deaths 
averted by 2030 [21]. These estimates, however utilized the outputs of a transmission model 
developed for the Global Technical Strategy for Malaria 2016–2030, which is almost exclusively 
focused on P. falciparum malaria transmission dynamics from Sub-Saharan African countries. This 
makes the model of limited usefulness for Asia, which has higher proportions of P. vivax and a lower 
overall burden. Furthermore, the model forecasts the cost of reducing malaria morbidity and 
mortality by 90% between 2015 and 2030 and not elimination per se. Costed National Malaria 
Strategic Plans (NSPs) for malaria in each of the 22 malaria-endemic countries have also be used as 
an indicator of financial need. However, the cost estimates in the NSPs are often shorter-term and 
are not purposefully calibrated for elimination. In addition, they do not build in efficiency measures 
and are therefore likely to be overestimates. 
 
Added value of this study: This is the first investment case developed using the output of a 
multispecies transmission model developed specifically for malaria elimination in the Asia Pacific 
region. In most cases, costs were obtained directly from the countries, making the estimates more 
plausible. The investment case, gap analysis and potential resource mobilization strategies 
presented are context specific making the evidence more likely to be used by policy makers in the 
region. 
 
Implications of all the available evidence: Declining financing for malaria is an imminent threat to 
malaria elimination. The investment case for malaria elimination is robust. Malaria elimination will 
cost USD 29.02 billion between 2017-2030. Although the short-term investment needed may seem 
substantial, these are time-limited as costs taper off significantly as more countries eliminate the 
disease. Interrupting local transmission can save over 400,000 lives and avert 123 million malaria 
cases, translating to almost USD 90 billion in economic benefits. This study provides compelling 
evidence for the benefits of continued prioritization of funding for malaria, and can be used to 
develop an advocacy strategy for increased domestic and external funding for the region to reach its 
goal to be malaria-free by 2030. Gaps in financing could potentially be filled using innovative health 
financing mechanisms to boost domestic spending as well as by mechanisms to increase efficiency 
and value for money. 
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6.5 Findings 
 
6.5.1 Projected declines in transmission 
The transmission model predicted that malaria elimination can be achieved by all the 
countries in the Asia Pacific region by 2030 by implementing a variety of scenarios.  
 
Table 6.2. Scenarios and predicted elimination dates 
 
Country Minimum elimination 
scenario and 
interventions 
MDA  LLIN Elimination date 
(predicted range) 
National 
elimination 
goal 
Afghanistan Effective usage Yes Yes 2025 (2025,2027) None 
Bangladesh Effective usage No No 2025 (2024,2029) 2035 
Bhutan Effective usage No No 2024 (2023, 2025) 2018 
Cambodia New LLINs  Yes No 2023 (2022, 2030) 2025 
China Business as usual 
(already eliminated by 
2017) 
No No 
 
2017 
 
2020 
DPRK 
 
New P. vivax treatment No Yes 2028 (2027, 2030) 2025 
India New LLINs No Yes 2028 (2026, 2030) 2030 
Indonesia Effective usage Yes No 2025 (2022,2028) None 
Lao PDR New P. falciparum 
treatment 
Yes Yes 2025 (2022,>2030)  
Malaysia IRS No No 
No 
2023 (2019, 2029) 2020 
Myanmar New P. falciparum 
treatment 
Yes Yes 2025 (2024,>2030) None 
Nepal Effective usage No No 2022 (2017, 2026) 2026 
Pakistan Effective usage Yes Yes 2022 (2021, 2030) None 
PNG Effective usage Yes No 2025 (2025,2028)  
Philippines Effective usage No No 2021 (2017,2023) 2030 
ROK Business as usual No No 2017 (2017,2019) 2017 
Solomon 
Islands 
New LLINs Yes No 2028(2026, 2029)  
Sri Lanka Business as usual 
(already eliminated by 
2017) 
No No Already eliminated in 
2013 
2012 
Thailand New P. vivax treatment No No 2026 (2025, 2029) 
  
2024 
Timor-Leste Universal coverage No No 2019 (2017,2024)  
Vanuatu Effective usage Yes No 2021 (2021, 2024) 2025 
Viet Nam Effective usage No No 2024 (2022, 2027) 2030 
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Table 6.2 illustrates the predicted output of the transmission model under an assumption of 
increasing artemisinin resistance and identifies the minimum elimination scenario defined 
as the scenario under which the country can achieve elimination on or before 2030 with the 
least amount of effort. 
 
The model predicted that it is possible for all 22 countries to achieve elimination of P. 
falciparum and P. vivax by 2030. China, ROK, and Sri Lanka22 are the only countries 
predicted to achieve elimination without scaling up current interventions. Elimination is 
possible in Cambodia, DPRK, India, Lao PDR, Myanmar, Solomon Islands, and Thailand by 
2030 using new tools and technological innovation. Elimination is predicted to be possible 
by 2030 only through the addition of MDA in Afghanistan, Cambodia, Indonesia, Lao, 
Myanmar, Pakistan, PNG, Solomon Islands, and Vanuatu. In all other countries, elimination 
is possible with the scale up of existing interventions. 
 
Figure 6.2 illustrates the median reported cases and deaths between 2017-30 under the 
“business as usual” scenario and minimum elimination scenarios for the region. These are 
predictions projected from the reported cases in 2015. Figure 3. Illustrates the median 
estimated cases and deaths between 2017-30 under the “business as usual” scenario and 
minimum elimination scenarios for the region. These are predictions projected from the 
estimated cases in 2015. 
 
Figure 6.2. Transmission prediction for the Asia Pacific region, 2016-2030 (reported cases 
and deaths) 
 
BAU – Business as usual scenario; Elimination – elimination scenario  
                                                        
22 Sri Lanka saw its last indigenous case in 2012 and obtained WHO certification in 2016. 
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Figure 6.3. Transmission prediction for the Asia Pacific region, 2016-2030 (estimated cases 
and deaths) 
 
In the business as usual scenario for all countries in the region, clinical cases rose from an 
estimated 7 million in 2016 to 15 million in 2030. Implementing the elimination scenario in 
each country will avert a total of over 123 million clinical cases and approximately 3.5 
million deaths in the region over 14 years. In a “reverse” or worst case scenario, where 
interventions are halted and reduced (reverse scenario), cases increase to about 180 million 
by 2030. There would be about 1 billion additional cases and 3.5 million additional deaths, 
costing an excess of USD 7 billion between 2016-2030. 
 
6.5.2 Cost of malaria elimination through 2030 
The cost of malaria elimination is shown in Figure 4 and Table 3 The total cost to achieve 
malaria elimination in the Asia Pacific between 2017-2030 was estimated to be USD 29.024 
billion (range: USD 23.65-36.23 million). The median cost in 2017 for the elimination 
scenarios was about USD 1.5 billion. Costs peak in 2020 at USD 4.29 billion, then decrease to 
less than USD 1 billion in 2027 and less than USD 450 million in 2030 when elimination is 
expected to be achieved in all 22 countries. Lower costs incurred are expected to continue 
after the elimination date as POR of malaria interventions continue. 
 
The reverse scenario would cost an excess of USD 7 billion between 2017-2030. If 
interventions were only applied to 70% of the PAR in the low transmission areas (a crude 
proxy for the effect of improved targeting of interventions), the total cost would be about 
USD 22.49 billion. 
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Figure 6.4. Modeled costs of the elimination scenario, 2016-2030 
 
 
 
 
 
2017-2020: 12,085,202,018  
Median cost of elimination 
scenarios (USD) 
 
2021-2025: 12,221,791,374 
 
 
 
2026-2030: 4,716,224,691 
 
 
Figure 6.5. Modeled regional and country level costs of the elimination scenario until 2030 
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Figure 6.5 illustrates the regional and country level costs for the total PAR for 2017-2030. 
The figure illustrates how the relative costs are skewed by sub region and country with over 
80 per cent of the costs expecting to be incurred in South Asia – most notably, India. 
 
6.5.3 Economic benefits estimation 
Compared to a business as usual scenario, interrupting local transmission can save over 
400,000 lives and avert 123 million malaria cases, translating to almost USD 90 billion in 
economic benefits. The economic benefits included costs averted for diagnosis and 
treatment costs as inpatients and outpatients, costs averted to individual and households 
and the monetized value of lost productivity due to premature death and morbidity and 
caretaker’s reduced economic output as a result of taking care of patients. Discontinuing 
vector control interventions and reducing treatment coverage rates to 50% will reverse the 
gains made, resulting in an additional 845 million cases, 3.5 million deaths, and excess costs 
of USD 7 billion.  
 
6.5.4 Return on investment 
The cost of malaria elimination should be weighed against the epidemiological and 
economic costs of inaction. When the net benefits of elimination compared to the cases and 
costs averted in the business as usual scenario of the transmission model for the period of 
2017 to 2030, the median ROI for each additional dollar invested in malaria elimination was 
calculated to be 6:1. This increases to 7:1 if interventions are better targeted in low risk 
areas. 
 
Table 6.3. Summary of costs and benefits, 2017-2030 
 
Scenarios 
compared 
Total cost 
(USD) 
Estimated 
clinical 
cases 
averted 
Deaths 
averted 
Economic 
benefits 
(USD) 
Incremental 
cost (USD) 
ROI 
Business as usual 
vs. elimination 
(with resistance 
assumption) 
29.024 
billion  
(range: 
23.64-36.23) 
 
 
21.85 billion 
 
 
123.14 
million 
(estimated)
23 
 
16.54 
million 
(reported)24 
386,167  
(estimated
) 
 
 
 
193,084 
(reported) 
 
87.73 
billion  
 
14.05 billion  
 
6:1 
Business as usual 28.953 92.23 264,322 72.90 13.79 billion  5:1 
                                                        
23 Projected from estimated cases 
24 Projected from reported cases 
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Scenarios 
compared 
Total cost 
(USD) 
Estimated 
clinical 
cases 
averted 
Deaths 
averted 
Economic 
benefits 
(USD) 
Incremental 
cost (USD) 
ROI 
vs. elimination 
(baseline) 
billion  
(IQR: 23.38-
35.72) 
 
million 
(estimated 
clinical)  
 
11.68 
million 
(reported)  
(estimated 
clinical)  
 
 
132,161 
(reported) 
billion  
Reverse vs. 
elimination (with 
resistance 
assumption) 
NA 845.73 
million  
 
3.487 
million  
 
N/A 6.693 billion  
 
N/A 
 
6.5.5 Financial gap 
A median resource envelope of about USD 3 billion is needed annually to achieve 
elimination between 2018-2020. Total financing for the region is projected to be USD 0.5 
billion annually for 2018-2020. Therefore, the anticipated gap is therefore likely to be over 
80% of the resources required for elimination between 2018-2020. 
 
3.5.6 Sensitivity analysis 
 
Figure 6.7.  Sensitivity analysis of cost of elimination (2016-2030) 
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Figure 6.7 illustrates the sensitivity of the total cost to the individual cost inputs. At the peak 
in 2020, costs vary from USD 2.5 billion to USD 7 billion. Figure 6. 8 illustrates that using 
minimum values of the benefits will still produce a positive ROI.  
 
Figure 6.8. ROI estimates for malaria elimination using outputs of sensitivity analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.6 Discussion 
 
This analysis compared the monetized value of expected benefits from malaria elimination 
to the investment costs over a 14-year investment period (2017–2030) in the 22 malaria 
endemic countries of the Asia Pacific, demonstrating a robust median return of about six 
times the incremental investment.  
 
The study found that by employing a variety of existing and new interventions, all countries 
in the Asia Pacific could eliminate malaria by 2028 – two years before the 2030 APLMA 
regional goal. The health, social, and economic returns are potentially formidable. Malaria 
elimination will save over 400,000 lives and avert over 123 million cases, translating to 
economic benefits of almost USD 90 billion.  
 
Successfully achieving elimination, however, will require sustained financial resources. Our 
model estimates that the total cost of achieving elimination and POR is about USD 29.02 
billion (range: USD 23.64-36.23 billion) over 14 years or USD 12 billion between 2017-2020. 
Total financing for malaria in the Asia Pacific in 2016 was estimated at USD 415 million. 
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Using co-financing data from Global Fund concept notes, total financing for malaria was 
projected at USD 1.4 billion between 2018-2020, leaving an annual gap of about USD 2.5 
billion or 80% of the estimated cost of elimination. 
 
Numerous countries in the region continue to rely on Global Fund resources to provide up 
to 50% of their total financing for malaria elimination. However, the allocation methodology 
adopted by the Global Fund in 2012, utilizes a combination of disease burden and gross 
national income (GNI) per capita to determine the financing that countries will receive. By 
definition, malaria-eliminating countries have lower disease burdens, have higher incomes 
and are therefore a lessor priority for donors. Country-specific funding from the Global Fund 
to the sub-set of countries attempting to eliminate malaria has declined by over 30% [2]. 
Further declines in allocations have been noted under a subsequently revised model 
adopted in November 2016 [22]. Given the downward trend in malaria burden and the 
region’s rising economic status, this level of support is likely to be even more diminished in 
subsequent years. 
 
Many malaria-eliminating countries are Middle Income Countries (MICs) as defined by the 
World Bank [23]. The International Monetary Fund (IMF) projects average annual GDP 
growth rates of 3-10%, which means that economies in Asia will double or triple in size in 
the next decade. By 2020, four countries in Asia that are currently Lower-Middle Income 
Countries (LMICs); Bhutan, Indonesia, the Philippines, Sri Lanka, will surpass the World Bank 
threshold for MICs of USD 4,125 GDP per capita. This means that while there is increased 
potential for domestic financing, more countries will also start to graduate out of aid 
eligibility. Of the 22 countries in the Asia Pacific region, three are currently LICs, 15 are 
LMICs, and three are UMICs and one is an UIC. Eighteen are currently eligible for Global 
Fund financing [24] – out of which an additional two countries will be receiving the final 
transitional grants in the next two years (the Philippines and Sri Lanka). Political and policy 
changes in other donor constituencies also pose similar risks.  
 
These changing polices have major implications for the financing and delivery of health 
services, for malaria elimination. Malaria financing will therefore need to depend on larger 
contributions from government budgets. Indeed, the expectation of the economic and 
health financing transition suggests that as countries develop they will spend more on 
health than they did before. Although domestic financing for malaria has increased by over 
40% in the Asia Pacific between 2015-2017 compared to 2012-2014 [7], the resources 
required far exceed the amounts available.  
 
The potential consequences of funding gaps at this critical juncture can be serious. This 
analysis estimates that scaling back interventions in the Asia Pacific could lead to an 
additional 3.5 million deaths, almost 1 billion cases, and economic costs of almost USD 7 
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billion. Emerging artemisinin resistance further threatens the gains made against malaria 
and regional health security with estimates of 9,560 excess deaths and USD 51 million in 
productivity losses annually [25].  
 
To ensure an uninterrupted availability of key malaria interventions, mechanisms to 
augment and prioritize domestic funding and improve efficiencies in the existing malaria 
envelope will need to be explored. The Addis Ababa Action Agenda calls on a number of 
resource mobilization efforts encompassing aid, domestic public resources, and support 
from the private sector [26].  
 
Many national governments are considering raising health budgets by improving the 
capacity to raise tax revenue including the implementation of Pigovian or sin taxes. In the 
Philippines, increased taxes on tobacco and alcohol generated USD 2.3 billion within just 2 
years, increasing the Department of Health budget by 63% in 2015 [27]. This revenue has 
freed up resources, which would have otherwise been used for social protection of the 
poor. Indonesia and Vietnam have similarly implemented such revenue generating 
structures.  
 
The diversification of Asia Pacific countries’ economies, present a unique opportunity to 
engage the private sector in malaria elimination [28]. Private Asian companies such as 
AirAsia, Samsung, the Tata group, and Alibaba have become internationally recognizable 
brands. Government incentives for the private sector engagement could include tax relief or 
tax credit schemes and policies that promote expansion or diversification of programs. For 
example, the Cambodian Ministry of Health has developed a policy framework for public-
private partnerships in the health sector.  Similarly, an airline levy such as the UNITAID 
model could raise more than USD 300 million per year [29]. 
 
Multilateral Development Banks (MDBs) and partners can provide new financing 
opportunities to governments and the private sector, including cross-sectoral financing for 
health programs, incentivizing companies to invest in health interventions [30]. Countries 
can seek out additional grants and soft-loans from MDBs to help frontload the costs of 
elimination. Several MDBs are currently engaged in innovative models including ADB, the 
Inter-American Development Bank, the Islamic Development Bank, and others in 
collaboration with the Bill & Melinda Gates Foundation, the Global Fund and other partners 
[31-33].   
 
Innovative financing options can also fill the gap between needs and resources until 
government budgets catch up with the financing transition. These may include health 
bonds, debt swaps, and blended financing mechanisms.  Social impact bonds and 
development impact bonds are other types of instruments that have been implemented in 
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selected settings. One example is the Mozambique Malaria Performance Bond, which is 
being used to raise funding from investors interested in both financial and social returns 
[34-36]. Such innovative instruments have been used to raise financing for health and other 
sectors, such as education and environment. 
 
In addition to increasing available health revenue and allocating additional resources, 
improved efficiencies can generate cost-savings, freeing up resources to cover financing 
gaps. Assessing and identifying current inefficacies and drivers of inefficiency can increase 
utilization of current funds.  
 
Many countries will graduate in income status and will graduate from donor financing. 
Malaria programs, given the low disease burden, may lose eligibility before then. In addition 
to pursuing additional domestic financing and meeting current co-financing requirements of 
existing grants, countries should appropriately plan the transition from donor to domestic 
funding sources 3-5-years in advance of the actual transition [37]. 
 
A number of unknown factors and limitations impact the findings of this report. The costs of 
medicines and other interventions have been estimated based on available data and proxies 
were used when data were unavailable. The cost of new interventions such as new LLINs 
and new treatments such as tafenoquine were based on historical estimates of the cost of 
new tools when they were first adopted rather than actual costs. In particular, separating 
out the cost of interventions in integrated systems is challenging and the analysts have 
relied on country-level partners to apportion the amounts spent on each intervention to 
arrive at disaggregated costs. 
 
The cost estimates produced are highly dependent on the output of the transmission model, 
which was designed with a single homogeneous patch for the whole of each country, using 
national level data on incidence and intervention coverage. Treating the whole country as a 
single unit in this way is likely to lead to over-estimates in costs of elimination. Furthermore, 
spatial heterogeneity within each country was not modeled. These estimates are therefore 
subject to error, particularly in countries with heterogeneous transmission patterns. 
Population movement was not included in the model and this is likely to have reduced the 
predicted costs. Additionally, elimination often requires targeted interventions to risk areas 
or populations, rather than ubiquitous coverage to an entire country. Without subnational 
estimates of incidence and coverage, targeted interventions are difficult to estimate and 
cost. 
 
We were unable to predict the impact that economic development and housing 
improvements may have on malaria transmission or how the costs of commodities or 
interventions may change at the global or national levels. While we modeled for a declining 
Chapter 6: An Investment Case for Eliminating Malaria in the Asia Pacific Region 
 
150 
 
 
PAR based on historical changes in PAR compared to changes in incidence, this method has 
limitations including a non-standardized definition of PAR. 
 
While we have tried to estimate the effect that drug and insecticide resistance would have 
on cost, it is impossible at this stage to predict accurately the future extent and effect of 
drug and insecticide resistance and the actual interventions that would be implemented to 
address these. In addition, the impact and cost of known tools in the innovation pipeline 
have been modeled, however, the impact of new tools and approaches not yet developed is 
unknown and will be likely to decrease costs in the long term given that the cost of new 
tools is greatest at the time of adoption with economies of scale and competition driving 
costs down over time. It is also difficult to predict how the costs of interventions may 
change at the regional or national levels over time. 
 
Lastly, current assessments of reported malaria incidence have limitations. Research 
suggests that there may be significant under-reporting in the scale of global malaria 
incidence and mortality due to the weakness of health reporting and information 
management systems as well as widespread and undocumented use of the private sector in 
many endemic countries. For example, the Institute for Health Metrics and Evaluation 
estimated a figure of 1.2 million malaria deaths in 2010—almost double the WHO’s figure of 
655,000 [38]. Similarly, a widely quoted study in the Lancet estimated that in India, 205,000 
deaths per year could be attributed directly to malaria, which differed by more than ten 
times the numbers reported by the malaria program in the same year [39]. 
 
There have been various attempts at quantifying the true burden of malaria and more 
recent publications of the World Malaria Reports contain data on reported cases to health 
facilities as well as estimated cases based on a number of assumptions. This report utilized 
reported cases from the World Malaria Reports as well as estimated cases for the Asia 
Pacific countries derived by the Mahidol-Oxford Tropical Medicine Research Unit in 
collaboration with a number of partners including the WHO [18]. These estimates were 
obtained by combining and triangulating data from a variety of data sources. Both reported 
and estimated cases are depicted in the graphs. Nevertheless, the wide variation in 
estimates of burden makes it harder to be sure of the resources required to eliminate the 
disease. Without an informed and complete understanding of the current cartography of 
malaria risk and prevalence, future projections of the cost of eliminating malaria face an 
overwhelming uncertainty. 
 
We believe that the estimated benefits of elimination are conservative. Beyond the benefits 
of achieving malaria elimination as explained in this report, other benefits are likely, but are 
harder to quantify as there are no reliable quantitative estimates on how malaria may 
impact these. As a by-product of national elimination, other positive externalities are 
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increased tourism, a strengthened health system, better cognitive development, and 
improved regional health security. In addition, elimination may bring significant benefits to 
other regional public goods including opportunities to create stronger cross-border disease 
coordination. These estimates can therefore be considered conservative. 
 
Because of these uncertainties, estimated costs can only provide an indicative guide or 
baseline to help determine financing needs. It is therefore important that economic 
estimates are constantly reviewed in the light of new information, through to 2030. 
Importantly, due to the diversity of the region, further analysis is required to adapt the 
model to individual country settings and develop country-level estimates based on the 
national context. This, however, makes it even more important that funds can be put in 
place quickly to match currently expected costs. 
 
Despite limitations above, this investment case provides robust evidence of the benefits of 
continued prioritization of funding for malaria. The ROIs remain robust, comparable to 
those obtained for other high impact investments such as immunization programs and 
cardiovascular disease research [40]. 
 
Focused advocacy at all levels is needed to reach key decision-makers in order to highlight 
the social and economic benefits of investing in malaria elimination and the risks of not 
doing so. In particular, emphasis on the threat of drug resistance in undermining success 
and posing a risk of regional health security is needed. Continued engagement is needed 
with governments to focus attention on increased domestic budgets to reach the regional 
goal of a malaria-free Asia Pacific by 2030. 
 
6.7 Conclusion 
 
Global progress against malaria has been dramatic over the past decade. These gains, 
however, have been driven by substantial political and financial commitments that must be 
sustained to avoid a resurgence of malaria. There are several critical reasons why malaria 
elimination should receive a special focus for financing. Malaria is a major ongoing cost 
driver burdening national health systems and eliminating the disease will confer public 
health benefits as well as major cost savings to national health systems. Although the short-
term investment needed may seem substantial, these are time-limited as costs taper off 
significantly as more countries eliminate the disease. Secondly, there is a strong correlation 
between the decline in malaria burden and financing. Declining financing for malaria is an 
imminent threat to malaria elimination, the spread of drug resistance, and regional health 
security in the Asia Pacific region. This investment case provides compelling evidence for the 
benefits of continued prioritization of funding for malaria, and can be used to develop an 
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advocacy strategy for increased domestic and external funding for the region to reach its 
goal to be malaria-free by 2030.  
 
6.8 Abbreviations 
 
ACT: Artemisinin-based Combination Therapy; ADB: Asian Development Bank; APLMA: Asia 
Pacific Leaders Malaria Alliance; ASEAN: Association of Southeast Asian Nations; GDP: Gross 
domestic product; Global Fund: Global Fund to Fight AIDS, Tuberculosis and Malaria; GMS: 
Greater Mekong Subregion; IMF: International Monetary Fund; IP: Inpatient; IRS: Indoor 
residual spraying; LIC: Low-income country; LLIN: Long-lasting insecticidal net; LMIC: Lower-
middle-income country; MDA: Mass drug administration; MDB: Multilateral development 
bank; MOH: Ministry of Health; NMCP: National malaria control program; NSP: National 
strategic plan; OECD: Organization for Economic Cooperation and Development; OOP: Out-
of-pocket; OP: Outpatient; PAR: Population at risk; PPP: Purchasing Power Parity; POR : 
Prevention of reintroduction; RDT: Rapid diagnostic test; ROI: Return on investment; STC: 
Sustainability, transition, and co-financing; UMIC: Upper-middle-income country; USD: 
United States dollar; VLY: Value of additional life year; WHO: World Health Organization. 
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7.1 Abstract 
 
Background:  Donor financing for malaria has declined since 2010 and this trend is projected to 
continue for the foreseeable future. These reductions have a significant impact on lower burden 
countries actively pursuing elimination, which are usually a lesser priority for donors. While 
domestic spending on malaria has been growing, it varies substantially in speed and magnitude 
across countries. A clear understanding of spending patterns and trends in donor and domestic 
financing is needed to uncover critical investment gaps and opportunities. 
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Methods: Building on the Institute for Health Metrics and Evaluation’s annual Financing Global 
Health research, data were collected from organizations that channel development assistance for 
health to the 35 countries actively pursuing malaria elimination. Where possible, development 
assistance for health (DAH) was categorized by spend on malaria intervention. A diverse set of data 
points were used to estimate government health expenditure on malaria, including World Malaria 
Reports and government reports when available. Projections were done using regression analyses 
taking recipient country averages and earmarked funding into account. 
 
Results: Since 2010, DAH for malaria has been declining for the 35 countries actively pursuing 
malaria elimination (from USD176 million in 2010 to 62 million in 2013). The Global Fund to Fight 
AIDS, Tuberculosis and Malaria is the largest external financial fund for malaria providing 96% of the 
total external funding for malaria in 2013, with vector control interventions being the highest cost 
driver in all regions. Government expenditure on malaria, while increasing, has not kept pace with 
diminishing DAH or rising national GDP rates, leading to a potential gap in service delivery needed 
to attain elimination. 
 
Conclusion: Despite past gains, total financing available for malaria in elimination settings is 
declining. Health financing trends suggest that substantive policy interventions will be needed to 
ensure that malaria elimination is adequately financed and that available financing is effectively 
targeted to interventions that provide the best value for money. 
 
7.2 Background 
 
The launch of the Roll Back Malaria Partnership (RBM) in 1998 and the Millennium Development 
Goals in 2000 catalysed unprecedented political and financial commitment for malaria from donors, 
such as the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), the US President’s 
Malaria Initiative  (PMI), the World Bank, and others as well as endemic countries themselves. As a 
result, global malaria incidence and deaths have dramatically declined by 41 and 62%, respectively, 
between 2000 and 2015 [3]. Between 2000 and 2015, 17 countries eliminated malaria, six of which 
have been certified as malaria-free by the World Health Organization (WHO) [1]. Thirty-five 
countries are currently actively pursuing malaria elimination, with elimination goals ranging from 
2016 to 2035 [2]. According to WHO, 21 countries are in a position to achieve at least one year of 
zero indigenous cases of malaria by 2020 [3]. 
 
Despite this unprecedented progress, donor funding for malaria has declined since 2010 and is 
projected to continue to decline [4, 5]. These reductions in external financing are even greater for 
the sub-set of malaria eliminating countries despite demonstrated evidence on the returns on 
investment from elimination [6]. By nature, these countries have lower disease burdens and are 
often lower-middle or middle-income countries and therefore a lesser priority for donors [5]. 
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The Global Fund, which has been the largest external financier supporting eliminating nations, has 
historically dispersed about 7% of its total portfolio to eligible malaria-eliminating countries. 
However, under the New Funding Model adopted in 2012, resources for this subset of countries 
declined to less than 5% [5] and have declined further under a revised allocation-based model 
adopted by the Global Fund Board in November 2016 [7]. Other bilateral and multilateral donors 
are similarly diverting resources to higher-burden countries with the least ability to pay as 
measured by their Gross National Income (GNI) [8, 9]. In some cases, donors are entirely moving 
away from disease-based funding to general system strengthening to address concerns of global 
health security [10]. While integrated systems might help countries in the final push to malaria 
elimination and prevent reintroduction of malaria, a well-funded malaria programme, maintaining 
a level of vertical oversight, is crucial in the short to medium term [10]. At the same time, as the 
disease becomes less “visible”, government funds for malaria are often diverted to other health 
priorities that are perceived to be greater health threats, risking a reversal of the recent gains made 
in malaria elimination [11]. 
 
Reductions in financing for countries eliminating malaria comes at a critical time—WHO’s Global 
Technical Strategy (GTS) for Malaria 2016–2030 and the Roll Back Malaria Partnership’s Action and 
Investment to Defeat Malaria 2016–2030 (AIM) together with the recently endorsed Sustainable 
Development Goals, set their sights on rapid progress with malaria elimination towards attainment 
of malaria free status in 35 countries by 2030. Total funding for malaria control and elimination was 
estimated at USD 2.9 billion in 2015 [1], representing just 46% of the GTS 2020 milestone of USD 
6.4 billion. Achieving the global goals will require sustained financial and political commitment at 
the global and domestic levels [2]. The investments have the potential to deliver strong health 
benefits through fewer deaths and less illness valued at over USD 49 billion, exceeding investment 
costs by a factor of 40 between 2015 and 2030 [12]. 
 
There is little published information about the international resources funding malaria elimination 
efforts, how these funds are spent and their association with domestic financing. Several published 
studies describe disbursements of development assistance for health (DAH) and government health 
expenditure (GHE).  The Institute for Health Metrics and Evaluation (IHME) [13] has been tracking 
DAH from 1990 onwards, disaggregating spending by the source of funding, intermediary channel, 
recipient country, and health focus area. Some studies have concentrated on specific health focus 
areas, such as HIV and the estimates produced by Countdown to 2015 [14], which focused on 
maternal, child and newborn health. WHO annually publishes a World Malaria Report [3], which 
includes government expenditure information obtained from countries’ national malaria control 
programmes. However, expenditure data are often unavailable and replaced by budget 
information. Pigott et al. [15] collated co-financing data from the Global Fund grant proposals to 
obtain government budgets on malaria interventions. The system of national health accounts, 
available in a limited number of countries, provide valuable information about financing flows, but 
are limited by issues of comparability, timeliness and level of reporting. Past analyses have either 
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focused on single countries and/or disease programmes or across multiple countries aimed at 
measuring the effectiveness of DAH by exploring how DAH is allocated across recipient countries 
and/ or health focus areas or interventions. 
 
To better understand past and future trends in financing for malaria elimination, this paper 
systematically tracks malaria-specific estimates of DAH expenditures from all major international 
development agencies from 1990 to 2013 with projections up to 2017, and splits this spending into 
13 malaria activities or intervention areas that describe how the resources were used. In addition, 
GHE as a source for malaria financing was tracked from 2000 to 2014 to explore associations 
between DAH and GHE to inform future decision-making and better align need with actual resource 
allocation. A clear perspective on where resources have been and will be available will uncover 
critical investment gaps and investment opportunities. 
 
Specifically, the paper aims to: (a) track development assistance for the prevention and treatment 
of malaria from channel to recipient country or region, for 1990– 2013; (b) generate lower-bound 
estimates of how development assistance for the prevention and treatment of malaria was used by 
activity or intervention area for the same time period; (c) estimate GHE for malaria from 2000 to 
2014; and, (d) estimate DAH projected financing from 2014 to 2017 in the 35 eliminating countries. 
 
7.3 Methods 
 
This analysis was conducted in 35 malaria-eliminating countries defined in 2015 as countries that 
have a national or sub-national evidence-based elimination goal and/or are actively pursuing 
elimination (zero malaria transmission) within its borders [16] (see Figure. 7.1). 
 
7.3.1 DAH 
DAH is defined as the financial and in-kind contributions for maintaining or improving health in low 
and middle-income countries. This analysis focuses on financial contributions, as there is no reliable 
database that captures in-kind contributions. Disbursement of development assistance for malaria 
was estimated to the 35 countries for 1990 through 2013. Building on the IHME’s annual Financing 
Global Health research, data were collected from primary agencies and organizations that channel 
DAH or third party organizations or private organizations that collect such data [13]. Detailed 
methodology is described elsewhere [17], however, in brief, resources were tracked from the 
channel back to the source (original donor) where possible, and further forward to the country or 
region recipient. This permits disaggregation of data into categories such as private or specific 
public sources, bilateral and multilateral agencies, and recipient countries. When underlying 
disbursement data were not available, disbursements were estimated using econometric time-
series methodologies and appropriations or commitment data. Double counting generated by 
transfers among channels was removed manually in order to estimate a total envelope without 
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exaggerating the true amount of resources provided. Throughout this analysis, figures are 
standardized to USD 2014 to allow for uniform comparisons. 
 
Fig 7.1. List of malaria-eliminating countries included in this analysis 
 
Asia Pacific 
• Bhutan 
• China 
• Democratic People's Republic of Korea 
• Malaysia 
• Nepal 
• Philippines 
• Republic of Korea (ROK) 
• Solomon Islands 
• Sri Lanka 
• Thailand 
• Vanuatu 
• Vietnam 
  
North Africa, Europe, Middle East, Central Asia 
• Algeria 
• Azerbaijan 
• Iran 
• Saudi Arabia  
• Tajikistan 
• Turkey  
 Latin America and Caribbean 
• Belize 
• Costa Rica 
• Dominican Republic 
• El Salvador 
• Guatemala 
• Honduras 
• Mexico 
• Nicaragua 
• Panama 
• Paraguay 
 
 
Sub-Saharan Africa 
• Botswana 
• Cape Verde 
• Mayotte* 
• Namibia 
• São Tomé and Príncipe 
• South Africa 
• Swaziland 
*No data available 
 
7.3.2 DAH by service delivery area 
DAH for malaria elimination was split into categories identifying the type of investment. The 
Organization for Economic Cooperation’s (OECD) Creditor Reporting System (CRS) database 
contains information on DAH that has been channeled through bilateral agencies [18]. From the 
CRS data, the amount of DAH disbursed per project, the recipient country, the project title, and the 
project description was collated. A keyword search was run to further disaggregate malaria DAH 
into intervention or activity categories. For Global Fund malaria grants, budget data were extracted 
by service delivery areas from programme grant agreements. The fraction of aid allocated to every 
service delivery area for each year in a grant was calculated, and the budgeted malaria aid fractions 
to actual DAH for each year of a grant were applied. When budget information was missing from a 
programme grant agreement, DAH was distributed to the service categories based on service 
delivery areas that were listed in the Global Fund online grants portfolio for the specific grant. 
Some funders, such as the World Bank, did not have this kind of information and therefore, funding 
by service delivery areas was unable to be disaggregated. 
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7.3.3 GHE 
A diverse set of data points and reports were used to estimate the share of domestic government 
health budgets spent on malaria from 2000 through 2014. The WHO annually publishes a World 
Malaria Report (WMR), which includes government expenditure (or budget information when 
expenditures are unavailable) obtained from countries’ national malaria control programmes. GHE 
as source data were extracted from these reports from 2008 to 2015 and from Pigott et al. [15], 
which collated co-financing data from the Global Fund grant proposals to obtain government 
budgets on malaria treatment. Each data source has its own concerns. Government expenditure 
published in the WMR does not generally provide comprehensive tracking of spending on 
healthcare workers and capital costs. In addition, reports from different years are inconsistent, 
mostly due to weak or non-existing expenditure tracking systems, impeding any temporal 
comparisons. Pigott et al. reports government expenditure that includes spending on human 
resources, but these numbers are from government budgets rather than actual expenditure. If 
budgets and spending differ in a non-random manner these estimates will be biased. To estimate 
government expenditure that is comprehensive of all public spending on malaria, a linear 
regression on data from both sources was performed. Country-specific regression analyses took 
into account country, the year the data were published, whether the data were comprehensive of 
human resources and capital costs, whether the data were expenditure or budget, and time. These 
were modeled using basis splines to avoid assuming linear growth. 
 
7.3.4 Estimates of DAH projected financing from 2014 to 2017 
To estimate projected DAH spending, a regression that took into account DAH averages to recipient 
countries and budgeted or earmarked funding was used. The dataset used to train the model was 
tailored to reflect the data available for each forecast. These individual training sets were made in 
order to take into account future malaria projects for which financial commitment data was not 
available at the time of writing this paper. 
 
7.3.5 Uncertainty estimates 
Uncertainty intervals for government health expenditure and DAH projected financing from 2014 to 
2017 were calculated by sampling the variance–covariance matrix generated by each linear 
regression 1000 times. 
 
7.3.6 GHE as a function of GDP and disease burden 
To assess the association between GHE and a country’s income as measured by the Gross Domestic 
Product (GDP) per capita, GHE for malaria as a %age of total health expenditure was plotted against 
GDP and further analysed by malaria disease burden as measured by Annual Parasite Index (API). 
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7.4 Results 
 
7.4.1 Funding landscape for malaria elimination 
Between 2000 and 2010, the overall funding for malaria for the 35 malaria-eliminating countries 
grew 2.5-fold from USD 179 million in 2000 to over USD 458 million. Despite a reduction in overall 
funding after 2010, total funding to these countries amounted to over USD 335 million in 2013 of 
which 81% was from domestic resources and 19% from donors. South Africa was later excluded in 
subsequent analysis as it had significant GHE for malaria until 2009, thereby skewing the results of 
the underlying trend in GHE by the remaining 34 countries. Without South Africa, total financing 
amounted to USD 430 million in 2010 (see Figure. 7.2). 
 
7.4.2 DAH 
DAH increased 33-fold between 2000 and 2010 for the 35 malaria-eliminating countries from just 
over USD 5 million in 2000, accelerating after 2007, and peaking at over USD 176 million in 2010. 
However, DAH sharply declined by over 65% between 2010 and 2013 to about USD 60 million. The 
largest declines in DAH were seen in China which was 90% externally financed in 2010 compared to 
only 10% in 2013 and in Democratic People’s Republic of Korea and the Solomon Islands with 
declines of over 25%. Nonetheless, external funding was 11.5-fold higher in 2013 than in 2000. In 
2013, DAH accounted for less than 10% in Azerbaijan and Belize. Overall financing trends are 
projected to continue to decrease between 2014 and 2017 with a low of USD 28 million in 2017 
(uncertainty interval USD 9.6 million to USD 66.4 million). Figure 7.3 illustrates malaria expenditure 
by donors (by the primary sources or intermediary channels) from 1990 and projected to 2017, and 
government from 2000 (when data was available from) for the 34 malaria-eliminating countries 
(excluding South Africa). 
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Fig. 7.2. Development Assistance for Health (DAH) and Government Health Expenditure (GHE) by 
funding channel graph for 34 countries (excluding South Africa). GHE data only available after 
2000  
  
The Global Fund was the largest source of external funding for malaria-eliminating countries, 
providing 96% of the total DAH in the 35 countries in 2013. However after peak funding in 2011, 
Global Fund resources for these countries decreased by approximately 58% from over USD 140 
million in 2011 to approximately USD 60 million in 2013. Other donors that provided funding to 
malaria-eliminating countries over the period 2007– 2011 included the World Bank, the Australian 
government (particularly for the Pacific islands), and the Bill & Melinda Gates Foundation (BMGF). 
Malaria-specific funding from the World Bank halted in 2012 with the conclusion of the World   
Bank   Booster Programme for Malaria.  Similarly bilateral funding from Australia decreased sharply 
in 2011 by 64% decreasing further with the integration of Australia’s aid programme into the 
Department of Foreign Affairs and Trade. 
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Fig. 7.3. Development Assistance for Health (DAH): past and future projections for 35 malaria 
eliminating countries 
 
 
 
7.4.3 DAH by service delivery area 
Figure 7.4 illustrates the trend in spending by service delivery area in the 35 malaria-eliminating 
countries. The graph indicates that DAH channels prioritise various service delivery areas at 
different times. In general, DAH increased along all interventions starting in 2003 and peaking in 
2010 at over USD 176 million. Treatment, diagnosis and vector control [indoor residual spraying 
(IRS) and bed nets], and to a lesser extent, health system strengthening and surveillance grew at 
faster rates than other service delivery areas, consistent with recommendations for malaria 
elimination. Exceptions included the Dominican Republic where surveillance accounted for 40% of 
expenditures in 2009 declining to less than 10% in 2013. Expenditures for malaria treatment 
increased between 2003 and 2007 but have declined since 2010. At the same time, DAH 
expenditures on diagnosis increased gradually, consistent with WHO recommendations on testing 
before treatment, peaking in 2010, but decreasing thereafter. In most countries, the ratio of DAH 
expenditure on diagnosis versus treatment increased after 2008, reaching a 50:50 split in Bhutan 
and Costa Rica by 2013.  
 
A notable exception is Thailand with 25% of total expenditure on treatment but very little on 
diagnosis. There was a high growth in vector control spend particularly on bed nets as well as other 
undefined vector control interventions peaking in 2010 and declining thereafter. By 2012, 
expenditures on bed nets were less than other vector control interventions. However, bed nets still 
accounted for 80% of expenditure in Bhutan. Other vector control interventions accounted for over 
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80% of total expenditure in Nepal, and up to 50% in Sao Tome and Nicaragua. There was some 
growth in community outreach and strengthening of surveillance systems, however, this growth 
was not uniform; with surveillance expenditure actually decreasing overall between 2010 and 2012. 
A large proportion of funds could not be allocated over any of the service delivery areas particularly 
between 2008 and 2011 (14%). 
 
7.4.4 GHE for malaria 
For the 35 malaria-eliminating countries in aggregate (excluding South Africa as an outlier), GHE as 
source for malaria elimination steadily increased since 2000 from about USD 131 million per year to 
about USD 250 million in 2014, outpacing DAH. In 2010, at the peak of external finding, government 
spending was 1.4 times higher than the donor resources available. 
 
Table 7.1 shows the growth rates across various time periods for both GHE and DAH for the 35 
malaria-eliminating countries. 
 
7.4.5 GHE as a function of GDP and API 
Figure 7.5 illustrates government health expenditure for malaria as a function of GDP and API. 
There is a wide variation in the GHE on malaria uncorrelated with GDP indicating that GDP is not 
directly associated with increased domestic spending in malaria. Higher GDP countries with low 
government expenditure on malaria include several countries in Latin America (Costa Rica, Panama, 
Belize) as well as Swaziland and Thailand. Most of the countries spent less than 0.05% on malaria 
with the exception of Vanuatu (0.1%). Furthermore, the Figure illustrates that malaria expenditure 
is also not directly associated with disease risk as measured by API. 
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Fig. 7.4. Development Assistance for Health (DAH) by service delivery area for 35 countries
 
Fig. 7.5. GHE for malaria as a % of health expenditure by GDP and API  
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7.5 Discussion 
 
This is the first study that tracks DAH and GHE specifically for malaria eliminating countries from 
1990 to 2014 with projections to 2017. This study also makes use of enhanced methods providing a 
more comprehensive tracking of DAH and GHE than has previously been utilized in other studies. 
The findings clearly demonstrate a growing uncertainty about the future availability of DAH for 
malaria elimination. At the same time, while government health expenditures have steadily 
increased, they have not kept pace with the declining DAH. Many malaria-eliminating countries 
could risk facing significant funding gaps, which can increase the risk of malaria resurgence 
highlighting the need for an interim solution until the economies of these countries have 
sufficiently grown to fill the gap. 
 
The findings demonstrate three periods for DAH for malaria: a period of moderate growth in the 
1990s, accelerated growth in the first decade of the 2000s of 97%, and a decline of 65% since 2010. 
In the 35 countries included in this review, total financing for malaria grew from USD 179.5 million 
to USD 301.7 million between 2000 and 2013 of which DAH accounted for 19% in 2013. DAH began 
to decline in 2011, coinciding with the Global Fund’s decision to halt its 11th grant cycle. During this 
period, DAH declined by 65% in the 35 malaria-eliminating countries overall and is projected to 
further decline through 2017. 
 
Table 7.1. DAH and GHE annualized growth rates for the 35 malaria eliminating countries 
 
 
2000-2004 2005-2009 2010-2013 or 2014 
Countries DAH GHE DAH GHE DAH GHE 
Afghanistan -42.25 11.10 115.97 11.21 74.73 -25.84 
Algeria 0 1.25 0 -0.17 0 -74.68 
Angola 52.77 23.42 -20.30 19.66 27.14 24.27 
Azerbaijan -100.00 7.38 306.69 27.84 -19.43 7.20 
Bangladesh -46.18 3.15 48.74 23.54 18.47 31.14 
Belize 0 2.27 0 9.93 0 4.896 
Bhutan -100.000 4.053 2.841 -0.720 -6.907 -2.74 
Bolivia 100.615 -6.049 4.214 7.651 4.132 -15.55 
Botswana 
 
-6.070 
 
29.333 -100.000 9.107 
Cambodia -21.264 13.611 -3.17 12.08 -24.696 -10.42 
Cape Verde 0 3.48 -100.00 7.71 0 -15.88 
China 51.187 6.21 49.758 31.03 -67.35 37.58 
Colombia -100.00 2.66 5.002 3.239 -16.60 -7.16 
Costa Rica 0 2.322 0 7.284 0 -9.15 
Democratic People's 
Republic of Korea 
(DPRK) 
-100.00 8.16 -100.00 5.94 -31.51 -0.16 
Dominican Republic 0 -26.33 0 15.53 -2.53 3.56 
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2000-2004 2005-2009 2010-2013 or 2014 
Countries DAH GHE DAH GHE DAH GHE 
Ecuador 0 5.91 0 4.67 -26.95 -17.79 
El Salvador 0 -9.52 0 31.83 0 14.23 
French Guiana 0 -2.04 0 -0.17 0 -22.20 
Guatemala 0 15.87 -29.73 17.16 0 -46.02 
Guyana 0 -26.57 6.85 6.59 -1.47 13.09 
Haití 0 -3.65 -7.65 -22.95 0 28.09 
Honduras 176.03 -1.35 -14.49 -12.500 -13.18 -14.51 
India -5.40 -1.48 -36.41 4.10 -24.09 -13.52 
Indonesia 59.17 2.38 37.71 2.16 -8.92 30.63 
Iran -100.00 7.45 18.18 4.83 10.72 -15.12 
Lao (PDR) 21.86 -4.73 -8.64 -17.92 5.48 2.14 
Malaysia 0 -0.74 0 16.46 0 10.78 
Mexico 0 0.29 0 2.96 0 -6.74 
Mozambique 61.40 7.17 1.42 10.25 -14.49 -2.07 
Myanmar -50.36 10.35 -44.94 36.76 1.76 7.13 
Namibia 92.00 11.86 24.49 -0.63 43.21 5.17 
Nepal 65.01 4.46 42.31 1.62 -22.15 14.02 
Nicaragua 0 -4.90 21.38 -7.11 3.83 -17.16 
Pakistan 181.89 0.82 34.03 6.74 16.25 6.58 
Panama 0 -23.04 0 17.00 0 38.53 
Papua New Guinea 0 -17.63 53.74 17.80 86.62 9.95 
Paraguay 0 1.53 0 11.23 0 13.13 
Perú 0 12.59 -100.00 35.43 -58.07 -49.57 
Philippines 74.09 -12.26 -17.26 50.41 -43.70 18.03 
Republic of Korea 0 -2.19 0 13.51 0 -13.39 
Saudi Arabia 0 1.97 0 7.574 0 -2.27 
Solomon Islands 78.20 11.23 56.29 37.85 -45.71 -27.87 
South Africa -12.90 5.08 -34.73 -1.80 31.62 -5.85 
Sri Lanka 101.76 12.98 53.20 1.63 -12.84 -34.37 
Surinam 0 27.36 1.08 5.57 -6.62 35.38 
Swaziland 0 -1.48 74.44 8.64 -2.69 -8.91 
São Tomé and 
Príncipe 
6.33 2.00 -49.88 28.57 49.09 37.10 
Tajikistan -54.13 5.01 99.02 21.17 -12.23 32.21 
Thailand -17.24 -5.61 -7.23 -14.26 46.57 6.53 
Timor Leste 129.50 23.91 8.16 22.15 -3.30 44.30 
Turkey 0 79.47 0 12.76 0 -2.86 
Vanuatu 0 -0.47 -25.54 6.61 -11.60 -8.42 
Venezuela 0 31.54 5.00 -10.89 -100.00 -36.29 
Vietnam 61.06 -0.22 8.58 0.35 -45.99 -11.48 
Zambia 28.36 38.63 -1.25 7.69 40.13 29.53 
Zimbabwe 144.84 -13.97 55.68 -16.02 3.75 -22.49 
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The allocation methodology adopted by the Global Fund in 2012, uses a combination of disease 
burden and GNI per capita to determine the financing that countries will receive for the three 
diseases. Under this New Funding Model, country-specific funding to the sub-set of countries 
attempting to eliminate malaria has declined by over 30% [5]. Further declines in allocations have 
been noted under a revised model adopted in November 2016. These changing polices have major 
implications for the financing and delivery of health services, particularly for malaria elimination. 
Eliminating countries typically have lower disease burdens and are often middle-income countries 
and therefore tend to be less attractive investments for donors looking for easy to measure high 
impact results. Of the 35 countries included in this review, 2 are high-income countries, 15 are 
upper middle income, 14 are lower middle income, and 3 are lower income (no data was available 
on Mayotte).  18 of these countries are ineligible to receive Global Fund financing. Three countries 
have graduated from Global Fund malaria financing in the past 6 years: China (2011), Dominican 
Republic (2013) and Iran (2012) and one country transitioned out of Global Fund support in 2016 
(Paraguay). Sri Lanka, which attained malaria-free certification by WHO in September 2016 and 
Botswana, will receive one more transitional grant from the Global Fund. The Philippines submitted 
their final proposal for funding in the first quarter of 2017 together with a transition plan for 
sustainable financing. Several other countries are approaching one or more donor eligibility 
thresholds in the next few years. Although the majority of funding in these countries comes from 
domestic sources, DAH still plays an important role in the delivery of health interventions, 
particularly to vulnerable populations that are often underserved by the government health 
system. Donors such as the Global Fund will need to continue to prioritize these populations to 
deliver on its 2017–2022 Global Fund Strategy, which aims to achieve progress toward a world free 
of the burden of HIV/AIDS, tuberculosis, and malaria. 
 
The Global Fund continued to provide the largest source of DAH to malaria-endemic countries 
accounting for over 90% of all external financing. It is not possible to unpack donor contributions 
specifically to malaria disbursed by the Global Fund, however, in general, the US government 
provides 35% of all funding, the United Kingdom, 16%, France, 9% and non-official sources 
including foundations and charities, 6%. A more diverse set of donors including the World Bank and 
various bilateral donors played a larger role in the malaria agenda prior to the establishment of the 
Global Fund. For example, Australia played a major role in funding malaria control in the Pacific 
Islands; however, this funding has been drastically reduced since with the creation of the 
Department of Foreign Affairs and Trade replacing Australian Aid whose new Health for 
Development Strategy 2015–2020 [9] focuses on health as development with little on disease-
specific funding. 
 
Across the 35 countries included in this review, GHE almost doubled between 2000 and 2010, 
ultimately resulting in about USD 249 million in 2014 (excluding South Africa as an outlier). In most 
countries, the upward GHE trend between 2008 and 2014 has been maintained or increased. Nine 
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countries included in the review (Algeria, El Salvador, Guatemala, Malaysia, Mexico, Panama, 
Paraguay, ROK, Saudi Arabia) are entirely domestically financed. 
 
DAH was disaggregated into 13 service delivery areas allowing for cross-country and regional 
comparisons. The observed trends in spending or allocation by service delivery area are not 
uniform or consistent with epidemiological profiles or regional policies demonstrating the need for 
greater emphasis on allocative efficiency. Vector control, mostly bed nets continues to be the 
largest cost driver across all regions, followed predominately by treatment costs. 
 
Thirty-one of 35 countries spent less than 10% of their malaria DAH funding on surveillance, a key 
malaria elimination intervention between 2010 and 2013. The ratio of DAH expenditure on 
diagnosis versus treatment increased after 2008 reaching a 50% split in most countries by 2013 
bringing countries closer to compliance with WHO’s Test: Treat: Track policy. Notable exceptions 
are Honduras, Tajikistan, and Thailand with minimal expenditure on diagnosis. As actual cases 
decrease, expenditure on diagnosis is expected to be at least twice the spending on treatment. 
However, discrepancies between use of DAH for certain service delivery areas and strategy for 
malaria elimination could be explained by governments using DAH to fund allowable expenses and 
GHE to pay for the rest, for example procurement of diagnostics. Nevertheless, the analysis does 
raise the question on whether DAH is being spent on the most effective strategies for malaria 
elimination. 
 
Morel and colleagues noted, “it is important to ask whether current interventions are used 
appropriately and what is the most cost-effective way to scale up activities to the levels needed” 
[19]. With declining DAH, available resource will need to be used more efficiently. This would 
include focusing the needs of the malaria programme on the most effective interventions coupled 
with better targeting of intervention delivery to strategic populations to maximize value-for-money 
and prevent drug and insecticide resistance and from available resources [20]. At the same time, 
there is a need to move donor funding for malaria control away from an input model that mostly 
focuses on the procurement and distribution of key inputs (most notably mosquito nets) towards 
more support for operational improvements, capacity building in programme management, 
improved disease and intervention surveillance as well as knowledge generation and sharing to 
strengthen the impact of elimination interventions. 
 
The WHO Global Technical Strategy for Malaria estimated that USD 6.8 billion will be needed 
annually to reduce malaria related morbidity and mortality by 90% between 2015 and 2030 and 
projected gaps of more than half of this financing need. Although gains in health system efficiency 
can be used to make reduce the discrepancy between available finances and need, current trends 
suggest that many countries may face gaps in financing for malaria elimination. If increasing 
domestic health financing is the solution, countries will need to increase their own spending on 
malaria beyond historical trends. The expectation of the economic and health financing transition 
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suggests that as countries develop they spend more on health than they did before. Of 35 currently 
low income and middle-income countries, included in this review, 22 countries currently meet the 
Chatham House goal of spending 5% of GDP or USD 86 per capita on health [21]. 
 
There are several complementary ways for countries to fill the gap between needs and resources 
until government allocations catch up with the financing transition. The Addis Ababa Action Agenda 
calls on a number of resource mobilization efforts encompassing aid, domestic public resources, 
and support from the private sector. Many national governments are considering raising health 
budgets by improving the capacity to raise tax revenue including the implementation of Pigovian or 
sin taxes. In the Philippines, the Sin Tax Reform Bill, passed in 2012, increased taxes on tobacco and 
alcohol, generating USD 2.3 billion within 2 years increasing the Department of Health budget by 
63% in 2015. This revenue has freed up resources, which would have otherwise been used for 
social protection of the poor and has trickled down for use for malaria and other diseases targeted 
for elimination. 
 
Two other areas of resource mobilization which have had limited traction are better harnessing of 
private financing as well as innovative approaches, such as social impact bonds, airline and financial 
transactions taxes. Blended approaches which refer to the use of funds to leverage or de-risk 
private investment in development are increasingly being explored. Although there are no current 
estimates on their scale, these financing instruments have been used with success in other sectors 
within and outside of health and have the potential to catalyse future additional private sector 
support. 
 
The Roll Back Malaria Action for Investment in Malaria (AIM) suggests that investment in malaria 
could deliver strong health benefits through fewer deaths and less illness that can be valued at over 
USD 49 billion. These benefits exceed investment costs by a factor of 40 over the period to 2030 
[12]. Focused advocacy at all levels is needed to reach key decision-makers in order to highlight the 
social and economic benefits of investing in malaria elimination and the risks of not doing so. In 
particular, emphasis on the threat of drug resistance in undermining success and posing a risk of 
regional health security is needed. Continued engagement is needed with governments to focus 
attention on increased domestic budgets. 
 
This analysis has several limitations. Many of the DAH expenditures could not be allocated to 
specific interventions, therefore introducing a potential bias. In addition, the spending by 
governments could not be further disaggregated by intervention area and it is possible that DAH 
was spent on particular interventions due to co-financing of others through domestic sources. 
Estimates of domestic expenditures on malaria were obtained from sources, which relied on self-
reporting by countries with little triangulation of data and the findings should therefore be 
interpreted as such. 
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Nevertheless, the findings provide strong evidence on the uncertainty about the future availability 
of DAH in malaria elimination settings and the wide variation in support for malaria programmes by 
governments [12]. Many malaria-eliminating countries could risk facing funding gaps, which could 
be compounded if countries face funding cliffs with multiple donors phasing out simultaneously. 
These disruptions in service delivery could also confer negative cross-border externalities to 
neighbouring countries, compromising regional elimination targets and ultimately global 
eradication. 
 
7.6 Conclusion 
 
Financing for malaria elimination is declining at a time when commitment to elimination will be 
crucial to paving the way to global malaria eradication. While government health expenditure has 
steadily increased in most countries, this increase has not been proportional to the rate of waning 
external funding, particularly in middle-income countries, increasing the risk of deadly and costly 
malaria resurgences. Notwithstanding, existing financing has not been used in the most cost-
effective or efficient manner. Mechanisms to increase efficiency and value for money are urgently 
needed as well as further analysis on the extent to which expenditures are in line with the 
interventions recommended by the WHO. Innovative health financing mechanisms may provide a 
respite—until domestic financing is able to fi the gap created by diminishing donor resources. 
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8.1 Abstract 
 
Background: The Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM) has been the 
largest financial supporter of malaria since 2002. In 2011, the GFATM transitioned to a new funding 
model (NFM), which prioritizes grants to high burden, lower income countries. This shift raises 
concerns that some low endemic countries, dependent on GFATM financing to achieve their 
malaria elimination goals, would receive less funding under the NFM. This study aims to understand 
the projected increase or decrease in national and regional funding from the GFATM’s NFM to the 
34 malaria-eliminating countries. 
 
Methods: Average annual disbursements under the old funding model were compared to average 
annual national allocations for all eligible 34 malaria-eliminating countries for the period of 2014–
2017. Regional grant funding to countries that are due to receive additional support was then 
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included in the comparison and analysed. Estimated funding ranges for the countries under the 
NFM were calculated using the proposed national allocation plus the possible adjustments and 
additional funding. Finally, the minimum and maximum funding estimates were compared to 
average annual disbursements under the old funding model. 
 
Results: A cumulative 31 % decrease in national financing from the GFATM is expected for the 
countries included in this analysis. Regional grants augment funding for almost half of the 
eliminating countries, and increase the cumulative % change in GTFAM funding to 32 %, though 
proposed activities may not be funded directly through national malaria programmes. However, if 
countries receive the maximum possible funding, 46 % of the countries included in this analysis 
would receive less than they received under the previous funding model. 
 
Conclusions: Many malaria-eliminating countries have projected national declines in funding from 
the GFATM under the NFM. While regional grants enhance funding for eliminating countries, they 
may not be able to fill country-level funding gaps for local commodities and implementation. If the 
GFATM is able to nuance its allocation methodology to mitigate drastic funding declines for malaria 
investments in low transmission countries, the GFATM can ensure previous investments are not 
lost. By aligning with WHO’s Global Technical Strategy for Malaria and investing in both high and 
low-endemic countries, the Global Fund can tip the scale on a global health threat and contribute 
toward the goal of eventual malaria eradication. 
 
8.2 Background 
 
Of the approximate 100 countries with endemic malaria, 34 were defined in 2010 as malaria-
eliminating (see Table 8.1), defined here as a country that has a national or subnational evidence-
based elimination goal and/or is actively pursuing elimination (zero malaria transmission) within its 
borders [1]. Among these 34 countries, 78% of financing for malaria programmes has been 
provided by governments themselves [2]; however, the %age of domestic funding can vary widely 
from country to country, ranging from under 10 % in some low and lower–middle-income countries 
(LMICs) such as the Philippines and Tajikistan, and up to 100 % in upper–middle to high-income 
countries such Costa Rica, South Korea, and Turkey [3]. 
 
As the largest international financier to national malaria programmes, the Global Fund to Fight 
AIDS, Tuberculosis, and Malaria (GFATM) has played a critical role in reducing global malaria 
burden. Between 2000 and 2011, global financing for malaria increased 18-fold, largely due to the 
creation of the GFATM in 2002 [4]. From inception until 2011, the GFATM granted funding through 
a “round” system whereby countries would submit proposals that were evaluated based on 
technical soundness, alignment with national strategy, and capacity for implementation [5]. Under 
this old funding model, a total of USD 8.65 billion had been disbursed for malaria, 93 % of which  
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was spent on high burden countries [2]. The remaining 7 % disbursed by the GFATM accounted for 
the largest source of donor assistance for 19 of the 34 malaria-eliminating countries that received 
support from the GFATM.  Although it is a small %age of the overall GFATM malaria portfolio, this 
amount has catalyzed national progress toward elimination [2], helping to reduce malaria cases in 
the 34 malaria-eliminating countries collectively by 85 % between 2000 and 2013 [6]. 
 
In an effort to become more transparent and systematic, the GFATM created the new funding 
model (NFM) in 2012 to increase value for money and focus investments to hardest hit countries 
with fewer available financial resources [7]. With the NFM, the GFATM formalized their allocation 
methodology, largely determined by disease burden and gross national income (GNI) per capita, 
which emphasized their priority on investments in higher burden, lower income countries [8]. 
Implemented during the 2014–2016 funding cycle, the NFM offers a pre-calculated allocation to 
each country for human immunodeficiency virus (HIV), tuberculosis (TB), and malaria. 
 
Under the NFM, countries are first assigned to one of four bands based on their disease burden and 
income level (Table 8.2). Then, the allocation formula is applied to determine the country’s national 
allocation, which includes any unspent money left over from grants under the old funding model, 
plus a new allocation amount. 
 
Table 8.1. 34 malaria-eliminating countries, national elimination goals (as of 2015), and study 
inclusion status 
 
Country National 
elimination goal 
Eligible for 
national funding 
in 2014 
Eligible for 
funding 
through a 
regional 
initiative 
Meets 
inclusion 
criteria for 
this 
analysis? 
Eastern Mediterranean and 
Europe 
Algeria 2015 not eligible n/a  no 
Azerbaijan 2013 not eligible n/a  yes 
Iran (Islamic Rep.)*  2025 not eligible n/a  yes 
Kyrgyzstan 2015 yes n/a  yes 
Saudi Arabia 2015 not eligible n/a  no 
Tajikistan 2015 yes n/a yes 
Turkey 2015 not eligible n/a no 
Uzbekistan 2015 yes n/a yes 
The Americas 
Argentina NNEG  not eligible n/a  no 
Belize1 2020 not eligible yes yes 
Costa Rica1 2020 not eligible yes yes 
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Country National 
elimination goal 
Eligible for 
national funding 
in 2014 
Eligible for 
funding 
through a 
regional 
initiative 
Meets 
inclusion 
criteria for 
this 
analysis? 
Dominican Republic1 2020 not eligible yes yes 
El Salvador1 2020 yes yes yes 
Mexico1 2020 not eligible n/a  no 
Nicaragua1 2020 yes yes yes 
Panama1 2020 not eligible yes yes 
Paraguay 2015 yes n/a  yes 
South-East Asia and Western 
Pacific 
Bhutan 2018 yes n/a yes 
China 2020 not eligible n/a no 
Korea, Dem. Rep. 2025 yes n/a  yes 
Malaysia 2020 not eligible n/a  no 
Philippines 2030 yes n/a  yes 
Republic of Korea 2017 not eligible n/a  no 
Solomon Islands 2035 yes n/a  yes 
Sri Lanka 2014 yes n/a yes 
Thailand 2030 yes yes yes 
Vanuatu 2025 yes n/a yes 
Vietnam 2030 yes yes yes 
Sub-Saharan Africa 
Botswana 2018 yes  yes yes 
Cape Verde 2020 yes n/a yes 
Namibia 2020 yes  yes yes 
Sao Tome and Principe 2020 yes n/a  yes 
South Africa 2018 not eligible yes yes 
Swaziland 2015 yes yes yes 
Notes: Although these 34 malaria-eliminating countries form the basis of this review, the UCSF Global Health Group’s 
Malaria Elimination Initiative now identifies 35 malaria-eliminating countries based on progress around the world over 
the last five years. [23] 
NNEG: No National Elimination Goal.  
a While not eligible for a new allocation under the NFM, Iran has funding through the Global Fund from a previous five-
year grant signed in 2011. 
b Elimination goal of 2020 declared under the EMMIE regional initiative. 
 
Once the national allocation is determined and publicly announced, countries can develop a 
concept note for submission to the GFATM. During concept note development and revisions, the 
country dialogue process is open and countries can make additional modifications to the allocation. 
Such adjustments include changes to the disease allocation split between HIV, TB, and malaria or 
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other adjustments based on the willingness to pay criteria, defined by the amount the country is 
willing to invest in their own programmes beyond the required counterpart financing. 
 
The final concept note is then reviewed by the GFATM’s Grant Approvals Committee. The 
committee can approve eligible countries for additional incentive funding, defined by the GFATM as 
“a special reserve of funding available on a competitive basis awarded to applications that 
demonstrate the greatest potential for high impact with additional funds” [10]. Incentive funding 
can increase the national allocation up to 15 % and is only available to eligible countries in bands 1-
3. 
 
Apart from the national allocations, the GFATM approved regional grants under the NFM to three 
regions that applied for malaria funding within an amount set aside for regional investments. As of 
January 2016, three regional grants have been signed: the Elimination 8 (E8) [11] in southern Africa, 
the Elimination of Malaria in Mesoamerica and the Island of Hispaniola (EMMIE) [12] and the 
Regional Artemisinin-resistance Initiative (RAI) [13] in the Mekong Region. While national grants 
tend to focus on in-country commodities and activities, regional grants   can   play   a   
complementary   role, supporting activities that may not be funded through country programmes, 
such as cross-border surveillance programmes. 
 
The malaria disease burden is calculated using the number of deaths + the number of cases + 0.5 × 
incidence + 0.5 × mortality rate, based on 2000 malaria incidence data (taken from the World 
Health Organization), and country income level defined by GNI per capita [9]. 
 
Since the GFATM has been such a significant supporter of malaria-eliminating countries, which are 
by definition, low burden and typically middle-income, and the financial impact of the NFM’s 
funding methodology is not clear, the authors initiated an analysis to understand the projected 
increase or decrease national and regional funding from the GFATM to the 34 eliminating countries. 
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Table 8.2. Band assignments for malaria-eliminating countries eligible for GFATM national 
malaria funding 
 
Band 1 Band 2 
Lower income, High burden Higher income, High burden 
Vietnam Korea, Dem. Rep. 
  Kyrgyzstan 
  Nicaragua 
  Sao Tome and Principe 
  Solomon Islands 
  Tajikistan 
  Uzbekistan 
Band 3 Band 4 
Lower income, Low burden Higher income, Low burden 
Botswana Bhutan 
Namibia Cape Verde 
Philippines El Salvador 
Swaziland Paraguay 
Thailand Sri Lanka 
  Vanuatu 
Source: The Global Fund to Fight AIDS, Tuberculosis and Malaria.   Overview of the Allocation Methodology (2014-2016): 
The Global Fund’s new funding model.2014 
http://www.theglobalfund.org/documents/fundingmodel/FundingModel_OverviewAllocation_Methodology_en/. (12 
January 2016, date last accessed) 
 
8.3 Methods 
 
8.3.1 Countries included in this analysis 
As of 2010, 34 countries have been identified as malaria eliminating [1]. Of these, 26 countries were 
included in the analysis; all met at least one of the following criteria: recently eligible for a GFATM 
malaria grant under the old funding model; has an active malaria grant from the GFATM; is eligible 
for a malaria grant under the NFM; and/or is expected to receive funds from the GFATM under a 
regional malaria grant. The list of countries with their stated national elimination goal is given in 
Table 8.1. Eliminating countries that have never been eligible for malaria funding from GFATM or 
that hold membership to the Group of 20 major economies were excluded from the analysis 
(Algeria, Argentina, China, Malaysia, Mexico, Republic of Korea, Saudi Arabia, and Turkey). 
 
Eligibility status of the 34 eliminating countries generated by the GFATM is shown in Table 8.1. 
Nineteen of the 34 eliminating countries are eligible for NFM national malaria funding with 
allocation amounts ranging from USD 500,000 to USD 27 million. Although 19 countries are eligible  
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for national malaria grants and were given allocations in the NFM, four did not receive an allocation 
with any additional funding apart from the existing, unspent funds from previous grants: 
Kyrgyzstan, Tajikistan, Thailand, and Vanuatu. Five countries are not eligible for national malaria 
grants, but are expected to receive funds through a regional malaria grant: Belize, Costa Rica, 
Dominican Republic, Panama, and South Africa. 
 
8.3.2 Analysis on national level funding changes 
Using publicly available GFATM grant data [14] collated in Microsoft Excel 2010, average annual 
funding from the old funding model was calculated using the total disbursed amounts from each 
country’s most recent active malaria grant(s) averaged over the respective grant start date through 
December 31, 2013, the GFATM specified cut-off date for the round based system. Disbursed 
amounts rather than the signed amounts in grant agreements from the old funding model were 
used in order to avoid “double counting” of money not yet disbursed that will later be incorporated 
into the new NFM national allocation. Using the average disbursements from the entire previous 
grant(s), rather than the last 3 years under the old funding model, ensures that this analysis 
compares previous full grants to potential full grants, while capturing any programme scale-up or 
frontloading. 
 
Estimated NFM average annual allocation amounts were calculated by averaging the GFATM 
specified national allocation [7] over the 4-year period of 2014– 2017. This time period was used 
since the next GFATM replenishment will take place in the last quarter of 2016. Thus, countries will 
likely not receive new funding until mid-2017. No regional grant amounts were included in this 
portion of the analysis. 
 
Average annual grant amounts disbursed under the old funding model were compared to average 
annual national allocated amounts under the NFM to determine the % change between old and 
new average annual funding. A cumulative % change between the old funding model and NFM was 
calculated between the sum total of the old disbursed and new allocated amounts. The cumulative 
percent change in funding accounts for countries that had an unquantifiable percent change (e.g. 
those that received no money under the old funding model, and then assigned an allocation under 
the NFM). 
 
8.3.3 GFATM NFM regional grants 
Funding channeled to malaria-eliminating countries through the E8, EMMIE, and RAI GFATM 
regional malaria grants was included. While the RAI grant has a predetermined country-level 
breakdown of funding, in this analysis country shares for EMMIE and E8 were assumed to be 
divided equally among the countries involved and are described in Table 8.5. 
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For eliminating countries included in a regional grant, the country share of regional grant funding 
was added to the national allocations and a new percent change of funding from the previous 
funding model compared to the NFM was calculated. 
 
8.3.4 NFM malaria funding ranges 
Since the national malaria allocation is the calculated amount a country is eligible for and not 
necessarily a final grant amount, the funding range (minimum and maximum) each country could 
receive was estimated, taking into account potential adjustments and/or additional funding (e.g. 
regional grant funding under E8, EMMIE, and RAI grants) (Table 8.3). Because regional grants have 
already been signed, regional funding amounts remain constant in this portion of the analysis. 
 
Table 8.3. Potential adjustments and additional funding to national allocations 
 
Potential 
Dimension for 
Adjustments 
Definition Adjustment Timing of 
Adjustment 
Willingness to Pay  Amount the country is 
willing to put forth 
beyond the required 
counterpart financing. 
The amount is negotiated 
between each country 
and the GFATM.  
-15% of national 
allocation if criteria is 
not met 
During Country 
Dialogue  
Disease Split 
between HIV, TB, 
Malaria 
Amount of funding 
allocated to each disease, 
decided upon by the 
Country Coordinating 
Mechanism. 
Up to +/- 10% of the 
national allocation 
amount for each disease 
 
During Country 
Dialogue 
Incentive Funding Aimed to reward high 
impact, well preforming 
projects.  
+15% for eligible 
countries (Bands 1-3) 
During grant-making 
with the Grant 
Approvals Committee 
Additional Funding 
Regional Grant 
Funding 
Any funding granted to a 
country from a regional 
grant (E8, EMMIE, and 
RAI) – this amount would 
be additive to any 
national grants. 
Country share 
breakdown per regional 
grant amounts 
Independent of 
national grant 
process 
Source: Global Fund to Fight AIDS, Tuberculosis and Malaria Resource Book for Applicants: The Global Fund’s New 
Funding Model (2014) 
 
In order to access the full national allocation, each country must meet a conditional counterpart 
financing requirement, or a minimum level of government contribution to the national disease 
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programme as a share of total government financing plus GFATM financing for that disease [9]. The 
counterpart financing requirement is based on a sliding scale of income level: low-income countries 
must reach a minimum threshold contribution of 5 %, lower LMICs must reach a minimum 
threshold contribution of 20 %, upper LMICs must reach a minimum threshold contribution of 40 %, 
and upper–middle-income countries must reach a minimum threshold contribution of 60%. 
 
Countries must then meet their willingness to pay criteria, which is an additional amount beyond 
the counterpart-financing requirement. If a country does not meet their willingness to pay criteria, 
15 % of the national allocation for each disease component can be withheld. Furthermore, during 
the country dialogue process, the country-level stakeholder partnership that manages the 
proposals and grants, also known as the Country coordinating mechanism, can adjust the GFATM’s 
suggested national disease split, potentially transferring up to 10 % of malaria funding to 
supplement HIV or TB or vice versa. Table 8.3 summarizes potential adjustments and additional 
funding used to determine the range of a country’s allocation from the GFATM. 
 
Percentage adjustments were calculated from the suggested national allocation amounts 
announced by the GFATM in March 2014 [15]. To calculate the minimum funding for a country’s 
malaria programme, the national allocations were decreased by 15 % to simulate unmet willingness 
to pay criteria and by an additional 10 % to account for a possible Country coordinating mechanism 
decision to move malaria funding to another disease. Independent of national allocation 
adjustments, any country’s share of regional grants is consistent in the minimum funding amounts. 
 
The maximum potential funding was then calculated based on meeting the willingness to pay 
criteria, a 10 % disease split increase, a 15 % increase for incentive funding (for those in bands 1–3 
that are eligible), and additional regional grant amounts. 
 
8.3.5 NFM minimum and maximum funding amounts compared to the old funding model 
Both the minimum and maximum funding amounts (national allocations plus regional grants) were 
averaged over the 4-year period of 2014–2017 and compared to the average annual disbursements 
under the old funding model to determine the range of % change in funding for eligible eliminating 
countries. 
 
8.4 Results 
 
8.4.1 Funding changes to the GFATM’s malaria portfolio 
Under the NFM, 4.3 % of the GFATM’s malaria portfolio of USD 4.5 billion (including national 
allocations and regional malaria grant funding) is allocated to the focus countries in this paper 
(Figure 8.1). Of the 4.3, 0.8 % of the malaria portfolio supports eliminating countries through three 
regional grants for malaria: E8, EMMIE, and RAI. Under the NFM, the total portion of the malaria 
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portfolio going to malaria-eliminating countries is lower (4.3 %) than under the old funding model 
(7 %). 
 
8.4.2 Analysis on national level funding changes 
Changes in annual national funding between the most recent grant(s) under the old funding model 
and the average annual allocation under the NFM are shown in Table 8.4. Overall, there is a 
projected 31 % decrease in average annual funding during the 2014–2017 timeframe for malaria-
eliminating countries. Twelve countries (Azerbaijan, Cape Verde, Dominican Republic, Iran, 
Kyrgyzstan, Philippines, Solomon Islands, Sri Lanka, Tajikistan, Thailand, Uzbekistan and Vanuatu) 
are expected to see an extreme decrease (30–100 %) in funding, with three (Democratic People’s 
Republic of Korea, Swaziland and Vietnam) expected to have a less severe decrease in funding (1–
29 %). Four countries (Bhutan, Namibia, Nicaragua, and São Tomé and Príncipe) will see increases in 
funding, ranging between 1 and 54%. 
 
Figure 8.1. The GFATM malaria portfolio under the New Funding Model including national 
allocations and signed regional malaria grants 
 
 
 
The percent change for three countries (Botswana, El Salvador, and Paraguay) could not be 
quantified, as they have not received any prior funding from the GFATM, but allocations and 
potential grants to these countries would be an increase. The remaining four countries (Belize, 
Costa Rica, Panama, and South Africa) have no change in national funding 
 
When percent changes for the national allocations were aggregated regionally (also shown in Table 
8.4), it is clear that the Eastern Mediterranean and Europe and the South-East Asia and Western 
Pacific regions are the hardest hit with declines of 93 and 32%, respectively. The majority of the 
95.7%
3.5%
0.8%
4.3%
Total: $4.5 billion 
Total allocated to malaria-
controlling countries
Total allocated to  malaria-
eliminating countries
Total allocated to malaria-
eliminating countries through
national allocations
Total amount (signed) to
malaria-eliminating countries
through regional grants
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eliminating countries in these regions are projected to experience mild to steep declines in funding. 
Malaria-eliminating countries in the Americas are expected to see an overall increase of 30%, while 
malaria-eliminating countries in sub-Saharan Africa will likely have an overall 37% increase in 
allocations under the NFM.  
 
Table 8.4. Average annual disbursements under the old funding model versus average annual 
NFM national allocations 2014–2017 
 
Countries Average annual 
disbursements before 
the NFM as of Dec 31st, 
2013b 
Average annual 
allocation under NFM: 
2014–2017 
Percent changea 
Eastern Mediterranean 
and Europe 
   
Azerbaijan D 1,049,387 D 0 −100 % 
Iran D 5,461,418 D 0 −100 % 
Kyrgyzstan D 884,028 D 113,074 −87 % 
Tajikistan D 2,721,312 D 335,802 −88 % 
Uzbekistan D 578,319 D 350,280 −39 % 
Regional subtotal D 10,694,464 D 799,156 −93 % 
The Americas    
Belize D 0 D 0 0 % 
Costa Rica D 0 D 0 0 % 
Dominican Republic D 1,592,747 D 0 −100 % 
El Salvador D 0 D 963,783 + 
Nicaragua D 2,431,682 D 2,921,343 20 % 
Panama D 0 D 0 0 % 
Paraguay D 0 D 1,338,783 + 
Regional subtotal D 4,024,429 D 5,223,908 30 % 
South-East Asia and 
Western Pacific 
   
Bhutan D 595,598 D 641,075 8 % 
Korea, Dem. Rep. D 4,878,128 D 3,966,350 −19 % 
Philippines D 8,594,847 D 5,543,637 −36 % 
Solomon Islandsc D 2,329,166 D 1,617,630 −31 % 
Sri Lanka D 5,310,434 D 3,194,798 −40 % 
Thailand D 13,611,345 D 8,914,463 −35 % 
Vanuatuc D 1,552,777 D 813,042 −48 % 
Vietnam D 4,895,794 D 3,778,554 −23 % 
Regional subtotal D 41,768,089 D 28,469,547 −32 % 
Sub-Saharan Africa    
Botswana D 0 D 1,282,149 + 
Cape Verde D 633,015 D 320,537 −49 % 
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Countries Average annual 
disbursements before 
the NFM as of Dec 31st, 
2013b 
Average annual 
allocation under NFM: 
2014–2017 
Percent changea 
Namibia D 2,431,682 D 3,018,565 24 % 
Sao Tome and Principe D 1,807,650 D 2,733,377 51 % 
South Africa D 0 D 0 0 % 
Swaziland D 1,420,225 D 1,290,603 −9 % 
Regional subtotal D 6,292,571 D 8,645,232 37 % 
Total D 62,779,553 D 43,137,843 −31 % 
a  + indicates a percent change was unquantifiable (e.g. a country who had received no previous GFATM funding is 
allocated funding under the NFM.) 
b This is calculated by taking the total grant disbursement through 2013 and dividing it by each grant’s start date through 
31-December-2013 
c These countries compose the multi-country Western Pacific, whose previous grant was split 60/40 (Solomon Islands: 
Vanuatu) 
 
8.4.3 GFATM NFM regional grants 
Regional grants provide USD 39.6 million over 3 years in extra support for 12 malaria-eliminating 
countries located in southern Africa, Central America, and the Mekong region (as shown in Table 
8.5) and boost overall funding for malaria elimination from −31% to an increase of 32%. Adding 
regional grant country shares to national funding have a clear positive affect to funding. With the 
addition of regional funding, malaria-eliminating countries in the Americas are expected to see a 
cumulative 171 % increase in funding compared to the old funding model. 
 
Similarly, malaria-eliminating countries in South-East Asia and Western Pacific are expected to see 
an overall 28 % increase in funding, and malaria eliminating countries in sub-Saharan Africa are 
expected to see an overall 179 % increase in funding. No regional grant funding for malaria has 
been provided to malaria eliminating countries in the Eastern Mediterranean and European 
regions. 
 
8.4.4 NFM malaria funding ranges 
As an example, Fig. 8.2 illustrates the breakdown of the estimated funding range available for 
Vietnam for the period of 2014–2017. The range is determined by the adjustments made during the 
country dialogue process and the addition of regional grant funding. The area at the bottom of the 
funding range represents Vietnam’s portion (USD 15 million) of the RAI regional grant. The solid fill 
area represents the full national allocation, which totals USD 15 million, with the various shaded 
areas showing the portion of the national allocation Vietnam would receive based on unmet 
willingness to pay criteria and/or a reduction of the disease split amount. Possible upward 
adjustments include an increase in disease split funding (an additional USD 1.51 million) and 
successful award of incentive funding (USD 2.27 million) and are represented at the top of the 
funding range. Accordingly, Vietnam’s minimum possible funding of about USD 26 million would 
include the RAI regional grant share plus the minimum national allocation (unmet willingness to pay 
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and a Country Coordinating Mechanism decision to move 10 % of malaria funding to HIV or TB). 
Vietnam’s maximum funding amount of nearly USD 34 million includes the RAI regional grant share 
plus the full national allocation and all upward adjustments (a Country Coordinating Mechanism 
decision to increase malaria by 10 % and successful award of incentive funding). 
 
Table 8.5. Regional grants for malaria under the NFM 
 
GFATM regional grant for 
malaria  
Total grant 
amount 
Total estimated to 
malaria-
eliminating 
countries included 
in grant scope 
Malaria-eliminating countries 
included in regional grant 
scope 
Elimination 8 (E8) USD 17,800,000 USD 8,900,000 Botswana, Namibia, Swaziland, 
South Africa 
Elimination of Malaria in 
Mesoamerica and the 
Island of Hispaniola 
(EMMIE) 
USD 10,000,000 USD 5,666,668 Belize, Costa Rica, Dominican 
Republic, El Salvador, 
Nicaragua, and Panama 
Regional Artemisinin-
resistance Initiative (RAI) 
USD 100,000,000  USD 25,000,000 Thailand and Vietnam 
Notes: The E8 is not structured such that it has country specific breakdowns of funding. For this analysis, it was assumed 
that the USD 17.8 million is divided equally among the eight countries (Angola, Botswana, Mozambique, Namibia, South 
Africa, Swaziland, Zambia and Zimbabwe).  
The USD10 million EMMIE regional grant covers 10 countries, 5 of which are eligible for startup funding (Costa Rica, 
Belize, El Salvador, Mexico, Panama), and 9 of which are eligible for payouts (all but Mexico). EMMIE is a cash-on-delivery 
model and of the USD 10 million, USD 3 million will go to Population Services International as the Principal Recipient. 
Because it will not be known which countries will be successful in meeting targets until the end of Years 2 and 3, this 
analysis assumed that the remaining amount (USD 7 million) was evenly split over the 9 eligible countries and added to 
startup funding, if applicable.  
15 % of the USD100 million RAI regional grant goes to Vietnam and 10% goes to Thailand. 
 
Applying the same structure, Figures 8.3, 8.4, 8.5, and 8.6 show the possible funding ranges for 
eligible eliminating countries for the period of 2014–2017, by region. The possible adjustments and 
additional regional grant funding have the potential to change the allocations by either 25 % more 
or less than the amount originally communicated to the countries in March 2014. In the Americas, 
Belize, Costa Rica, Dominican Republic and Panama are not eligible for national grants and thus do 
not have national allocations, however they can receive funding through the regional EMMIE 
award. Similarly, South Africa is not eligible for a national allocation, however is assumed to receive 
one-eighth of the E8 regional grant. 
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Figure 8.2. Estimated Global Fund NFM malaria funding range for Vietnam as an example, for the 
period of 2014-2017 using adjustments and additional funding 
 
 
 
Figure 8.3. Estimated Global Fund NFM malaria funding ranges for malaria-eliminating countries 
in the Eastern Mediterranean and Europe regions, for the period of 2014-2017 using adjustments 
and additional funding  
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Figure 8.4. Estimated Global Fund NFM malaria funding ranges for malaria-eliminating countries 
in the Americas, for the period of 2014-2017 using adjustments and additional funding 
 
 
 
Figure 8.5. Estimated Global Fund NFM malaria funding ranges for malaria-eliminating countries 
in the South-East Asia and Western Pacific, for the period of 2014-2017 using adjustments and 
additional funding 
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Figure 8.6. Estimated Global Fund NFM malaria funding ranges for malaria-eliminating countries 
in Sub-Saharan Africa for the period of 2014-2017, using adjustments and additional funding  
 
 
 
8.4.5 NFM minimum and maximum funding amounts compared to the old funding model 
The range of percent differences between the estimated minimum and maximum average annual 
allocations for 2014–2017 determined in Figs. 8.3, 8.4, 8.5, 8.6 are compared to average annual 
disbursements under the old funding model and are shown in Fig. 8.7. Percentages on the left side 
of a country’s range indicate the percent change between a country’s minimum funding amount 
compared to their funding under the old funding model. Similarly, percentages to the right side of 
the range indicate the change between a country’s maximum funding amounts compared to 
funding under the old funding model. In the best-case scenario (receiving maximum funding from 
the GFATM for malaria), 46 % of the countries included in this analysis will still see decreases in 
funding (Cape Verde, Philippines, Solomon Islands, Sri Lanka, Tajikistan, Thailand, Uzbekistan, and 
Vanuatu). For countries like Bhutan, Namibia, Nicaragua, Sao Tome and Principe, Swaziland and 
Vietnam, the extra adjustments, if made, could mean a considerable increase in support for their 
elimination efforts. Azerbaijan, Dominican Republic, Iran, and Kyrgyzstan are no longer eligible for 
funding due to either their low malaria burden or income level. 
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Figure 8.7. Percent changes between the average annual disbursements under old funding model to average annual NFM 
minimum and maximum funding amounts 
 
 
Min and max funding 
(2014-2017) range 
percent changes 
compared to OFM
-100 
to -91
-90 to 
-81
-80 to 
-71
-70 to 
-61
-60 to 
-51
-50 to 
-41
-40 to 
-31
-30 to- 
-21
-20 to 
-11
-10 to 
-1 0%
1 to 
10
11 to 
20
21 to 
30
31 to 
40
41 to 
50
51 to 
60
61 to 
70
71 to 
80
81 to 
90
91 to 
100
No 
previous 
funding
Azerbai jan -100%
Iran* -100%
Kyrgyzstan -87%
Tajikis tan -91% -85%
Uzbekis tan -55% -24%
Bel ize +
Costa  Rica  +
Dominican Republ ic -94%
El  Sa lvador +
Nicaragua -6% 54%
Panama +
Paraguay +
Bhutan -19% 18%
Korea, Dem. Rep. -39% 2%
Phi l ippines -52% -29%
Solomon Is lands  -48% -13%
Sri  Lanka -55% -34%
Thai land -33% -10%
Vanuatu -61% -42%
Vietnam 34% 73%
Botswana +
Cape Verde -62% -44%
Namibia -12% 47%
Sao Tome and Principe 13% 61%
South Africa +
Swazi land -32% 14%
*Although Iran is marked as -100%, they still have funding from  grants under the OFM that were not rolled in to grants under the NFM since they are no longer eligibile. 
Eastern Mediterranean and Europe
The Americas
South-East Asia and Western Pacific 
Sub-saharan Africa
Chapter 8 – Global Fund Financing to the 34 Malaria-Eliminating Countries under the New 
Funding Model 2014 – 2017 
192 
 
 
 
8.5 Discussion 
  
Under the NFM, a total of USD 4.5 billion has been allocated to 75 countries deemed eligible 
for GFATM malaria support through national allocations and countries included in three 
regional grants to E8, EMMIE, and RAI [7]. The proportion of the overall GFATM malaria 
portfolio to eligible malaria-eliminating countries has decreased—from 7 % under the old 
funding model to 4.3% under the NFM, less than a quarter of which is from funding through 
the three regional grants. Despite this small and shrinking portion of GFATM funding, this 
money has been and will continue to be catalytic in accelerating toward malaria elimination 
in these countries. In contrast, roughly 20 % (USD 0.9 billion) of the GFATM malaria portfolio 
goes to just two countries (Democratic Republic of Congo and Nigeria) [7]. 30 % (USD 1.3 
billion) goes to ten countries (Burkina Faso, Cameroon, Côte d’Ivoire, Ethiopia, Ghana, 
Kenya, Mozambique, Tanzania, Sudan and Uganda) [7]. 
 
Currently, there is a projected overall decrease of 31 % in allocated national funding to 
eliminating countries from the GFATM. The change in total allocations to the eligible 
eliminating countries compared to previous disbursements under the old funding model 
varies widely by country: some countries are allocated up to 100 % more than previous 
disbursements and other countries are allocated significantly less. However, this allocation 
formula provides a preliminary guideline for the signed grant amounts, which are shaped by 
the Country coordinating mechanisms who have the opportunity to negotiate for additional 
resources based on the country’s needs and timelines. This flexibility in the NFM allows for 
countries to take full ownership of the grants once implemented on the ground. 
 
Still, uncertainties remain for countries around the grant making process and the 
adjustments that could be applied, including the domestic counterpart financing 
requirement and willingness to pay criteria. All allocations are conditional on countries 
reaching their minimum counterpart-financing requirement, based on income level. While 
78 % of financing for malaria elimination is generated at the domestic level, many of the 
low-income and LMICs depend heavily upon GFATM financing (such as Bhutan, Nicaragua, 
Philippines, the Solomon Islands, Sri Lanka, and Vietnam) [16] and any reduction in donor 
financing could hinder their efforts to eliminate malaria and prevent re-introduction. Past 
estimates calculated from World Malaria Report 2012 data for years 2005 through 2010 
indicate that roughly 20 % of eliminating countries have not historically met what would be 
a 5–60 % domestic counterpart-financing requirement [4].  
 
Along with the counterpart-financing requirement, the willingness to pay adjustment is an 
effort to increase domestic financing and promote sustainability of GFATM investments. 
While intended to support sustainability, the domestic funding contribution criteria require 
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additional facilitation from the GFATM, especially for countries transitioning to higher 
income levels. The GFATM can help countries advocate for increased domestic financing 
through a variety of channels, using tools such as the WHO’s Global Technical Strategy for 
Malaria 2016–2030 [17] and Roll Back Malaria’s Action and Investment to Defeat Malaria 
2016–2030 [18] to demonstrate the strategies and economic investment cases for funding, 
and by leveraging regional organizations such as the African Leaders Malaria Alliance [19], 
the Asia Pacific Leaders Malaria Alliance [20], and the Asia Pacific Malaria Elimination 
Network [21] to help garner the high-level political support and to implement tools needed 
to increase domestic financing. 
 
Analysis of the funding ranges suggests that projected funding amounts are quite variable. 
Countries could receive roughly 25 % more or 25 % less than their allocated amounts, as 
exemplified by the variance in Vietnam’s funding range for the period of 2014–2017. If 
Vietnam does not meet the willingness to pay requirement and their Country Coordinating 
Mechanism prioritizes HIV or TB over malaria, their GFATM’s national malaria allocation can 
decrease from about USD 15 million to just over USD 11 million (about 25 % less than the 
full national allocation amount). In this case, the minimum funding amount would equal a 
USD 11 million national allocation plus USD 15 million in regional grant funding. 
Furthermore, if Vietnam’s minimum funding amount is compared to their average funding 
under the old funding model, they are expected to see a 34 % increase in funding. If the 
Country Coordinating Mechanism prioritizes malaria funding, and the GFATM determines 
the country should receive their full incentive allocation in addition to their national 
allocation and regional grant funding, it is possible that Vietnam could receive almost USD 
34 million (about 73 %) more funding than under the old funding model. However, this is 
not the case for about half of the malaria-eliminating countries. Even if they receive their 
maximum funding amount, 46 % of eliminating countries are projected to see a decrease in 
funding from the GFATM under the NFM when compared to the old funding model. It is 
unlikely that many countries would receive the estimated maximum funding calculated by 
the post-allocation adjustments. 
 
These findings suggest an unpredictable environment for malaria programmes to operate 
in. Due to competing disease priorities, some eliminating countries may not be able to 
continue to adequately fund national malaria programmes, putting them at higher risk of 
resurgence. Historical evidence suggests that if malaria funds are interrupted, programmes 
are weakened, or interventions are disrupted before malaria has been eliminated, there is a 
danger of malaria resurgence [22]. Furthermore, this reduction in funding is not limited to 
malaria-eliminating countries; many control countries such as Ethiopia, Haiti, Côte d’Ivoire 
and Uganda are also projected to see a decline in funding [7], straining resources in these 
settings as well. To mitigate the risk of resurgence, account for progress in burden 
reduction, and address the malariogenic potential of endemic countries, the GFATM has 
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used malaria epidemiology data from the World Health Organization from 2000 to 2010 in 
the allocation methodology. 
 
With the addition of regional grants, a 31 % decrease in national funding is augmented to a 
cumulative 32 % increase in funding for malaria-eliminating countries. Regional trend 
analysis suggest the malaria-eliminating countries in the Eastern Mediterranean and Europe 
region are expected to see a 93 % decrease in GFATM national financing, mainly due to 
steep declines in malaria cases. Malaria-eliminating countries in Southeast Asia and Western 
Pacific are expected to experience an overall 32 % decline in aggregated national funding, as 
countries such as the Philippines, the Solomon Islands, Sri Lanka, and Vanuatu all are 
expected to experience decreases in funding ranging from 30 to 50%. 
 
However, with the addition of the RAI regional grant, the eliminating countries in the region 
are expected to see a 28 % increase in funding, mainly through RAI support to Thailand and 
Vietnam. The RAI grant is a particularly strategic investment and is expected to have a 
positive impact for elimination in the region, providing additional support to higher burden 
Mekong countries. This is especially critical given the serious threat of anti-malarial drug 
resistant malaria. Despite the Dominican Republic’s recent ineligibility for malaria funding, 
eliminating countries in the Americas are expected to see an overall 171 % increase with the 
additional funding through EMMIE, particularly to countries that would otherwise be 
ineligible for national malaria funding. The malaria-eliminating countries in sub-Saharan 
Africa are expected to see an overall 179 % increase in funding due to the addition of the E8 
grant funds and because Botswana, although previously eligible, did not receive funding 
under the old funding model but did receive a malaria allocation of roughly USD 1.3 million 
under the NFM. The E8 regional grant, which will support eight countries in the southern 
Africa region, also includes South Africa, who is otherwise ineligible for national malaria 
funding. 
 
Despite providing much needed additional funding for elimination, funds granted through 
regional channels will likely not fill all the gaps from reduced national level allocations as 
they usually will not cover country specific activities or necessary commodity procurement. 
Regional grants can, however, leverage country-level efforts by providing complementary 
investments to sup- port cross-border initiatives and collaboration that would not otherwise 
be included in country grants. Another benefit is that the regional approach is two-pronged; 
it supports both high- and low- transmission countries by creating a platform for data and 
information sharing and provides an opportunity for enhanced collaboration between 
countries. 
 
 
Chapter 8 – Global Fund Financing to the 34 Malaria-Eliminating Countries under the New 
Funding Model 2014 – 2017 
195 
 
 
Because the eliminating countries are a critical part of a global movement toward 
eradication and maintaining essential national level funding is crucial, a mix of regional and 
country investments by the GFATM can leverage the gains already made toward eradicating 
malaria. Country grants support core malaria interventions, while regional grants support 
collaborative surveillance platforms and demonstrate strong value for money by driving 
economies of scale among low burden countries. The regional grants can also hold regions 
accountable for reaching goals for elimination and eventual global eradication by jointly 
monitoring national and regional activities that are mutually reinforcing. Funding from the 
GFATM has been essential to many of the eliminating countries, and maintaining this level 
of funding, through a mix of national and regional funding streams, will be needed in order 
protect investments and sustain progress toward a malaria-free world. 
 
8.6 Limitations 
 
The adjustments made to the national allocation introduce important limitations in this 
analysis, which affect the quantification of the funding ranges for each country. These 
ranges were quantified based on the information provided by the GFATM; however, other 
factors are evaluated on a case-by-case basis and how decisions affect funding is ultimately 
determined by the GFATM and the Country coordinating mechanism. Thus, these funding 
ranges should be taken as estimations to provide guidance on potential funding ranges from 
the GFATM. 
 
Another major limitation is the analysis is that due to a significant time lag between 
programme implementation and impact on malaria epidemiology, the analysis cannot fully 
assess the financial impact on in-country malaria burden. 
 
There are likely other benefits of the NFM on malaria eliminating countries that are outside 
the scope of this analysis. GFATM funding for health system strengthening, separate from 
the three disease streams, would likely improve overall outcomes across the board. 
 
8.7 Conclusion 
 
Funding from the GFATM has been critical for many countries to accelerate progress toward 
malaria elimination. As the GFATM prioritizes higher burden, lower income countries, 
national funding streams to many eliminating countries are projected to be at risk. A 
decrease in national funding could reverse all the hard earned gains and returns on the 
GFATM’s investment to-date. For some of these eliminating countries, regional grants for 
malaria have augmented funding for elimination activities and helped encouraged regional 
collaboration but they are unable to fill all the gaps in funding created through reductions in  
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national funding. Without strong national malaria programmes, regional grants may be less 
effective in achieving regional goals. By creating a more nuanced allocation formula or a mix 
of other mechanisms to invest in malaria eliminating countries, the GFATM has an 
opportunity to ensure their previous investments in malaria are not lost. As the global 
community sets its sights on a malaria-free world, the GFATM’s continued investments in 
both high and low burden countries will signal alignment with countries and regions that are 
paving the way toward malaria elimination and eventual eradication. 
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9.1 Abstract 
 
Despite global commitments to “leave no one behind” [1], many donors, including the 
Global Fund to Fight AIDS, Tuberculosis and Malaria are now focusing their limited 
resources on countries with the highest disease burden and the least ability to pay.  As 
donors reduce their financial support to geographies that do not meet these criteria, the 
implicit expectation is that domestic resources finance critical activities previously 
supported by foreign aid. This managed “transition” from donor aid to domestic-supported 
health programmes is novel and fraught with challenges. In this policy piece, we outline key 
challenges faced by countries undergoing this transition, explore gaps that exist in current 
evidence, and highlight policy recommendations for donors and national malaria 
programmes to facilitate a more successful transition process. 
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9.2 Background 
 
Since its inception in 2002, the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global 
Fund) has been the world’s largest financier of malaria programmes, providing in excess of 
USD 9.1 billion to more than 100 countries between 2002 and 2016. This investment 
contributed to declines in global malaria incidence and deaths of 20 and 26%, respectively, 
between 2010 and 2016 [2]. However, since 2010, donor aid for malaria globally has 
plateaued and declined by more than 60% for the 35 countries actively pursuing malaria 
elimination [3, 4]. This trend is projected to continue due to changes in donor investment 
strategies, which increasingly prioritize support to the highest-burden countries with the 
least ability to pay. Historically, the Global Fund has dispersed approximately 7% of its total 
portfolio to eligible malaria-eliminating countries. However, under a formula-based 
allocation model adopted by the Global Fund Board in 2012, malaria resources for this sub- 
set of eliminating countries declined to less than 5% and are projected to decline further 
under the revised 2017-2022 strategy [5, 6]. 
 
These policy changes have major implications for the delivery of health services, particularly 
in countries that are nearing malaria elimination, many of which relied on considerable 
financial support from the Global Fund to reduce their disease burden in the past decade. 
Malaria-eliminating countries typically have a lower disease burden, are often categorized 
as middle-income, and under the new allocation model are no longer eligible for Global 
Fund financing.  At the same time, the Sustainable Development Goals include a target of 
ending malaria, and the World Health Organization (WHO) Global Technical Strategy for 
Malaria 2016–2030 [7] calls for malaria to be eliminated from at least 35 countries by 2030. 
The newly ineligible countries must therefore find new ways to continue financing their 
malaria elimination plans in order to meet these global expectations. Eliminating countries 
are already funding the majority of malaria activities domestically, relying on donor 
financing primarily for the delivery of high-impact interventions to high-risk populations 
living in border areas and the management of health programmes and systems [8]. As these 
countries no longer meet donor eligibility requirements, these critical aspects of their 
national malaria programmes may be at risk, unless the transition is carefully managed so 
that domestic funding can be secured to fill the emerging gap [9].  
 
This issue is pervasive. Many malaria-eliminating countries are approaching one or more 
donor eligibility thresholds. Since 2011, seven countries (Brazil, China, Colombia, Dominican 
Republic, Ecuador, Equatorial Guinea and Iran) have graduated from Global Fund malaria 
financing and now implement their national malaria programmes independent of this 
support. Seven additional malaria-eliminating countries are in their final round of Global 
Fund Support or will reach the Global Fund’s eligibility thresholds in the next five years:  
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Bolivia, Botswana, El Salvador, Guatemala, Sri Lanka, Paraguay, and the Philippines [10]. In 
spite of these anticipated transitions, and the emphasis in the 2017-2022 Global Fund 
strategy on the critical importance of sustainability, there is currently no planning process in 
place for transition or consensus on the best model for an effective strategy to withdraw aid 
for malaria. 
 
Without adequate time and careful advance planning to replace donor aid with domestic 
resources, gains in malaria elimination made with decades of investment from the Global 
Fund and others are in jeopardy. Abrupt withdrawal of donor funding may lead to 
disruptions in a country’s delivery of critical malaria interventions, confer negative cross-
border externalities to neighboring nations, and increase the risk of deadly and costly 
malaria resurgences [11, 12]. The resulting potential excesses in mortality and morbidity 
may undermine progress towards national elimination goals, compromising regional 
elimination targets, and ultimately preventing global eradication. Such risks may be 
compounded if countries face multiple funding cliffs from donors that are phasing out 
simultaneously from various disease-specific programmes.  
 
In this commentary, we outline the key challenges faced by countries undergoing transitions 
from donor funding to fully domestically financed programmes, and offer policy 
recommendations to support eliminating countries’ continued progress towards a malaria-
free future. 
 
9.3 Challenges 
 
Countries need sufficient and advance notice from donors to ensure that the transfer of 
responsibilities for programmes to deliver critical health care services happens in a planned 
and sustainable fashion. Experiences with HIV programme transitions demonstrate that a 
process lasting at least five years is necessary. For example, the Avahan HIV/AIDS 
programme, which was transitioned from the Bill and Melinda Gates Foundation to the 
Government of India over a period of nearly eight years, is hailed as a successful transition 
[14, 15]. Both GAVI and the Global Fund have been credited with providing public 
information about the transition timeframe and procedures. The Global Fund’s Eligibility 
Policy [16] allows for up to one allocation of three years of transition funding following a 
change in eligibility. However, as described in the following challenges, transitions often can 
have a deep impact on the health system, programme management, and the delivery of 
health care, that go far beyond financing.  
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9.3.1 Challenges in management capacity  
Donor transitions are not just about money. The most salient and yet often neglected issue 
for many national malaria programmes is management. Many programmes rely heavily on 
donors not only for funding of health delivery, but also for support of the technical and 
programmatic leadership. Key staff positions are often supported by the Global Fund 
especially in countries where restrictive human resource processes can prevent malaria 
programmes from hiring technical experts or deploying field staff during an outbreak. In 
addition, salaries for staff implementing a donor programme may differ substantially from a 
fully government-funded employee, which may cause problems retaining talent. Without 
greater attention to developing transition strategies for the donor-supported management 
and stewardship functions, including retaining essential human capital, programmes risk 
losing essential technical and management capacity for implementation.  
 
9.3.2 Lack of financial planning data  
Many malaria programmes operate without financial data needed to effectively budget, 
mobilize, and allocate resources because they have been supported by external funds for so 
long. Few programmes have strong financial management systems in place to track the 
sources of funds and expenditures, and many lack the capacity to establish accurate 
estimates of short- and long-term financing needs.  Without an understanding of the actual 
cost of the programme or financing available, it is challenging for programmes to anticipate, 
quantify, and mitigate financial gaps that will occur during a transition.  
 
9.3.3 Diminishing political will  
Even though donor financing for malaria represents only a small share of a country’s total 
health expenditure – less than 2 % in countries outside of Africa, such as Indonesia, 
Philippines and Sri Lanka in 2014 [17] – these grants lead to valuable political support and 
visibility for malaria programmes. For example, Sri Lanka’s robust national malaria 
programme, bolstered by additional financing from the Global Fund, cultivated high-level 
political support during the malaria elimination and malaria-free certification phase. The 
programme, a heralded success in the region, is now undergoing a transition from Global 
Fund support as it no longer meets eligibility requirements. However, it is critical that the 
programme continue to prevent reintroduction of malaria even as national political 
priorities shift towards other threats, such as Dengue fever. Maintaining the high-level 
ministerial support to maintain successful programmes without the political pressure 
exerted by providers of foreign aid will require significant advocacy efforts by national 
malaria programmes and others.  
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9.3.4 Concurrent epidemiological changes and changing priorities after elimination 
Many malaria-endemic countries are undergoing an epidemiological transition at the same 
time as they experience a donor financing transition, adding complexity to their strategic 
planning and prioritization of efforts. There is little available technical guidance on the 
minimum level of interventions needed to prevent reintroduction once elimination is on the 
horizon or has been achieved. National malaria programmes must juggle a delicate balance 
of scaling back interventions without risking the reversal of previous progress. This shift 
from control to elimination requires countries to adopt increasingly sophisticated and 
targeted strategies; using analysis of high quality sub-national data to deploy focused 
interventions to the remaining clusters of malaria transmission. However, sub-national data 
and surveillance systems are often poor, and the mechanisms needed to identify and treat 
every case are often human resource intensive and costly. Given the historical reliance on 
donor funds for system strengthening efforts, transitions may limit resources available for 
these pending infrastructure needs. This becomes even more difficult in the context of a 
financial transition that constrains available budgets and intensifies pressure to find 
efficiencies.  
 
9.3.5 Parallel donor and government systems  
In many countries, donors and national programmes operate parallel systems for 
information, supply chain, and service delivery and in some cases malaria programmes rely 
on the donor-operated systems alone. As funding transitions, so too must the integration 
and ownership of these systems and the historical data they possess to avoid gaps in 
essential services when donors are no longer playing a key role in malaria programmes. The 
practical matter of ensuring that these systems, including the data, hardware, software, and 
trained operators can be maintained by the government, is a critical aspect of the transition 
process. This effort will take time and financial resources to do effectively, which may not be 
top of mind in transition planning that is focused primarily on funding. 
 
9.3.6 Integration of vertical programmes 
As countries move towards elimination there is often a need to integrate the malaria 
programmes into other public health and vector control programmes. In addition to being 
led and delivered by different individuals, in many countries, vertically managed disease 
programmes operate separate surveillance, information, and vector control systems. While 
integration may offer opportunities for greater efficiency, the loss of specialized knowledge 
and experience and the challenges of integrating disparate information systems can be 
costly. Staff integration may mean that the malaria elimination programme is left to rely on 
health care workers without specialized training to deliver complicated interventions. Data 
system integration often takes significant time and resources and may mean that some data 
is lost or granularity of information sacrificed. Integration of human resources and data  
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systems needs to be approached carefully due to the potential risk of further reduced 
attention on malaria and the corresponding risk of outbreaks. 
 
9.3.7 Procurement pricing and quality commodities 
When no longer eligible for Global Fund support, countries lose access to the Fund’s 
volume-based commodity pricing benefits. The use of wambo.org, an online platform for 
countries to procure health products through a pooled procurement mechanism, is 
currently only available to Global Fund recipients. The Global Fund’s policies require 
countries to procure quality-assured products, but when medicines and commodities are no 
longer procured using donor systems and domestic resources are limited, there is an 
incentive to procure less expensive and potentially lower quality products. In addition, 
without access to a pooled procurement mechanism, countries that require smaller 
quantities of key commodities often must spend much more on the same volume of 
products. The overall cost for their programme will increase and they may face challenges in 
maintaining adequate stocks or prepositioning commodities for future outbreak responses. 
 
9.3.8 Strategic programme delivery and management 
In many contexts, health programmes financed by donors are delivered through contracts 
with non-governmental organizations (NGOs). This arrangement is often made to reach 
marginalized populations that do not have access to government-run public facilities or 
because donors are unwilling to directly finance government health systems. When they 
lose eligibility for donor support, countries may face legal impediments to contracting with 
the same NGOs, find that managing delivery partners’ activities is too difficult, or learn that 
private service providers are too expensive. These potential changes in the structure of the 
system may cause interruptions in the delivery of health services to high-risk populations 
without access to public facilities. 
 
9.4 Policy recommendations 
 
Despite challenges inherent in the withdrawal of donor support, transitions create an 
opportunity for countries to assess the strength of their governance, financing, and service 
delivery systems. By providing adequate time and resources to ensure a successful and 
sustainable transition, donors can protect their investments in the health systems and 
safeguard the gains made in morbidity and mortality. Countries must conduct a review of 
their programmes and develop a robust transition plan that allows for sustainability of core 
functions that they share and coordinate with donors. Through the transition planning 
process, national malaria programmes enumerate the need for and request additional 
financing to be used to strengthen and integrate affected systems. It is the goal of these 
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policy recommendations to offer suggestions to maintain the progress made toward the 
elimination and prevention of the reintroduction of malaria.  
 
9.4.1 Country-level actions 
The transition plan starts with a readiness assessment to identify areas of strength and 
weakness of the malaria programme. These findings are used to build a transition plan that 
addresses priority financing, management, and programme delivery gaps [18]. Countries 
need to determine their “true need” by developing or strengthening surveillance and 
financial tracking systems, as well as strategic planning capacity within the government. 
They must understand the changing epidemiological patterns, the impact of changes to the 
delivery system, and the effect of increased pricing levels in order to enumerate the 
resource needs. To address the financing gaps left by the withdrawal of foreign aid, national 
malaria programmes can then effectively implement efficiency measures, or advocate for an 
increased budget from domestic sources. 
 
To strengthen management capacity, national malaria programmes can seek and leverage 
transitional financing grants to build staff expertise and skills, strengthen and integrate 
surveillance, reporting, human resources and information systems that are essential to 
inform decision-making, and assess the overall reach and strength of the delivery system. 
Country preparations for transition should include plans and resources to mitigate turnover 
of staff in key technical and leadership positions, particularly in cases where the grant is 
being managed outside of the national government. It may be important to develop or 
review the facilities in which malaria related health care is delivered by NGOs or private 
providers to identify where direct relationships with the government may need to be built. 
And finally, a review of short- and long-term health workforce needs can also strengthen 
planning and advocacy, especially in countries where recruitment and staffing policies are 
restrictive.  
 
Furthermore, the malaria programme’s strategy may need to evolve during transition to 
address new epidemiological challenges. To improve efficiencies and integrate essential 
donor-supported staff and systems, health ministries may need to consider opportunities to 
integrate and align the malaria programme’s surveillance, reporting, and information 
systems with those from other disease programmes. The malaria programme may consider 
sharing personnel with other disease efforts, but with an eye toward a limit of 
compromising staff technical capacity, overburdening the health worker, or losing the focus 
on finding every malaria case. Regional malaria elimination initiatives, if available, could also 
offer national malaria programmes pooled procurement options to guarantee competitive 
pricing of quality commodities.  
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9.4.2 Donor-level actions 
Donors can provide guidance and support to national malaria programmes to conduct 
transition assessments and institute country-led transition plans, particularly by helping to 
engage to key stakeholder groups. Inclusion of relevant national (e.g., ministry of finance) 
and sub-national (e.g., regional malaria programme staff) partners in the process is 
important to facilitate broad support for and effective implementation of the transition 
plan. In addition, the donors and the country need to work closely with technical partners, 
(e.g., WHO) to ensure there is technical support for planned interventions during the 
expected epidemiological changes as malaria cases decline. 
 
Most importantly, donors should be responsive to the needs described in the transition 
plans developed by countries. To support countries in preparing for transition, donors will 
likely need to increase their investments and shift existing investments from supporting 
commodity procurement and service delivery to long-term investments in capacity building, 
system development (e.g. surveillance, information management, financial management), 
and human resources. Donors may also consider sustaining investments to NGOs or private 
sector partners already engaged in delivering health services, or working with governments 
to develop direct relationships with these organizations to ensure that high-risk populations 
are consistently able to access malaria services. Finally, additional donor investments may 
be required for regional and cross-border initiatives that target high-risk vulnerable 
populations (e.g., migrants) or malaria transmission hotspots that would otherwise not be 
prioritized by national governments.  
 
As the risks of transition can be compounded with multiple donors (or diseases) phasing out 
simultaneously, coordination amongst donors and country programmes is vital to avoid 
unforeseen, concurrent funding cliffs. Donors can play an important role in convening 
stakeholders to develop shared action plans at the regional and global levels and advocating 
to create pressure to maintain political support and allocate domestic resources to 
programmes that are facing transition. 
 
9.5 Conclusion 
 
As donors, including the Global Fund, increasingly focus their investments on high-burden 
countries with the least ability to pay, low-burden and middle-income countries face steep 
challenges as they navigate the transition from donor to domestic financing. This is a 
particularly acute problem for efforts to eliminate malaria, as many of the countries that 
have become ineligible or are rapidly approaching ineligibility are those that are actively 
pursuing malaria elimination. An abrupt or mismanaged donor transition affects more than  
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just funding. Countries may face programmatic challenges related to gaps in management 
or technical capacity, misaligned information systems, uncompetitive procurement, and 
inflexible human resource systems. In the face of these challenges, countries must develop 
clear transition plans based on evidence of the needs and potential gaps their programmes 
will face as donor aid is reduced or terminated. 
 
While it is important to prioritize the use of limited resources as the disease burden 
decreases and financial means grow in middle-income countries, the Global Fund and other 
donors must be cautious and careful during transitions. There are significant risks with an 
untimely withdrawal, most critically losing hard fought progress toward the elimination of 
malaria. Transition planning should catalyze national malaria programmes to assess gaps 
and opportunities for strengthened governance, financing, and service delivery and build a 
clear transition plan based on this information on which they work closely with donors and 
other stakeholders. While the success of a donor transition largely depends on the capacity 
of a country to assume autonomous responsibility for its programmes, donors do bear 
responsibility to ensure that countries are well prepared and equipped to manage the 
process. Anything less will undermine decades of investment and unprecedented gains 
towards achieving a global public good - a world free of malaria. 
 
9.6 Acknowledgements 
 
The authors would like to thank Geoff Clark for his thoughtful comments on an earlier draft. 
 
  
Chapter 9 – Transitioning from Global Fund Financing: Challenges and Implications for 
Malaria Elimination 
208 
 
 
 
9.7 References 
 
1. United Nations General Assembly. 2015. Resolution adopted by the General 
Assembly on 25 September 2015, A/Res/70/1. Transforming our world: the 2030 
Agenda for Sustainable Development, 2015. 
2. WHO. Global Malaria Programme. 2016. World Malaria Report 2016. Geneva: 
World Health Organization. 
3. Shretta R, Zelman B, Birger M, Haakenstad A, Singh L, Liu Y, Dieleman. 2017. Tracking 
Development Assistance and Government Health Expenditures for 35 malaria- 
eliminating Countries: 1990-2017. Malaria Journal 16:251. 
4. Kumar K, Pigazzini A, Stenson B. 2014. Financing malaria elimination. Cambridge 
Economic Policy Associates.  
5. Zelman B, Melgar M, Larson E, Phillips A, Shretta R. 2016. Global fund financing to 
the 34 malaria-eliminating countries under the new funding model 2014–2017: an 
analysis of national allocations and regional grants. Malaria Journal 15(1):118.  
6. Global Fund. 2017. Global fund country allocations: 2017–2019. The Global Fund to 
Fight AIDS, Tuberculosis and Malaria. Accessed Nov 2017.  
7. World Health Organization. Global Technical Strategy for Malaria 2016-2030. 
Geneva: 2015. 
8. Schäferhoff M, Fewer S, Kraus J, et al. 2015. How much donor financing for health is 
channelled to global versus country-specific aid functions? Lancet; 386(10011): 
2436-41. 
9. Kavanagh M. M. 2014. The Politics and Epidemiology of Transition. JAIDS Journal of 
Acquired Immune Deficiency Syndromes 65(3):247-250. 
10. Global Fund. 2016. Projected Transitions from Global Fund support by 2025 – 
projections by component. The Global Fund to Fight AIDS, Tuberculosis and Malaria. 
https://www.theglobalfund.org/media/5641/core_projectedtransitions2016_list_en.
pdf. 
11. Cohen J, Smith D, Cotter C, Ward A, Yamey G, Sabot O & Moonen B. 2012. Malaria 
 resurgence: a systematic review and assessment of its causes. Malaria Journal 
11:122.  
12. Liu JX, Newby G, Brackery A, Smith Gueye C, Candari CJ, et al. 2013. Determinants 
of Malaria Programme Expenditures during Elimination: Case Study Evidence from 
Select Provinces in the Philippines. PLoS One 8(9):e73352.  
13. Piot P, Abdool Karim SS, Hecht R, et al. 2015. A UNAIDS–Lancet Commission on 
Defeating AIDS—Advancing Global Health. Lancet 386(9989):171-218. 
14. Bennett S, Rodriguez D, Ozawa S, et al. 2015. Management practices to support 
donor transition: lessons from Avahan, the India AIDS Initiative. BMC health services 
research 15(1):232. 
Chapter 9 – Transitioning from Global Fund Financing: Challenges and Implications for 
Malaria Elimination 
209 
 
 
15. Bennett S, Singh S, Rodriguez D, et al. 2015. Transitioning a Large Scale HIV/AIDS 
Prevention Programme to Local Stakeholders: Findings from the Avahan Transition 
Evaluation. PLoS One 10(9):e0136177. 
16. Global Fund. 2016. The Global Fund Eligibility Policy. 35th Board Meeting. GF/B35/06 
– Revision 1 Board Decision. The Global Fund to Fight AIDS, Tuberculosis and 
Malaria. https://www.theglobalfund.org/media/4227/bm35_06-
eligibility_policy_en.pdf. 
17. World Bank. 2017. External resources for health (% of total expenditure on health).  
https://data.worldbank.org/indicator/SH.XPD.EXTR.ZS. 
 
 
Chapter 10 – Discussions and Conclusions 
210 
 
 
 
CHAPTER 10 
 
Discussion and Conclusions 
 
10.1 General Discussion 
10.2 Limitations of the methodologies used 
10.3 General recommendations 
10.4 Areas for future research 
10.5 Conclusion 
10.6 References 
 
10.1 General discussion 
 
Despite international consensus that malaria elimination leading to global eradication is a 
worthwhile goal [1], sustaining domestic and international funding as the malaria burden 
declines is a serious concern for many countries. The World Health Organization’s (WHO) 
Global Technical Strategy (GTS) estimated that an annual investment of USD 6.4 billion 
would be needed to achieve the 2020 target of a 40 % reduction in malaria-related mortality 
and morbidity by 2020. Total funding for malaria control and elimination was estimated at 
USD 2.9 billion in 2015 [2], leaving a significant gap of about 54 %. 
 
Lessons learned from the Global Malaria Eradication Programme (GMEP) affirm that while 
well-funded interventions can have a major impact on the disease, such gains are fragile and 
can easily be reversed. This is affirmed by a review of malaria resurgence which 
demonstrated that almost all historical resurgence events could be attributed, at least in 
part, to the weakening of malaria control programmes resulting from resource constraints 
[3]. At the same time the detection and spread of drug and insecticide resistance [4-7], 
particularly in Asia, has the potential to undermine past gains and compromise future 
effectiveness. There is general consensus that the only way to curb the spread of drug 
resistant malaria is to eliminate the parasite altogether [8]. However, accelerating and 
sustaining malaria elimination goals will require focused implementation of effective and 
high-impact strategies supported by unrelenting financial and political commitment at the 
global and domestic levels. Thus in turn will need to be backed by robust evidence on the 
health, social and economic benefits of malaria elimination. 
 
Although the economic impact of malaria has been studied for well over a century, recent 
evidence on the financing and economics of malaria elimination remains disparate. There is 
little published information about the how much malaria elimination will cost in the short, 
medium and long-term; whether the cost savings of elimination will offset the initial 
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investment that elimination requires; what the economic returns of elimination are, versus 
maintaining the status quo; the sources of financing and how these funds are spent; and the 
impact of changing donor policies on elimination efforts. 
 
This body of work provides strong evidence on the costs and benefits of malaria elimination. 
It demonstrates that while malaria elimination will cost more in the short term, these costs 
taper off as more countries eliminate and move to more efficient Prevention of 
Reintroduction (POR) strategies. In addition, it analyzes the trends in financing and the 
future availability of funding for malaria elimination and the potential implications of 
changing donor policies on malaria elimination programs. The findings are highly relevant 
and topical to inform policies and strategies to support the continued investment in malaria 
elimination. 
 
One of the strongest arguments against eliminating or eradicating any disease involves the 
costs associated with finding and treating the decreasing numbers of cases [9], which will 
likely require an outlay of resources that appear to be disproportional to the marginal 
return. Maintaining a high level of financial support when transmission has been reduced to 
low levels therefore remains a challenge. Articulating the country-specific costs of 
elimination and the relative benefits of investment in elimination versus maintaining the 
status quo will help the advocacy argument to influence these decisions. 
 
Although past analyses can provide some guidance on the costs of malaria control and 
elimination, most have used varying methodologies, cost inputs, intervention mixes and 
discount rates. Earlier studies did not incorporate post-elimination costs of surveillance and 
other interventions to prevent re-introduction of the disease and most used a public sector 
perspective for economic analysis, which only represents part of the equation [10]. Costs 
also differ by the region and smaller countries may have higher costs due to diseconomies 
of scale. Historical costs should therefore be used with caution to inform contemporary 
decisions.  
 
Nevertheless, past studies provide some evidence that the immediate costs for elimination 
will initially be equal to, or higher than those of a control programme, due to initial 
investments in programme re-orientation to strengthen surveillance systems. Costs 
however, tend to decrease as the focus progresses to the POR phase [11-13] due to 
streamlining of surveillance activities, reductions in commodity expenditures and in some 
cases, integration of supporting health system activities [14]. This study estimated the total 
economic cost of the malaria program in Sri Lanka to be USD 0.57 per capita per year with a 
financial cost of USD 0.37 per capita. In the early 1980s, the cost of the control programme 
was estimated at USD 1.7 per capita, supporting the assumption that costs for POR are likely 
to decline in the medium term.  
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Using the outputs of a transmission model, our findings demonstrate that the cost of 
elimination of both Plasmodium falciparum and Plasmodium vivax malaria in all 22 
countries in the Asia Pacific region would be about USD 1.5 billion, peaking to USD 4.29 
billion annually in 2020. The costs drastically decrease to less than USD 1 billion in 2027 and 
less than USD 450 million in 2030 when elimination is expected to be achieved in all 22 
countries. While these immediate costs may appear to be high, the benefits, many 
immeasurable, vastly outweigh the epidemiological and economic costs of inaction. This 
study estimated that in the Asia Pacific, malaria elimination will avert over 123 million cases 
and approximately 3.5 million deaths in the region over 14 years, saving almost USD 90 
billion in economic benefits as measured by savings in health facility costs and human 
productivity. In a “reverse” scenario, where malaria elimination interventions are halted and 
reduced there will be an excess of 3.5 million additional deaths and 1 billion additional cases 
equating to an excess economic cost of about USD 7 billion between 2017-2030. The return 
on investment (ROI) for each additional dollar invested in malaria elimination in the Asia 
Pacific region was calculated to be 6:1. 
 
Similarly in Sri Lanka, the financial cost required to maintain the current level of malaria 
activities in Sri Lanka in 2015 was estimated to be on average about USD 7,673,961 million 
annually. Domestic financing covered approximately 53% at USD 4,054,878. However, 
keeping the country free of malaria of malaria produced economic benefits of 169 million or 
an investment return of 13 times the cost of maintaining existing activities or 21 times 
based on financial costs alone. This by far exceeds the threshold on returns that are 
considered to be high- impact investments such as those from immunization programs and 
cardio-vascular disease research [15].  
 
Nevertheless there is likely to be significant funding gap in Sri Lanka unless the government 
markedly increases the levels of funding available for malaria or alternative sources of 
financing are identified. The financial cost required to maintain the current level of malaria 
activities in Sri Lanka in 2015 was estimated to be an average of about USD 7,673,961 
million annually. Government financing covered approximately 53% at USD 4,054,878. 
 
Most studies monetize the value of the expected benefits from malaria elimination by 
quantifying the increased labour productivity due to reductions in premature mortality, 
morbidity and absenteeism as well as the direct savings accrued to the health system 
through reductions in malaria related outpatient and inpatient expenditures. However, 
many of the economic benefits associated with malaria interventions extend to other areas 
within and beyond health to include larger macroeconomic and demographic effects not 
included in our analysis. For example, past studies have been shown the benefits to include 
reduced private out-of-pocket expenditures on prevention and treatment [16,17], increased 
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agricultural output via reclaimed land [18-20]. Lower child mortality may reduce fertility 
[21], increase literacy and human capital [22] and eventually increase labour productivity. 
Domestic and foreign investment may be channeled to formerly malarious areas, also 
contributing to fiscal growth.  
 
Elimination can also improve health equity because the last remaining foci of infection are 
often concentrated within poor or marginalized populations [22]. POR also protects against 
resurgences. Furthermore, eliminating malaria within a single country may confer 
substantial regional externalities and global public good, fostering collaboration. Elimination 
may also confer threshold benefits by permanently reducing the receptivity of an area to 
the reestablishment of local transmission [7, 14, 23], but methods to measure the value of 
the diminished resurgence risk have yet to be established. Lastly, the benefits of achieving 
and maintaining elimination include a strong public good component—an incremental 
contribution to global malaria eradication. As benefits become less tangible, they are more 
difficult to measure. However gaining an understanding of this larger set of economic 
benefits will require better macroeconomic models that quantify the links between 
elimination and other outcomes to give more realistic benefit estimations  [19]. Moreover, 
the underlying assumptions in a cost-benefit analysis (CBA) comparing the net benefits of 
elimination with those of control are that both programmes are operating at their maximum 
potential. Ideally CBAs and the associated investment cases should begin with cost-
minimization analysis to establish the optimum package of interventions with which to 
achieve control and elimination. Nevertheless, the overall favourable Benefit Cost Ratio 
(BCR) in both studies discussed here supports the case for continued investment in malaria 
elimination within individual countries and globally. 
 
Despite these demonstrated returns from malaria elimination, countries who have 
successfully lowered their malaria burden are faced with the risk of losing or severely 
reducing their recurrent expenditure for elimination and preventing the re-introduction of 
malaria at a critical period in the malaria elimination efforts. Donor funding is on the decline 
in favour of programmes with seemingly greater potential impact on mortality and morbidly 
[24-26]. Although middle-income countries will eventually be able to fund their 
programmes, domestically; they are faced with competing priorities for the current limited 
government resources from other pressing disease priorities.  At the same time, malaria-
eliminating countries are also faced with the risk of resurgence due to the persistent 
importation of new cases placing an additional health and economic burden on the health 
system. 
 
In the 35 malaria-eliminating countries, total financing for malaria grew from USD 179.5 
million to USD 301.7 million between 2000 and 2013 of which DAH accounted for 19% in 
2013. Development Assistance for Health (DAH) began to decline in 2011, coinciding with 
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the Global Fund’s decision to halt its 11th grant cycle [27]. During this period, DAH declined 
by 65% in these countries and is projected to further decline. While government health 
expenditure has almost doubled in the eliminating countries between 2000 and 2010, this 
increase has not been proportional to the rate of diminishing external financing leading to a 
potential gap in service delivery needed to attain elimination, particularly in middle-income 
countries. 
 
The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) is the largest external 
financier for malaria providing 96% of the total external funding for malaria in 2013. The 
new allocation methodology adopted by the Global Fund in 2012, uses a combination of 
disease burden and Gross National Income (GNI) per capita to determine the financing that 
countries will receive for the three diseases [25]. In 2014, a total of USD 4.5 billion was 
allocated to 75 countries deemed eligible for GFATM malaria support through national 
allocations and to the countries included in three regional grants to Elimination Eight (E8) in 
Southern Africa, the Malaria Elimination Program in Mesoamerica and the Island of 
Hispaniola (EMMIE) and the Regional Artemisinin Initiative (RAI) [28,29]. The proportion of 
the overall Global Fund malaria portfolio to eligible malaria-eliminating countries has 
decreased—from 7 % under the old funding model to 4.3 % under the New Funding Model 
(NFM), less than a quarter of which is from funding through the three regional grants [30]. 
Malaria-eliminating countries in South- East Asia and Western Pacific are expected to 
experience an overall 32 % decline in aggregated national funding, as countries such as the 
Philippines, the Solomon Islands, Sri Lanka, and Vanuatu all are experienced decreases in 
funding ranging from 30 to 50 % [31]. Overall, the findings showed a cumulative 31 % 
decrease in financing for malaria elimination from the Global Fund as a result of the 
allocation model. Further declines in allocations have been noted under a subsequently 
revised strategy adopted in November 2016, potentially leaving critical gaps in essential 
program activities. 
 
Although 78 % of financing for malaria elimination is generated at the domestic level, Global 
Fund financing is catalytic in delivering of high-impact interventions to high-risk populations 
living in border areas and the management of health programmes and systems [31]. 
Reductions in financing could hinder their efforts to eliminate malaria and prevent 
reintroduction. These risks could be compounded if countries face funding cliffs with 
multiple donors phasing out simultaneously. 
 
Notwithstanding, existing financing has not been used in the most cost-effective or efficient 
manner and spending is often not uniform or consistent with epidemiological profiles or 
regional policies. Mechanisms to increase efficiency and value for money are urgently 
needed as well as further analysis on the extent to which expenditures are in line with the 
interventions recommended by the WHO. Thirty-one of 35 eliminating countries spent less 
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than 10% of their malaria DAH funding on surveillance, a key malaria elimination 
intervention between 2010 and 2013.  Morel and colleagues noted, “it is important to ask 
whether current interventions are used appropriately and what is the most cost-effective 
way to scale up activities to the levels needed” [32]. With declining DAH, available resource 
will need to be used more efficiently. This would include focusing the needs of the malaria 
programme on the most effective interventions coupled with better targeting of 
intervention delivery to strategic populations to maximize value-for-money and prevent 
drug and insecticide resistance and from available resources. 
 
Since 2011, seven countries (Brazil, China, Colombia, Dominican Republic, Ecuador, 
Equatorial Guinea and Iran) have graduated from Global Fund malaria financing and now 
implement their national malaria programs independent of this support. Seven additional 
malaria-eliminating countries are in their final round of Global Fund Support or will reach 
the Global Fund’s eligibility thresholds in the next five years: Bolivia, Botswana, El Salvador, 
Guatemala, Sri Lanka, Paraguay, and the Philippines [33]. As these countries no longer meet 
donor eligibility requirements, critical aspects of their national malaria programmes may be 
at risk, unless the transition is carefully managed so that domestic funding can be secured to 
fill the emerging gap. Furthermore, there is currently no planning process in place for 
transition or consensus on the best model for an effective strategy to withdraw aid for 
malaria. Countries are faced with challenges in management capacity; lack of financial 
planning data; diminishing political will; concurrent epidemiological changes and changing 
priorities after elimination; parallel donor and government systems; integration of vertical 
programs; procurement pricing and quality commodities and; strategic program delivery 
and management. Donors and national malaria programs will need to engage in a process 
and plan for adequate time and resources with a robust transition plan that allows for 
sustainability of core functions that they share and coordinate with donors. At the same 
time, there is a need to move donor funding for malaria control away from an input model 
that mostly focuses on the procurement and distribution of key inputs (most notably 
mosquito nets) towards more support for operational improvements, capacity building in 
programme management, improved disease and intervention surveillance as well as 
knowledge generation and sharing to strengthen the impact of elimination interventions. 
 
This discussion around the financing of malaria elimination is no different to that of other 
elimination and eradications programmes. Since the start of the Global Polio Eradication 
Initiative (GPEI), the burden has been reduced by over 99%. Finishing the job of eradicating 
polio will cost an additional USD 1.5 billion to enhance vaccination and surveillance efforts 
in hard- to-reach places and eliminate the remaining 37 cases worldwide in 2016 [34]. This 
translates into a cost of about USD 0.5 billion a year or USD 14 million per case averted. 
However, eradicating polio will have saved at least USD 40–50 billion between 1988 and 
2035. In the USA alone, eradicating polio is estimated to have saved about USD 220 billion 
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since 1955. In 2003, certain states in Nigeria briefly stopped delivering vaccines in 2003 and 
as a result, GPEI spent USD 220 million dealing with the resultant outbreak [35]. 
Withdrawing support will have devastating health, social and economic effects. In the same 
vein, high-level advocacy to policy makers and donors is needed to ensure sustained 
financing for malaria. This study provides compelling evidence on the economic benefits of 
continued prioritization of funding for malaria, which can be used to strengthen the 
advocacy argument for increased domestic and external funding.  
 
10.2 Limitations of the methodologies used 
 
The detailed limitations of each of the analyses conducted is presented in each chapter, 
however, an overarching summary is provided below. 
 
The costs of medicines and other interventions have been estimated based on available 
data and proxies were used when data were unavailable. Obtaining accurate data on the 
cost of program operations, particularly in an integrated health system, is challenging. 
Several malaria program resources are shared across other public health programs and 
peripheral level staff are often designated to perform other public health functions leading 
to difficulties in attributing specific resources to malaria alone. 
 
Furthermore, activities for malaria were paid for through a combination of government and 
external resources. Costs were estimated using self-reported hours by country-level 
partners during the interview process and apportioned to the respective malaria activities 
or intervention to arrive at disaggregated costs. While this is a common methodology used 
in other studies, the authors acknowledge the potential reporting bias in the estimates. 
 
For the regional investment case, the projected costs are highly dependent on the output of 
the transmission model, which was developed using national-level data on incidence and 
intervention coverage. These estimates are subject to error, particularly in countries with 
heterogeneous transmission patterns. Furthermore, elimination often requires targeted 
interventions to risk areas or populations, rather than ubiquitous coverage to an entire 
country. Without subnational estimates of incidence and coverage, targeted interventions 
are difficult to estimate and cost.  Assumptions were also made on the effect of drug and 
insecticide resistance on cost however, it is impossible to predict accurately the future 
extent of these phenomena. In addition, the impact and cost of known tools in the 
innovation pipeline have been modeled, however, the impact of new tools and approaches 
not yet developed is unknown and will be likely to decrease costs. 
 
This investment cases utilize reported cases from the World Malaria Reports as well as 
estimated clinical cases for the countries in the Asia Pacific region derived by the Mahidol-
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Oxford Tropical Medicine Research Unit in collaboration with a number of partners 
including the WHO [36]. This was calculated by combining and triangulating data from a 
variety of data sources and used to populate the models used in the analysis. Nevertheless, 
the wide variation in estimates of burden makes it harder to be sure of the resources 
required to eliminate the disease. 
  
Beyond the direct benefits of achieving malaria elimination on health system savings and 
worker productivity, other benefits are likely, but are harder to quantify. As a by-product of 
national elimination, other positive externalities such as increased tourism, a strengthened 
health system, and improved regional health security could result. In addition, elimination 
may bring significant benefits to other regional public goods including opportunities to 
create stronger cross-border disease coordination. The investment case therefore quantifies 
the minimum benefits of continued prioritization of funding for malaria. 
 
The total income approach [37] was used to compute income losses from malaria mortality. 
Although this methodology provides more generous estimates of losses than other 
methods, given the small number of deaths in the resurgence scenario, the use of this 
method is not likely to have resulted in a significantly higher than expected Return on 
Investment (ROI).  
 
The findings of the investment case in Sri Lanka and the resulting ROI are based on a 
hypothetical resurgence scenario, which may or may not be realistic. While uncertainty 
analyses have been conducted, the findings should be interpreted as such. 
 
For the financial tracking, many of the DAH expenditures could not be allocated to specific 
interventions, therefore introducing a potential bias. In addition, the spending by 
governments could not be further disaggregated by intervention area and it is possible that 
DAH was spent on particular interventions due to co-financing of others through domestic 
sources. Estimates of domestic expenditures on malaria were obtained from sources, which 
relied on self-reporting by countries with little triangulation of data. 
 
For the Global Fund analysis, adjustments were made to the country allocations based 
information provided by the GFATM; however, other factors are evaluated on a case-by-
case basis and the final allocation levels are ultimately determined by the Global Fund and 
the Country Coordinating Mechanism (CCM). 
 
10.3 General recommendations 
 
While achievements made in the past 15 years give reason for optimism, a concerted effort 
at ensuring that adequate resources are available for countries to continue with the 
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necessary interventions is crucial. There are several complementary ways for countries to fill 
the gap between needs and resources until government allocations catch up with the 
financing transition.  
 
The Addis Ababa Action Agenda calls on a number of resource mobilization efforts 
encompassing external financing, government resources and support from the private 
sector [38]. Many national governments are considering raising health budgets by improving 
the capacity to raise tax revenue. In the Asia Pacific countries, tax revenue, in 2016 as a 
percent of GDP varied between 10.5 % in Bangladesh to 34.6 % in the Solomon Islands [39]. 
In Sri Lanka, tax revenues constituted about 13.1 % of Sri Lanka’s total GDP in 2013, 
although the government of Sri Lanka has recently announced new adjusted tax proposals 
[40-42]. Raising tax revenues to 20 % of GDP as recommended by the by the Addis Ababa 
Accord for the Sustainable Development Goals would generate an additional revenue of 
USD4.35 million per year—a potential funding source for malaria POR. 
 
The diversification and socioeconomic changes in Asia Pacific countries, presents a unique 
opportunity to engage the private sector in malaria elimination. It is likely that as the 
contribution of the private sector to the economy increases, they will also become 
increasingly involved in social development efforts across Asia. In Sri Lanka, a total of 40 
companies collectively spend about USD 30.5 million annually on Corporate Social 
Responsibility (CSR) covering a wide range of development issues [43]. The CSR consortia 
has recently partnered with Sri Lanka’s Public Health Department for dengue eradication. 
Tapping into the resources from CSR programs of large multinational firms operating in 
countries to fight malaria may also be a potential resource.  
 
The implementation of Pigovian or sin taxes is another mechanism for increasing resources. 
In the Philippines, the Sin Tax Reform Bill, passed in 2012, increased taxes on tobacco and 
alcohol, generating USD 2.3 billion within 2 years increasing the Department of Health 
budget by 63 % in 2015 [44]. This revenue has freed up resources, which would have 
otherwise been used for social protection of the poor and has trickled down for use for 
malaria and other diseases targeted for elimination. Similarly, Sri Lanka has recently 
adopted a policy for discouraging alcohol consumption and smoking by raising taxes on both 
products in recent years to providing additional government revenue.  
 
Innovative approaches, such as social impact bonds, airline and financial transactions taxes 
also have the potential to increase domestic financing [45-47]. Air travel has doubled 
between 2010 and 2015 in Asia, increasing connectivity and facilitating trade and tourism, 
which has almost quadrupled since 2000. An airline levy such as the UNITAID model could 
raise more than USD 300 million per year just in the Asia Pacific [48].  
 
Chapter 10 – Discussions and Conclusions 
219 
 
 
Blended approaches which refer to the use of funds to leverage or de-risk private 
investment in development are increasingly being explored. Although there are no current 
estimates on their scale, these financing instruments have been used with success in other 
sectors within and outside of health and have the potential to catalyze additional private 
sector support. The Inter American Development Bank (IDB) and the Bill & Melinda Gates 
Foundation (BMGF) recently announced a partnership which would allow countries in 
Central America to benefit from combining concessional loans with “buy-downs” based on 
performance of certain health indicators [49]. A similar mechanism is being planned by the 
Asian Development Bank and the Global Fund [50]. Multilateral and Regional Development 
Banks can also provide new financing opportunities, including cross-sectoral financing for 
health programs incentivizing companies to invest in health interventions. MDBs can be 
encouraged to incorporate health impact assessments, which include malaria indicators as a 
pre-requisite for infrastructure or other loans. 
 
In addition to increasing available health revenue and allocating additional resources, 
improved efficiencies can generate cost-savings, freeing up resources to cover financing 
gaps. Assessing and identifying current inefficacies and drivers of inefficiency can increase 
utilization of current funds. Greater efficiency can be achieved by targeting and 
implementing an optimal mix of malaria interventions that will create the most impact; or 
by maximizing the impact of current inputs to the malaria programme. 
 
As with any disease elimination programme, the final few cases is likely to require an outlay 
of resources that may be considered disproportionate to the marginal return [51]. These 
higher costs must be built into programme budgets with appropriate actions to ensure that 
financing is maintained well after elimination is achieved. 
 
Many countries will soon improve their income status and therefore graduate from donor 
financing. Malaria elimination programs, given the low disease burden, may lose eligibility 
before then. In addition to pursuing additional domestic financing and meeting current co-
financing requirements of existing grants, countries should appropriately plan the transition 
from donor to domestic funding sources 3-5-years in advance of the actual transition. 
 
Given the context of declining malaria case numbers across the region, malaria advocacy 
will need to be tied to a wider narrative that includes other communicable diseases such as 
dengue, which has seen a dramatic resurgence in recent years as part of a regional health 
security response. In addition, malaria elimination can be viewed as an entry point to 
strengthen health systems and can be used to highlight how elimination can lead to 
increased equity. In low transmission settings, where cases cluster among high-risk 
populations, programs must tackle areas and communities that do not have access to 
critical health services. These systems will also be able to better deliver universal health 
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coverage, and the funds no longer needed for malaria, can be redirected to tackle other 
pressing health challenges. Many malaria-endemic countries have political assets that can 
be leveraged to increase political influence. Deploying support to mobilize these political 
assets towards a country resource mobilization objective will ensure strategies are aligned 
with the malaria programme and will increase the sustainability of future advocacy and 
accountability efforts. Leaders, political figures and celebrities can serve as ambassadors for 
malaria. Drawing on country-level political assets can also ensure continuity in political 
engagement.  
 
10.4 Areas for future research 
 
There are several gaps in the current toolbox of economic evidence and priorities for 
research remain: 
 
1. The benefits of achieving and maintaining elimination include a strong public good 
component—an incremental contribution to global malaria eradication. Gaining an 
understanding of this larger set of economic benefits will require better 
macroeconomic models that quantify the links between elimination and other 
outcomes to give more realistic benefit estimations. 
2. Methods to measure the value of the diminished resurgence risk need to developed 
as does a mechanism for quantifying malariogenic potential of countries or 
territories. 
3. There is an urgent need to develop a standard methodology or guidance for 
computing the cost of malaria control and elimination. Past studies have employed 
a wide range of inputs to compute the cost of malaria control and elimination to 
arrive at the costs, making meaningful comparisons difficult. For elimination, this 
standardization needs to include the cost likely to be incurred in a post-elimination 
scenario to allow appropriate budgeting and planning.  
4. While comprehensive WHO guidance exists on interventions for the control of 
malaria, there is a need for better direction on the epidemiological and economic 
efficiencies of various mixes of interventions utilized for malaria elimination. 
5. The start-up costs of malaria elimination, particularly the cost of strengthening 
surveillance systems for enhanced case identification, the true cost of the human 
resources and programmatic management and health system are also largely 
unknown and need to be estimated.  
6. Enhanced methods to comprehensively quantify the non-health benefits to the 
economy will greatly enable stakeholders to strengthen the elimination argument.  
7. Due to changing strategies and costs, it is important that economic estimates are 
constantly reviewed in the light of new information. 
8. Further analysis is required to adapt the existing transmission model to individual 
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country settings and develop country-level estimates based on the national context. 
9. There is a need to continue to track changing donor policies and financing trends to 
ensure that upcoming gaps in financing and be identified early and alterative 
sources of funding be mobilized.  
10. Innovative financing solutions need to be pilot tested and lessons learned 
documented and disseminated widely. 
 
These areas for research should be considered for inclusion into the Malaria Eradication 
Research Agenda (malERA) Refresh process to accelerate malaria elimination [52]. 
 
10.5 Conclusion 
 
Global progress against malaria has been dramatic over the past decade. These gains, 
however, have been driven by substantial political and financial commitments that must be 
sustained to avoid a resurgence of malaria. There are several critical reasons why malaria 
elimination should receive a special focus for financing. Malaria is a major ongoing cost 
driver burdening national health systems and eliminating the disease will confer public 
health benefits as well as major cost savings to national health systems. If successful, 
countries would no longer need to implement prevention measures, thereby reaping an 
“eradication dividend” and accruing substantial economic benefits for all countries. As with 
any disease elimination programme, the cost of ‘finishing the job’ is likely to be higher than 
merely controlling the disease. Although the short-term investment needed may seem 
substantial, these are time-limited as costs taper off significantly as more countries 
eliminate the disease. These costs must be built into programme budgets with appropriate 
advocacy actions to ensure that financing is maintained well after elimination is achieved. 
Secondly, there is a strong correlation between the decline in malaria burden and sustained 
financing.  Declining financing for malaria is an imminent threat to malaria elimination, the 
spread of drug resistance, and regional and global health security. At the same time, it is 
tacit that the total benefits of elimination, many immeasurable, vastly outweigh its cost. The 
investment cases provide compelling evidence for the benefits of continued prioritization of 
funding for malaria, and can be used to develop an advocacy strategy for increased 
domestic and external funding for elimination. While increasing numbers of countries are 
moving toward financing their own programs, external assistance to the last affected 
countries will be essential—possibly through a dedicated “last-mile fund”—to ensure that 
the resources required to complete eradication are available in the final phase. Failure to 
sustain financing until the end game will undermine decades of investment and 
unprecedented gains towards achieving a global public good - a world free of malaria. 
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